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Abstract
 
This research investigates a new South African street drug called nyaope. It is not 
exactly known what the ingredients of this drug are, but some reports say it is a 
cocktail of many illegal substances ranging from heroin, cannabis, 
methamphetamine, cocaine to pain killers, where in each case, the material also 
includes anti-retroviral drugs. The main ingredient is believed to be the anti-retro 
viral drug, efavirenz (EFV), thought to prolong the effects of other narcotic drugs in 
the nyaope mixture. Following reports of an overwhelming increase of its abuse, 
nyaope was eventually brought under legal control in 2014. Originally nyaope was 
mixed with cannabis for smoking but more recently people also choose to chew, 
snort, inject or heat the mixtures over aluminium foil and inhale the fumes.  
The work presented in this thesis involves the first development and validation of a 
methodology for the routine isolation of pyrolysis products of efavirenz in mixtures 
with other alleged components of the nyaope street drug. The products (generated 
during pyrolysis) can be used to study the abuse potential of efavirenz in terms of a 
verification of its presence or otherwise in nyaope residues seized by law 
enforcement. Pyrolysis products were analysed using Gas Chromatography Mass 
Spectrometry (GCMS) and High Performance Liquid chromatography (HPLC).  
Pyrolysis products of EFV on its own and then in mixtures with other suggested 
components of the nyaope street drug (methamphetamine, amphetamine, heroin, 
cannabis and opium) were sequentially investigated. The successful use of activated 
carbon strips in trapping pyrolysis products of the various illicit drugs and drug 
mixtures during this research was demonstrated and a novel robust analytical 
methodology developed.  
Each drug was first heated separately and analysed to generate their background 
pyrolysis product signature.  This was followed by mixing each drug with efavirenz 
and heating the mixture. The results revealed that the presence of efavirenz in 
mixtures of Amphetamine type stimulant drugs and heroin did not disrupt the 
production of the expected pyrolysis products of these drugs and vice versa. 
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However, heating a mixture of opium and EFV revealed only the presence of EFV 
and its pyrolysis product suggesting that the presence of EFV prevented the 
pyrolysis of the cannabis and opium. 
The pyrolysis of methamphetamine and amphetamine interestingly, also revealed 
the presence of synthetic reaction impurities from starting materials and 
intermediate products of chemical reactions applied during the various synthesis 
processes. These were further examined and were successfully used to determine 
the potential synthetic routes used during the manufacture of the 
methamphetamine samples used for this research. This provides new opportunities 
to generate intelligence information regarding the manufacturing process of these 
materials from physical evidence such as residues of smoked or heated materials. 
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Thesis Overview 
 
Chapter 1 discusses the global challenges regarding illegal substances as well as 
information (in figures) supplied by the United Nations (UN) on numbers of people 
estimated as being affected by the illicit drug trade over the years. Also presented is 
the summary of progress made by the UN, throughout the years, in the fight against 
drugs. World drug laws including measures put in place by different countries 
towards the curbing of drugs are also discussed. The worsening drug situation in 
South Africa including challenges caused by the new South African street drug, 
nyaope, is discussed in detail. Also included in this chapter are the objectives of this 
research. 
Chapter 2 discusses the principles and applications of the analytical techniques 
used during this research. Two chromatographic techniques; Gas Chromatography 
Mass Spectroscopy (GCMS) and High Performance Liquid Chromatography (HPLC), 
were used during this research. The discussion also includes individual components 
of each instrument and their role in achieving the desired results.  
In chapter 3, the development and validation of the analysis method used for this 
research is discussed in detail. This includes the procedure for testing column 
performance to ensure repeatability of results, instrument calibration and other 
work necessary for proper validation.  Also covered is the optimisation of the 
Activated Carbon Strip (ACS) method for the extraction of the pyrolysis products of 
EFV and other drugs from a drug mixture sample.  
Chapter 4 discusses two illegal synthetic drugs (amphetamine and 
methamphetamine), alleged to be part of the ingredients used in the nyaope 
mixture. We also investigate how the presence of the target analyte, efavirenz 
(EFV), (alleged to be main ingredient of the drug mixture) influences the pyrolysis of 
each illicit drug and vice versa. This is achieved through the comparison of 
analytical results obtained when EFV was first heated on its own and when it was 
heated in mixtures with other alleged components of the nyaope.  
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Chapter 5 discusses three illegal drugs which are derived from plants (cannabis, 
opium and heroin) and alleged to be part of the ingredients used in the nyaope 
mixture. The influence of the EFV on the pyrolysis of these three drugs is 
investigated and discussed.  
Overall conclusions of this research are discussed in Chapter 6 including suggestions 
for future work regarding the analysis of pyrolysis products of the nyaope street 
drug mixture. 
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CHAPTER 1: INTRODUCTION 
1.1 World drug situation and war on drugs 
According to the 2017 World Drug Report (WDR), an estimated quarter of a billion 
or (5%) of the global adult population used controlled drugs at least once in the 
year 2016. The report further states that about 29.5 million (0.6%) of that number 
suffer from drug use disorders [1]. The magnitude of the harm caused by drug use is 
underlined by the estimated 28 million years of ‘healthy’ life (disability –adjusted 
life years (DALYs)) lost worldwide in 2015 as a result of premature death and 
disability caused by drug use. Amongst those, 17 million are wholly attributed to 
drug use disorders across all drug types. DALYs attributable to morbidity and 
mortality due to drug use have been observed to have increased in the past decade 
[1].  
Different countries and different regions of the world face different illicit drug 
challenges; in general drug sales, possessions and use are regarded as illegal by 
most countries [2-5]. Substance abuse and deterioration of personal health cannot 
be separated and both have become a common topic addressed by both the United 
Nations (UN) and the World Health Organisation (WHO). Psycho-active substances 
cause significant health and social problems for the people who use them, and also 
for others in their community [6-8].  Policies which influence the levels and patterns 
of substance use and related harm can significantly reduce public health issues 
caused by substance abuse [8]. The WHO seeks to promote the rehabilitation and 
treatment of the affected individuals by challenging countries to generate 
interventions at health care system levels that can work towards the restoration of 
health in affected individuals. The organisation insists that it has strategies to help 
reduce the burden of psychoactive substance use and is committed to assisting 
countries with the development, organisation, monitoring and evaluation of 
treatment and other services [7, 8].  
The UN promotes the policy of bringing the illegal drugs market under control 
through the punishment of drug traffickers and provision of treatment and 
rehabilitation to those affected. As a result, member states are challenged to adopt 
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the developed policies.  The approach has since been adopted and adapted by most 
European countries where both legislation and resources for rehabilitation and 
education are in place [6-8].  
Law enforcement in most countries is focused towards the punishment of drug 
dealers and traffickers rather than making use by an end user a criminal offence. 
This approach however does not seem to bring the situation under control because 
the number of drug users continue to grow [1]. Many countries have spent, and 
continue to spend, funds to put resources in place towards public education against 
drug use, rehabilitation of those affected as well as on their medical care [4]. 
Scientists are mandated to continue their support for the war against drugs through 
research; to come up with strategies for the detection and identification of 
emerging drugs.  
 
1.2 History of the United Nations ‘on war’ against drugs 
The UN suggests the use of proper legislation as one of the many solutions towards 
counteracting the spread of illicit drugs, and has been involved with drafting and 
the adoption of international treaties for the control of drugs since the early 1900s. 
The International Opium Conference held in Shanghai in 1909 is seen as the first 
international effort to control illicit drugs [9]. The forum had initially met to 
exchange data and information on the illegal sale, consumption and production of 
opium in Asia, but the topic was later extended to include other countries as well. 
As this was a commission, participants could not make binding international 
agreements but were able to recommend actions necessary to prevent the 
trafficking of opium and its abuse.  Resolutions passed urged national governments 
to make the necessary legislation to curb opium smoking in their countries, initiate 
the regulation of opium for non-medical purposes, ban opium exportation to 
countries that prohibited its importation and control the manufacture and 
distribution of opium derivatives [9]. 
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The commission was the first effective step taken by the international community 
to combat drug abuse. It served as a catalyst for countries to pass domestic 
legislation addressing drug problems within their borders. Most importantly, the 
commission united countries in an international cooperative effort to address the 
problem of the opium trade. The work of the commission led to the convening of 
the Hague Opium Conferences (1912-1914) and to the adoption of the 1912 
International Opium Convention, sometimes called the Hague Opium Convention, 
and succeeding treaties that effectively restricted opium production and trade to 
legitimate purposes [10].  
 Resolutions from the Shanghai conference were used as the basis for the first 
international drug convention, The International Opium Convention of The Hague 
signed in 1912 and entered into effect in 1915 [10]. The convention banned the 
production and shipment of opium and its derivatives except those used for 
medicinal purposes. The Peace Treaty of Versailles signed on the 28th June, 1919 
(Paris) supported the convention by including a clause that required all its 
signatories to adhere to the provisions of the International Opium Convention of 
The Hague [10]. 
 
As of 1920, issues regarding international drug control became part of the tasks 
assumed by the League of Nations, a predecessor of the United Nations. Under the 
auspices of the League, three main conventions were developed (1925 Convention, 
1931 Convention and 1936 Convention). The three conventions provided the 
groundwork for the practical operations of an international drug control system 
which resulted in considerable progress being made towards the reduction of licit 
trade in narcotic drugs.   
 
The League of Nations, established after the World War I, took over as the 
custodian of the Opium convention. This convention was later upgraded and signed 
in 1925, and over the following years the signing of conventions for limiting the 
manufacturing and distribution of narcotics only to medical and scientific purposes, 
the adoption of legal documents to allow certain drugs to become international 
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offences were achieved [10]. Also accomplished were the transfer of The League of 
Nations to the United Nations (1945) and the assignment of the Commission of 
Narcotic Drugs [11] as the central policy making body of the United Nations drug 
related matters in 1946.  Many substances were later placed under international 
control by the Synthetic Narcotics Protocol (1948) [12]. The opium protocol (1953) 
also ensured that opium production and trade were also only limited to scientific 
and medicinal needs [12]. 
 
In 1961, the Single Convention on Narcotic Drugs was adopted as the first 
international treaty used to control the manufacture and trafficking of narcotic 
drugs [13]. The convention consolidated and broadened previous treaties to include 
cannabis and also ensured that drugs with similar effects to those specified in the 
convention were listed as controlled. It empowered the Commission on Narcotic 
Drugs and the World Health Organisation to add, remove, and transfer drugs 
among the treaty’s four schedules of controlled substances.  It also ensured the 
establishment of the International Narcotics Control Board (INCB). The board was 
mandated with the administration of issues relating to drug control and production, 
International trade, and dispensation [13]. This treaty was supplemented by both 
the Convention on Psychotropic Substances 1971, which ensured the control of 
LSDs, ecstasy, and other psychotropic pharmaceuticals and the United Nations 
Convention against Illicit Trafficking in Narcotic Drugs and Psychotropic Substances 
(UNCITNAPS), which strengthens provisions against money laundering and other 
drug related offences [14].  
 
During the 1960s drug use increased greatly around the world, especially in 
Western nations. Inspired by psychedelic advocates like Aldous and Timothy Leary, 
millions of people experimented with powerful hallucinogens and many drugs of all 
kinds became more freely accessible [14]. The Single Convention of 1961 failed to 
ban many newly discovered drugs because its scope was only limited to drugs with 
similar effects such as cannabis, coca and opium. The Convention on Psychotropic 
Substances 1971 was therefore introduced, ensuring the control of psycho active 
drugs such as amphetamines, barbiturates and psychedelics [14]. 
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In 1988 United Nations Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances was introduced to include the newly discovered drug 
compounds. This is one of the three major drug control treaties currently in force. It 
provides additional legal for enforcing the 1961 Single Convention on Narcotic 
Drugs and the 1971 Convention on Psychotropic Drugs [14]. 
In 1997, the United Nations Office on Drugs and Crime (UNODC) was also 
established and made responsible for monitoring of drugs situation in each country 
and to work with national authorities at ensuring compliance with the Single 
Convention. 
All these efforts by the United Nations to fight illicit drugs have since become a 
foundation through which countries develop and adopt strategies to address the 
challenge of illegal drugs. The scope of control of drugs has broadened over the 
years; from opium to cocaine to cannabis to psychotropic substances, including the 
regulation of production of trade of medical drugs; the international cooperation to 
fight complex problems associated with illicit drugs is now a reality. The legal 
framework for the whole international drug control system is now based on these 
three international conventions (1961, 1971 and 1988). 
 
1.3 Drug laws and policies in different countries 
Penalties involving illicit drugs are usually dictated by the social norms of every 
country or region, and will therefore differ from country to country. In general, 
most countries will impose lengthy jail terms and/or heavy fines on those caught 
trafficking or selling illicit drugs. The following is a brief review of some of the 
differences in drug policies/laws from various countries: 
 In some countries such as The Philippines, Singapore, China, Saudi Arabia, 
Malaysia, Thailand, Iran and Vietnam a death sentence is automatically imposed on 
anyone caught trafficking drugs. In Vietnam and Singapore the possession of even 
the smallest amount of drugs can lead to a long jail term or even execution. In 
China and Thailand, rehabilitation in a government facility is mandatory for 
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possession of drugs [15]. In Singapore, as recently as July 2017, a man was executed 
for illegal possession of 22.4g of diamorphine [16] despite outcries by the UN and 
other human rights organisations. 
Most European countries prioritise the rehabilitation of those involved in drug 
trafficking over punishment however tougher legislation against drug trafficking is 
also the norm across Europe [17]. 
In the Netherlands, the government approaches the drug problem as a health issue 
rather than a criminal offence. The country provides more funding towards the 
treatment of those affected by drug use and in supporting education around drug 
abuse prevention than it does towards the imprisonment of potential users. Most 
notably, the Netherlands is the only country to completely decriminalise the use 
and sale of cannabis [1, 17].  
 
Drug policies in Germany are considered amongst the strictest in Europe, with 
significant penalties attached to the sale or possession of large quantities of drugs. 
Notwithstanding this, no criminal action is taken against small-scale possession or 
the use of many narcotics including cannabis. Rehabilitation of those affected is 
prioritised; this is witnessed by the provision of supervised “drug rooms” where 
individuals can safely use their drug of choice and receive counselling when needed 
[17].  
 
Switzerland has the most liberal policies in the world for drug-related offences. The 
government put emphasis on “prevention, therapy, harm reduction and 
prohibition”. The country puts special emphasis towards helping drug addicts 
receive comprehensive treatment and ensuring the safety of active users. Safe 
rooms for addicts are also provided [17].  
 
In the United Kingdom, drug related offenses are broken down into three 
categories by The Misuse of Drugs Act of 1971: Class A, Class B and Class C – with 
class “A” being the most dangerous (in terms of harmful medical effects) drugs and 
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class “C” being the least dangerous drugs. Possession with intent to supply carries 
with it the potential of life imprisonment [2, 17].  
Australia advocates for certain harm reduction measures, such as needle exchange 
programs and also places strong emphasis on drug education in schools at an early 
age [17]. The laws concerning drug abuse and sale in Australia are similar to those 
in the United States in that both drug dealers and users are tried in courts of law. 
 
Like most countries around the world, the African continent is also experiencing the 
challenges of illicit drug use. West Africa has long been associated with the 
production of cannabis, mainly for local consumption, but it is now also becoming a 
producer and exporter of synthetic drugs such as amphetamine-type stimulants 
(ATS). The West Africa Commission on Drugs has declared in their 2014 report that 
some countries in West Africa are being used as drug transit hubs between South 
America and the rest of the world. Drug cartels have collaborated with local 
partners to turn the region into a significant transit route for synthetic drugs 
produced in South America and Asia to be trafficked into Europe and North America 
[18]. 
 
1.4 Drug laws in the African continent 
Most African countries are member states to the UN and have ratified to its treaties 
and conventions on drug control, therefore legislation on drugs and/or drug-related 
offences in these countries is influenced by the UN conventions [18, 19]. 
Categorisation of offences and severity of penalty differ from country to country (in 
some cases ranging from 10 to 15 years for minor offences and from 15 years to life 
imprisonment for more serious offences) [20-23]. Certain countries like Botswana 
and others have inherited rules of procedure and evidence from former colonial 
powers, such as the English common law rules of admissibility of evidence. Such 
rules and procedures are however, not always easy to apply especially in certain 
countries of West Africa [21].  
 
Unlike in Europe and other parts of the world, most African countries have not 
always prioritised the rehabilitation of end users or put in place measures towards 
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public education relating to drug abuse.  Many have instead always prioritised 
interventions for the spread and control of HIV/AIDS and malaria or other 
epidemics over the control of illicit drugs [22-24]. This lack of attention has being 
used by drug traffickers and a worsening of the illicit drug abuse situation in some 
countries is evident [24-26]. 
 
An analysis in 2009 of grants from the Global Fund to Fight AIDS, Tuberculosis and 
Malaria – a major source of external funding for West Africa and the world’s leading 
donor for harm reduction – found that Nigeria was the only West African country to 
include programmes for people who inject drugs in their grant-funded programmes 
[26]. In most African countries, treatment services are provided by psychiatric 
hospitals which are generally poorly funded, have inadequate numbers of 
personnel with no skills and experience in managing substance use disorders. This 
situation exists in part due to a glaring absence of drug treatment policies, 
standards and monitoring systems. It is also due to the fact that people who use 
drugs are often heavily stigmatized, and are deemed as not meriting the 
expenditure of state resources [26]. 
 
Progress towards rehabilitation has however, been made especially after the 
adoption of the African Union Plan of Action on Drug Control in January 2013. The 
plan ran from 2013 to 2017 and encouraged member states to ensure that their 
policies reflect the importance of human rights and public health in drug control 
[27]. A good example has been observed in West Africa where the West African 
Commission on Drugs is working to mobilise public awareness and political 
commitment, develop local and regional capacities and ownership and produce 
evidence-based policy recommendations focusing on the security and governance 
impacts of drug trafficking as well as prevention and treatment of drug dependency 
[27]. 
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1.5 South African legislation on drugs 
South Africa is made up of nine different provinces (figure 1.1) and has land borders 
with Namibia, Botswana, Lesotho, Swaziland, Mozambique and Zimbabwe.   
 
 
Figure 1.1 Map of South Africa showing different provinces [28] 
 
South African law criminalizes three categories of what are known as “dependence-
producing drugs” and these are: dependence-producing substances, dangerous 
dependence-producing substances, and undesirable dependence-producing 
substances [29]. Offenses relating to “dangerous drugs” (including fentanyl and 
methadone) and “undesirable drugs” (including cannabis, known as dagga, and 
heroin) are subject to harsh penalties depending on the form of the offense 
involved. Dealing in any such substances is, on conviction, punishable by a fine 
and/or a prison term of up to twenty-five years.  Use or possession is, on 
conviction, subject to a fine and/or imprisonment not exceeding fifteen 
years.  Some exceptions apply in both instances [29] 
 
10 
 
1.5.1 Availability and Diversity of Illicit Drugs in South Africa  
In 2015, the World Health Organization identified South Africa as one of the drug 
using capitals of the world and also that 15 percent of South Africans had a 
substance addiction problem [30]. Eleven percent of the South African population 
has also been estimated to experience an addiction disorder during their lifetime 
[30]. The escalation of drug related crimes in South Africa has allegedly been 
attributed to the fact that the country has a sophisticated and diversified economy 
which includes a first world infrastructure which exists alongside widespread and 
severe poverty [31]. As a result, those in poverty often either sell or use drugs as a 
coping mechanism. Also when compared to other countries in the continent, South 
Africa is relatively affluent and diverse and therefore offers the most attractive 
consumer market for illicit drugs in the sub-continent [30, 31].  
 
The South African government does not publicise any information about the extent 
to which its people have been affected, therefore available data is only obtained 
from privately owned drug treatment centres, the media and non-governmental 
organisations.  
 
Available information on the nation’s drug abuse problem (2013) [30] shows that 
cannabis was at the top of the list, followed by methamphetamine, and heroin as 
third most abused; that information is summarised in figure 1.2.  
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Figure 1.2 Drug abuse numbers from South African treatment centres in 2013 [30] 
 
In 2016, cannabis was the most abused drug in South Africa; with 60% of substance 
abuse cases reported. Other drugs mostly encountered were codeine, cocaine, 
Benzodiazepines, methamphetamine type stimulants, opiates, hallucinogens and 
methcathinone. Scanty reports on solvents abuse such as glue, petrol and others 
also exist [34].  
 
1.5.2 Nyaope, the new South African street drug  
In addition to experiencing an increase in the prevalence of the above mentioned 
drugs, South Africa is also facing an overwhelming increase in the abuse of an 
adulterated new street drug called ‘nyaope’. It is alleged to be highly addictive and 
composed of a cocktail of illicit drugs including cannabis [34-35, 38-45]. There are 
no formal studies about nyaope and most of available information is obtained from 
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the media, awareness campaigns, workshops or other materials (figure 1.3) from 
non-governmental organisations (NGOs) [32].  
 
Figure 1.3 An example of a nyaope flyer from a private rehabilitation centre [33] 
 
According to media reports, nyaope first appeared in the townships of Durban in 
the early 2000’s and has since spread to other parts of South Africa and to some 
neighbouring countries [39 -41]. It is reportedly prevalent amongst the youth and in 
high demand, which has since turned it into a multimillion-rand business, mostly 
run by Nigerian drug lords [41]. Even though the drug is relatively new, a lot of 
youth and poor people have reportedly become addicted over the years. 
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Nyaope was eventually criminalised by an amendment of anti-drug laws in March 
2014, even though there are still insufficient formal studies about its addiction and 
its identification in other illicit drug mixtures [46-47]. Under the new law, nyaope 
users and traffickers are now punished in the same manner as any other traffickers 
namely, through direct imprisonment [42, 43].  Many people however think that 
the situation was left unattended for too long and do not think the new legislation 
will bring things under control [41, 45].  
 
Since nyaope is a relatively new drug combination, its ingredients vary but some 
reports say it is a cocktail of many illegal substances ranging from heroin, cannabis, 
methamphetamine and cocaine to pain killers where in each case the material also 
includes the anti-retroviral drug efavirenz.  Efavirenz is believed to prolong the 
effects of other narcotic drugs in the nyaope mixture [38-45].  Originally nyaope 
was mixed with cannabis for smoking but nowadays some people choose to chew, 
snort, inject or heat it up and inhale the fumes [44].   
 
Common names for nyaope differ from province to province; for example,  it is 
known as ‘sugars’ in KwaZulu-Natal, ‘Ungah’ in the Western Cape, ‘Pinch’ in 
Limpopo and Mpumalanga and ‘Kataza’ in Johannesburg [49]  
 
Nyaope is the cheapest illicit drug in South Africa; one joint sells for around R30 (£2) 
[45]. This makes it very affordable and may contribute to its high prevalence 
amongst the youth. Users are attracted by the initial ‘rush and euphoric’ effects 
caused by the drug.  These effects however reportedly do not last for long as and 
are quickly replaced by feelings of drowsiness and deep relaxation. Drug 
dependency has been reported by the majority of users, who in most cases struggle 
to get help with their addiction [44-45, 48-50]. Very few drug rehabilitation facilities 
exist in South Africa and most are privately owned.  As a result most people do not 
get any assistance since they cannot afford the cost or when they do, they soon find 
themselves in relapse due to lack of availability of proper after-care programmes 
[48-51].  
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1.5.3 The relationship between nyaope prevalence and the South African anti-
retroviral treatment programme 
South Africa has the biggest and most high profile HIV epidemic in the world, with 
an estimated 7 million people living with HIV in 2015. In the same year, about 
380,000 new infections were recorded while 180,000 deaths that occurred were 
attributed to AIDS-related illnesses (figure 1.4) [48]. 
 
Figure 1.4 South African HIV figures as recorded in 2015 [48] 
 
The South African anti-retroviral treatment is one of the largest anti-retroviral 
treatment (ART) programmes in the world with all efforts largely financed from its 
own domestic resources. More than $1.5 billion is invested annually to run the 
country’s HIV and AIDS programmes [46-50]  
Efavirenz is used as part of the HIV/AIDS management programme in South Africa 
[47-49]. It is prescribed free of charge to patients but due to extreme poverty, some 
patients are forced to sell their medication to the nyaope industry [38, 41]. One of 
the new strategic aims adopted by the UNAIDS board is to end the AIDS epidemic as 
a public health threat by 2030 [50], but this is not going to be possible in South 
Africa if the nyaope situation is not resolved. So there is a need to both support and 
address the drug using communities as well as devising new analytical 
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methodologies for the identification of nyaope and its residues in drug use 
paraphernalia  
1.5.4 People who inject drugs (PWID) and HIV in South Africa 
Data on HIV prevalence among people who inject drugs (sometimes referred to as 
PWID) in South Africa is very limited and, where it does exist, is based on small 
sample sizes [49]. According to a study carried out in 2015, an estimated 19.4% of 
people who inject drugs in South Africa were living with HIV.  The study also 
reported that people who injected drugs accounted for a comparatively low 1.3% of 
new HIV infections. It was also revealed that 32% of men and 26% of women 
regularly shared syringes and other injecting equipment and nearly half reused 
needles [51]. 
People who inject drugs are also associated with other high-risk behaviours such as 
sex work and unsafe sexual practices. For example, the above study reported fewer 
than half of those surveyed used a condom during their last sexual encounter [51]. 
One implication for this is that the number of people who inject drugs will continue 
to grow thereby increasing the chances of having new HIV infections; the cycle will 
continue to repeat itself over and over.  
Recently (February of 2017) [52-54], both the South African people and media were 
shocked by a wave of reports showing injected drug users sharing drugs through a 
new drug trend called ‘blue-tooth’. In these videos and reports, drug users are 
shown injecting nyaope, and then immediately drawing blood back into the syringe 
to be injected into a fellow user. This has since raised health concerns for the 
government, Non-Governmental Organizations as well as rehabilitation centers [53, 
54].  Again only the media seems to be outspoken about this new trend. 
The South African National Blood Service (SANBS) has since issued a warning about 
the serious dangers involved with the practice. The general public has been 
cautioned about the risks involved like the transmission of blood-borne virus or 
pathogens through the procedure, particularly in South Africa which has one of the 
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highest HIV infection rates in the world. People are also warned about the fatal 
consequences of mixing incompatible blood types which is likely to occur if ‘blue 
tooth’ is practised [54].  
There are also some NGOs and other prominent members of society who insist that 
‘blue-tooth’ is not widely practiced, and blame the media for being careless in 
reporting  and for starting a drug trend that never truly existed. They believe this 
has escalated the risk for an already vulnerable group [53].  
 
 1.6 Background information on efavirenz (EFV) 
Efavirenz, ((4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-
1H-3,1-benzoxazin-2-one; trade names: sustiva, stocrin)  (figure 1.5) - is a powerful 
and specific inhibitor for the HIV-1 reverse enzyme recommended for the treatment 
of HIV/AIDS infections [56-58]. It works by binding directly to the human 
immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, 
blocking further replication [60-62]. EFV is a white to slightly pink crystalline 
powder with a molecular mass of 315.68 g/mol and practically insoluble in water 
[58].  
 
 
Figure 1.5 Chemical structure formulas for efavirenz 
 
EFV is a weakly acidic molecule, which means it will remain unionised in the acidic 
environment of the stomach. Thus, theoretically, it is expected to be absorbed 
primarily in the stomach, where the pH is low. However, some studies have shown 
that peak plasma concentrations for EFV are reached after 5 hours [59], meaning 
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that the majority of its absorption takes place in the small intestines. Weakly acidic 
drugs will still be absorbed in the small intestines even though the pH is higher; this 
is because of the much longer transit time and the larger absorption surface area 
[59]. EFV has been viewed as the drug of choice for the treatment of HIV/AIDS 
infections due to its effectiveness. When combined with other antiretroviral drugs, 
it has been shown to significantly reduce HIV viral load, which helps prevent 
damage to the immune system and reduces the risk of developing AIDS [60, 61]. 
However, EFV has been acknowledged to be psychedelic and that almost half of 
patients will experience at least one neuropsychiatric side effect at the beginning of 
treatment. These include nightmares, depression, anxiety, sleep disturbances, 
impaired concentration, aggressive behaviour, hallucinations, paranoia, and 
psychosis [62-66]. 
 
1.6.1 Prescription EFV 
Information from literature shows that EFV is prescribed either as tablets or a liquid 
(figure 1.6) and should only be taken orally [58]. No alternative methods of taking 
the drug were suggested. Also, known EFV side effects were reported by patients 
who had been taking the medication orally; it is not known whether the same side 
effects would be experienced if patients were to take their medication in ways 
similar to nyaope users. No literature or scientific evidence exists to support or 
refute the claim that EFV prolongs the effects of other drugs if taken as a mixture 
(like nyaope). The investigation of the abuse potential of EFV is of interest for this 
research.  
  
 
Figure 1.6 Different types of EFV tablets/capsule [58] 
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A few studies have been performed to investigate the undesirable side effects 
produced by injecting EFV into healthy laboratory mice. One such study, aimed at 
investigating the effects of acute and sub-chronic (2 weeks) EFV administration in a 
series of behavioral tests for anxiety-like and depression-like behavior in healthy 
rats, confirmed that acute treatment with EFV led to anxiety-like behavior, while 
sub-chronic treatment induced both anxiety-like and depressive-like behavior [67].  
Another study confirmed that the behavioural pharmacology produced by EFV in 
mice was very similar to that produced by Lysergic acids (LSDs), this was deemed 
consistent with hallucinogen-type abuse potential and correlates with some of its 
medication-induced side effects described as adverse neuropsychiatric events [68]. 
 
No study however exists to show the behavioural changes produced by EFV or its 
drug mixture when smoked (i.e. as in the case of nyaope). 
 
To date there is no published work investigating the chemical analysis of samples of 
EFV which have been heated with other illicit drugs within the nyaope type 
mixtures.  The analysis of the thermal decomposition products of EFV can be used 
as a potential mechanism for confirming this and therefore elucidate its use in the 
nyaope mixture and as such has a critical importance within. 
 
1.7 Other alleged ingredients of the nyaope drug mixture 
1.7.1 Opium and Opiates  
Opium is the sticky or dried latex obtained from unripe poppy seed pod of plant 
species Papaver somniferum L. [69, 70]. Raw opium is a non-homogeneous material 
often containing poppy capsule fragments. It is sticky, tar-like and dark brown when 
fresh and is air dried to produce the opium latex, which becomes brittle and hard as 
it ages.  Opium may be cut into small blocks or any other shape and can be taken 
orally through chewing or inhalation [69, 70]. Opium can also undergo rudimentary 
refinement to produce a sticky dark product obtained after various treatments of 
raw opium such as water extraction, in order to make it suitable for smoking. It can 
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be presented in the form of opium sticks for smoking or in any other shape for 
inhalation [70].  
 
A number of psychoactive substances (opiates) can be chemically extracted from 
opium including morphine, codeine, thebaine, papaverine and noscapine. Table 1.1 
presents typical percentages concentrations of each opiate present in opium 
although this can be highly variable.  
 
Table 1.1 Five main alkaloids of opium [70] 
 
 
 
 
 
Opiates are naturally occurring alkaloids of the opium poppy (Papaver somniferum 
L.) and can used both medically and illicitly because of their analgesic 
characteristics [69]. They have a general chemical structure (figures 1.7 and 1.8), 
where R represents either –CH3, -H or –COCH3) 
 
 
 
Major alkaloids Percentage concentration  
Morphine 3.1-19.2 
Codeine 0.7-6.6 
Thebaine 0.6-10.6 
Papaverine ≤0.1-9 0 
Noscapine 1.4-15.8 
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Figure 1.7 General chemical structure for opiates 
Morphine R1=R2= H 
Diacetyl morphine R1=R2= COCH3 
Codeine R1= CH3, R2= H 
 
 
   
(a) Diacetylmorphine                   (b) Morphine 
 (c) Codeine 
Figure 1.8 Structural relationships between heroin, morphine and codeine 
 
Morphine can exist as a fine white powder which is often compressed into blocks 
with a variety of trademarks or names. Its colour ranges from off-white to dark 
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brown.  It can also be presented in tablet form. The powder form is mainly injected 
while tablets are taken orally [70].   
Diacetylmorphine (sometimes called diamorphine) is a semi-synthetic opiate 
synthesized from morphine. There are two main formulations; the water soluble 
diacetylmorphine hydrochloride salt and the relatively water insoluble 
diacetylmorphine base.  Diacetylmorphine, when mixed and diluted with other 
compounds is known as heroin, (in some parts of the world, heroin is also the term 
used for diacetylmorphine) and can appear in a range of colours from white to 
brown [70]. Heroin production is generally limited to only four regions of the world 
namely South-West Asia, South-East Asia, Central America and South America; as 
such there are a variety of names that are used to designate the heroin in its 
various stages of refinement/purification which depend on the complexity of the 
processes used. These can include, for example, brown heroin and black tar heroin. 
Heroin is mainly taken by injection, nasal insufflation or smoking. Following 
injection, diacetylmorphine is rapidly broken down in the blood to the 
pharmacologically active 6-monoacetylmorphine (6-MAM) and then to morphine, 
the major active metabolite [70]. 
Compared to morphine, diacetylmorphine is more fat-soluble (due to its two acetyl 
groups), and crosses the blood-brain barrier more rapidly, reportedly in 15-20 
seconds, and achieves relatively higher levels in the brain following intravenous 
injection, with almost 70 per cent of the dose absorbed into the brain. Following 
oral administration of diacetylmorphine undergoes extensive breakdown to 
morphine [69, 70].   
The pharmacological effects of morphine, diacetylmorphine and other opiates are 
mediated through their interaction with opioid receptors and inhibitory 
neurotransmitters (table 1.2). Opioid receptors are responsible for triggering brain 
reward systems and producing analgesia (pain relief) by decreasing pain 
transmission. Different types of opioid receptors exist; among them are mu (μ) 
receptors, which mediate analgesic and behavioural effects [70]. 
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Table 1.2 Pharmacological effects of opiates [70] 
 
Desired effects 
 
 
 
Severe  effects 
 
Effects due to long term 
abuse 
Euphoria Drowsiness Rapid development of 
tolerance,  physical and 
psychological dependence 
Contentment 
 
Potential nausea and 
vomiting 
Malnutrition 
Detachment from emotional 
and physical stress 
Potential stimulatory 
effects 
Chronic sedation and 
apathy 
Analgesia Constriction of pupils 
 
Respiratory problems if 
smoked 
 Possible respiratory 
depression leading to 
death 
Irregular menstrual 
periods 
  
 
Withdrawal syndrome 
  Damage to nose  due to 
snorting or sniffing 
 
 
1.7.2 Cannabis Products 
Cannabis products are produced from the Cannabis sativa L plant [70], which exists 
in many different biological, chemical and morphological varieties; a “dioecious” 
species in which the plant can be staminate (male) or pistillate (female), but also 
the “monoecious” or hermaphrodites, where both sexes coexist on one plant [3].  
The major psychoactive substance of the Cannabis sativa L. is (-)-trans-delta- 9-
tetrahydrocannabinol (delta-9-THC or THC), which has some hallucinogenic effects. 
Other minor psychoactive substances like cannabidiol, cannabinol and delta-8-THC 
also exist [70, 71]. The chemical structures are presented in figure 1.9. 
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
9 THC   
 
 
                   
   Cannabinol           Cannabidiol 
 
 8 THC 
Figure 1.9 Chemical structures of the four main cannabinoids 
 
1.7.2.1 Cannabis herb 
Cannabis (herb), also known as grass or weed, is a green or brown dried material 
generally made from the dried leaves and flowering parts of the female plant and 
looks like tightly packed dried herbs (figure 1.10)  listed in Schedule I and IV of the 
Single Convention on Narcotic Drugs of 1961 [13]. A commonly encountered form is 
the loose material (in a small roll wrapped in paper or onto sticks) and administered 
by inhalation (smoking, vaporization). There is also ground material which is melted 
in butter to produce “cannabutter” or “hash brownies”, or “space-cake” for oral 
consumption. The powder can also be infused with hot water as a drink [70] 
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Figure 1.10 Cannabis herbs [72] 
 
Skunk’ (figure 1.11) is comprised of a range of stronger types of cannabis, grown for 
their higher concentration of tetrahydrocannabinol (THC). It can be grown either 
under grow-lights or in a greenhouse, often using hydroponic techniques. It has 
been reported to have THC content 2-3 times higher than the cannabis herb [73].  
 
 
Figure 1.11 Skunk cannabis [74] 
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It has also been reported to work much quicker, and capable of producing 
hallucinations with profound relaxation and elation – along with nervousness, 
anxiety attacks, projectile vomiting and a strong desire to eat [73]. Skunk has 
reportedly ‘invaded’ the UK cannabis street market over the last 15 years. This is 
mainly attributed to the fact that people are allowed to buy seeds over the internet 
[73]. 
 
 1.7.2.2 Cannabis resin  
Cannabis resin (figure 1.12) is a dried brown or black resinous secretion obtained 
from the flowering tops of the cannabis plant which can be categorised further as 
crude or purified depending on its quality and consistency [70]. Cannabis resin is 
placed under Schedule I and IV of the Single Convention on Narcotic Drugs of 1961 
[15]. The resin may be encountered as fine powder compressed into slabs or as 
loose or pressed sticky powder or pressed into slabs, rods, or other shapes. It may 
be inhaled, taken within food or as tea [70] 
 
 
Figure 1.12 Cannabis resin [70] 
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1.7.2.3 Cannabis (hash) oil 
Cannabis oil (figure 1.13) is obtained by extraction of the crude plant material, or 
cannabis resin with an organic solvent. The extract is then filtered and evaporated 
to give oil. It is tar-like reddish to brown or green viscous liquid which is normally 
mixed with tobacco for smoking, used within a vaporiser or taken orally [70]. 
 
 
Figure 1.13 Cannabis oil and resin [70] 
 
The potency of the various manifestations of cannabis depends very much on the 
concentration of the active ingredient (delta-9-THC) which varies depending on 
formulation and refinement.  Moving from plant to resin to oil concentrates the 
active ingredient as presented in figure 1.14. 
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Figure 1.14 Production of various cannabis products and their potency [70] 
 
1.8 Methamphetamine 
Methamphetamine (figure 1.15) found in illicit markets is predominantly produced 
in clandestine laboratories [70]. This is mostly related to the simplicity of its 
manufacture and the availability of a variety of precursor chemicals and methods of 
synthesis; some of which are readily available on the internet.  
 
 
Figure 1.15 Chemical structures for methamphetamine 
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Methamphetamine is synthesised though various synthetic routes. Two major 
groups of synthesis can be distinguished: (a) syntheses starting from 1-phenyl-2-
propanone (P-2-P) and yielding racemic methamphetamine, such as the Leuckart 
route and reductive amination; and (b) synthesis routes using optically pure l-
ephedrine or d-pseudoephedrine as starting materials, thus yielding the more 
potent d-methamphetamine. The latter include the Nagai route, Birch reduction, 
Rosenmund hydrogenation, and the Emde route with chloroephedrine as 
intermediate [70, 76] 
 
1.8.1 Ephedrine based precursor methamphetamine  
Methamphetamine synthesised in clandestine laboratories using ephedrine 
compounds is mostly through the Emde [70, 77] (figure 1.16) and Nagai routes [79-
89] (figure 1.17). The Birch reduction (figure 1.18) method is not popular due to 
potential hazards involved [70, 78].  
 Ephedrine synthetic methods involve non-metal reductions (Nagai), dissolving 
metal reductions (Birch) and heterogeneous catalytic reductions (Emde) reactions 
[79, 80]. 
 
1.8.1.1 The Emde synthetic route 
This method proceeds through the reaction of ephedrine or pseudoephedrine with 
thionyl chloride to give the intermediate chloroephedrine, which is then 
hydrogenated over a platinum or palladium catalyst to yield methamphetamine. 
The chloroephedrine intermediate is rarely found as an impurity when using gas 
chromatography analysis because it decomposes to form aziridines. It also 
decomposes rapidly during basic extraction of methamphetamine [70, 82-85]. 
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Figure1.16 Methamphetamine synthesis via the Emde synthetic route 
 
1.8.1.2 The Nagai synthetic route 
The synthesis starts by heating ephedrine or pseudoephedrine with red phosphorus 
and hydriodic acid. The reaction mixture is then filtered, basified and extracted into 
a solvent. Methamphetamine base is formed. It is an oily liquid, commonly referred 
to as “meth oil”. This is followed by crystallisation of hydrochloride salt using 
ether/acetone and hydrochloric acid. Alternatively, hydrogen chloride gas is 
bubbled through the meth oil causing the hydrochloride salt to precipitate out of 
the solution [70, 80]. 
Hl and red phosphorus can be replaced by iodine and hypophosphoric acid (sodium 
hypophosphate), or by water and iodine. In rare occasions, the reaction mixture, 
sometimes known as “ox-blood”, is used without further purification, mostly by 
injection. The red coloured mixture, caused by an excess of iodine, contains “meth 
oil” and different impurities related to the Hl/red P route [79, 80]. Typical impurities 
found in samples produced by reductions involving Hl/red P or 
iodine/hypophosphoric acid are ephedrine or Pseudoephedrine, aziridines and 
dimethylnaphthalenes [77-79, 85]. Aziridines cannot be considered as route-specific 
impurities since they can be also produced from chloroephedrine by halogen 
elimination and ring closure (Emde method), or from an oxime intermediate and N-
hydroxymethamphetamine [77, 78, 85]. 
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Figure 1.17 Methamphetamine synthesis through the Nagai synthetic route 
 
1.8.1.3 Birch reduction synthetic route 
The process involves mixing ephedrine or pseudoephedrine with anhydrous 
ammonia gas and either sodium or lithium metal. The mixture is allowed to stand 
until the ammonia has evaporated. Isolation of the meth oil is carried out by direct 
solvent extraction and filtration. The product is further purified by formation of the 
hydrochloride salt and re-crystallisation. In illicit practice, Birch reduction is usually 
completed in a one-step reaction using widely available ammonia, and lithium strips 
from batteries [70]. Several route-specific impurities such as N-methyl-1-(1-(1, 4-
cyclohexadienyl))-2-propanamine are reportedly produced through this route. 
Reactions involving anhydrous ammonia have been associated with clandestine 
laboratory explosions [70, 81]. 
 
 
Figure 1.18 Methamphetamine synthesis via the Birch synthetic route 
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1.8.2 Methamphetamine synthesis using Phenyl- 2-propanone (P2P) 
The most popular synthetic route employed for the illicit manufacture of 
methamphetamine is the Leuckart reaction method (figure 1.19) [70, 75]. It 
involves a non-metal reduction reaction usually carried in three steps. First a 
mixture of P-2-P and methyl formamide (in the presence of formic acid) is heated 
until a condensation reaction results in the production of an intermediate product 
N-formylmethamphetamine. In the second step, N-formylmethamphetamine is 
hydrolysed typically using hydrochloric acid. The reaction mixture is then basified, 
isolated, and (steam) distilled. In the final step, the product is precipitated out of 
the solution, typically as the sulphate salt [70, 76]. 
 
 
Figure 1.19 Methamphetamine synthesis via the Leuckart synthetic route 
 
The second common methamphetamine synthesis method involves a reductive 
alkylation reaction of an aldehyde or ketone with a primary or secondary amine in 
the presence of hydrogen and a hydrogenation catalyst (figure 1.20). The reductive 
alkylation of P2P and methylamine with hydrogen and Pd/C (palladium on carbon) 
produces methamphetamine. The reductive alkylation of P2P and IV-
benzylmethylamine produces N-benzylmethamphetamine-also known as 
benzphetamine. Subsequent hydrogenolysis of benzphetamine produces 
methamphetamine [9, 70, 77-80]. 
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Figure 1.20  Methamphetamine synthesis via the reductive alkylation of phenyl-2-propanone with 
methylamine 
 
Commonly encountered methamphetamine forms are the white to light brown 
powder for nasal insufflation or smoking, the injected solution form (drug powder 
dissolved in saline or distilled water), tablets and capsules (in different shapes and 
colours) for oral consumption and crystalline methamphetamine for nasal 
insufflation or smoking [70]. The different methods through which these forms are 
administered impacts the onset and duration of action; for example, insufflation 
causes quick absorption into the bloodstream through the mucosa and so enables a 
more rapid onset of effects than oral consumption. In general, only 
methamphetamine is commonly found in the crystal form. Methamphetamine is 
placed under Schedule II of the Convention on Psychotropic Substances of 1971 
[14]. The common methods for synthesis described are summarised in figure 1.21. 
 
  
Figure 1.21 Common synthetic methods for methamphetamine 
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1.9 Analytical challenges of the nyaope street drug  
A lot of qualitative research has been conducted on the nyaope street drug [31-47], 
from which information regarding the various ingredients used to make the mixture 
is now available. It has been revealed that the drug can contain a mixture of illicit 
substances including opium, heroin, cannabis, some amphetamine type stimulant 
drugs as well as the anti-retro viral drug, efavirenz, as the main ingredient. Even 
though this information is available, no laboratory studies have been conducted to 
confirm the alleged components of the nyaope.  
 
Analytical methods for the identification and quantification of pyrolysis products of 
most illicit drugs which are alleged to be components of nyaope street drug have 
already been developed [73, 81-85]; however none of these includes the 
identification of efavirenz or its pyrolysis products. An analytical strategy for the 
identification of alleged components of the efavirenz in both powder and smoked 
products was therefore necessary. Gas Chromatography Mass spectroscopy (GCMS) 
is the most common technique used by forensic laboratories to analyse of illicit 
substances [86, 87]. It is a very discriminatory technique and does not require a lot 
of sample. Volatile pyrolysis products of efavirenz can be easily analysed with the 
GCMS technique while non-volatile products can be identified with High 
Performance Liquid Chromatography (HPLC) technique coupled with Mass 
Chromatography or other techniques such as Ultra Violet-Visible Spectroscopy (UV-
Vis) or Infra-Red Spectroscopy (IR). The two techniques are also common in forensic 
analysis of drugs [83, 86] Other techniques which can be applied for the analysis of 
nyaope samples and its smoked products include Fourier Transform Infrared 
Spectroscopy (FTIR) for elemental additives such as calcium and magnesium and 
Time of Flight Mass Spectroscopy (TOF-MS), capable of detecting illicit substances 
and other substances present in minute quantities in the nyaope mixture. The last 
two techniques are however not commonly encountered in most forensic 
laboratories in Africa and were not considered for this research. 
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1.10  Objectives of the study  
 
The main objective of the study was to develop and validate an analysis method for 
the pyrolysis products of efavirenz within common drug mixtures (heroin, opium, 
cannabis, methamphetamine, tobacco) using both the GCMS and the HPLC.  
Other objectives include: 
 
i. To optimise extraction conditions for activated carbon strips (ACS) as a 
trapping media.   
ii. To analyse, and where possible identify, the extracted pyrolysis products for 
each drug using the GCMS and HPLC.  
iii. To analyse, and where possible identify, the extracted pyrolysis products for 
each drug mixture in the presence of EFV, as simulated nyaope samples, 
using the GCMS and HPLC.  
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CHAPTER 2:  ANALYTICAL TECHNIQUES  
2.1 Introduction 
Abuse of certain drugs involves smoking, which results in the generation of thermal 
decomposition products. These products can be studied to reveal certain 
information such as the drugs’ pyrolysis patterns or their behaviour with change in 
temperature. The ability to analyse the thermal decomposition products of 
efavirenz (EFV) may present an objective analytical method for confirming the use 
of efavirenz in residues of smoked nyaope mixture. Pyrolysis products of most illicit 
drugs including those from the five alleged components of nyaope drug (cannabis, 
opium, heroin, amphetamine and methamphetamine) have been successfully 
studied using both the GCMS and LC coupled with other detectors such as MS, UV-
Vis and Diode Array detectors [88]. Information obtained was in some cases used to 
establish linkages between two or more drug samples, drug toxicity studies, 
guidance to analytical approach, or determination of methods of drug synthesis as 
the case with methamphetamines [81-85]. It was therefore proposed that the two 
analytical techniques of Gas Chromatography-Mass Spectrometry (GCMS) and High 
Performance Liquid Chromatography coupled with Diode-Array Detector (HPLC-
DAD) be used to establish the identity of the various thermal decomposition 
products resulting from thermal decomposition of 5 well known controlled drugs 
(cannabis, opium, heroin, amphetamine and methamphetamine), EFV and the 
combination of each drug with EFV which mimics nyaope samples.  
When using the two techniques, volatile organic pyrolysis products of the nyaope 
can be detected by the GCMS following adsorption and desorption with a suitable 
solvent after collection of headspace sample with the Activated Carbon Strips (ACS). 
The HPLC-DAD can used to detect both volatile (from the ACS) and non-volatile 
(from the sample matrix) pyrolysis products. When using the HPLC both volatile and 
non-volatile products can be collected in the mobile phase as they elute from the 
column, using a fraction collector downstream of the detector flow cell. The process 
is called preparative chromatography [89] [figure 2.1]. 
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Figure 2.1 Schematic representation of selective preparative Chromatography [89] 
 
In preparative chromatography, individual analytes are selected and collected as 
they elute from the column.  The fraction collector selectively collects the eluate 
that only contains a purified analyte, for a specified length of time. The vessels are 
moved so that each collects only a single analyte peak [89] 
 
2.2 Derivatisation 
Drugs are often chemically derivatised before analysis with the GC-MS for the 
following reasons: (a) to bring the analytes to the chemical forms that are more 
compatible to the chromatographic environment, (b) to create a separation 
mechanism or to maximize resolution efficiency, (c) to improve detection or 
structural elucidation effectiveness or (d) to make use of the analytes’ specific 
structural features for analytical needs [90]. Analytes that are strongly acidic, basic 
or with functional groups, that may not vaporize or may interact with (irreversibly or 
reversibly) silanol groups or contaminating compounds present in the 
chromatographic system, can be more effectively analysed after chemical 
derivatisation. Enantiomers can be chromatographically resolved by achiral columns 
after being converted into diastereomers using chiral reagents; derivatisation may 
also bring the retention time of the targeted analytes to a more desirable range. 
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Introduction of certain elements or groups through chemical derivatisation may 
enhance the detector’s response or generate mass spectra helpful to the 
elucidation of the analytes’ structural features [91]. Most drugs alleged to be 
components of nyaope, some of which are used in this study have been derivatised 
before [92]. However derivatisation may also complicate the interpretation of the 
analytical data because the resultant reaction may introduce impurities, uncertainty 
on the completeness of the analytes’ conversion, and other interference factors. For 
this reason and also since it was the first study involving the analysis of EFV with the 
GCMS, derivatisation was not performed.  
The pyrolysis experiment was conducted based on the temperatures obtained from 
literature on the pyrolysis of a cigarette, where pyrolysis products are mostly 
generated through mild pyrolysis. Through this type of pyrolysis, products 
generated are in the form of smoke particles in which pyrolysis products and other 
compounds are in their gaseous state; as a result these can be concentrated in the 
sample headspace, trapped with a porous medium and later be extracted with 
suitable solvents for analysis. The choice of trapping media is not limited; studies 
involving the use of different trapping media including the use of activated carbon 
strips have been conducted [93-103].  ACS is a porous mixture of activated charcoal 
on Teflon bedding [104, 105].  It is normally suspended above the headspace of the 
material during pyrolysis to adsorb the released gaseous products. The advantage of 
using ACS is that it is fairly easy to set up, quick, cheap, sensitive, portable, non- 
destructive [103-106] and does not undergo oxidation. The non-destructive nature 
of the technique allows for archiving of extracts either as adsorbed strips or as the 
extraction solution. The strips are also hydrophobic in nature and therefore not 
affected by moisture. All these advantages make the ACS a suitable trapping for 
pyrolysis products of nyaope especially in Africa where analysis of samples can take 
longer than expected due to instrument breakdowns or power outages. It is also 
common to send samples across boarders for analysis or in between laboratories 
hence the need for robust trapping media like the ACS.  However, these have never 
been used before for the adsorption of pyrolysis products of drug, a validated ACS 
method was therefore necessary. 
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2.3 Principal of chromatography 
Chromatography is an analytical technique commonly applied during the separation 
of a mixture of chemical substances (in a sample) into its individual components, so 
that each component can be thoroughly analysed [106]. The process can be both 
qualitative and quantitative as it allows the analyst to estimate the numbers of 
components in the mixture and to quantify them as well. The sample gets 
separated under the influence of a mobile phase over a stationary phase [107, 108] 
. The separated components can be identified later and quantified. The stationery 
phase can be either a solid or liquid supported on a solid while the mobile phase 
can be either a liquid or gas [106, 107] .The mobile phase flows through the 
stationary phase and carries the components of the mixture along. Different 
components travel at different rates depending on their affinity to the stationery 
phase. Components with more affinity to the stationery phase will spend more time 
in the column than those with less affinity.  
Retention time (RT) is a measure of how long each component takes to travel from 
the instrument sample injection port to the detector. It is characteristic of the 
identity of the component under the operating conditions [108]. Identity of the 
component can be confirmed through the analysis of reference material under the 
same operational conditions. The matching of retention time of reference material 
and the component peak is used to confirm the identity of the unknown sample 
component [108]. Detector response for each component is presented in the form 
of a chromatogram (figure 2.1) [109]. A chromatogram is a two-dimensional plot of 
analyte concentration versus retention time [108], whose height or area represents 
the concentration of the particular component.  
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Figure 2.1 Schematic diagram of a GC chromatogram [109] 
 
2.4 Gas Chromatography (GC) 
Gas chromatography facilitates the analysis of substances within gaseous chemical 
mixtures by separating the sample into individual components and timing how long 
each spends interacting with the stationary phase of the analytical column after 
injection, before reaching the detector where compound identification can occur. 
Compounds with less affinity to the analytical column will have a shorter retention 
time compared to those with high affinity for the stationary phase [110]. 
A mobile phase of (normally) high purity inert carrier gas is used to sweep the 
vaporised samples out of the injection block of the instrument (where vaporisation 
occurs) through an analytical column containing the stationary phase to a detector 
for identification.  Helium or hydrogen gases are normally used as carrier gases 
even though argon, nitrogen and carbon dioxide are also suitable [109-112]. 
Moisture and gas traps/filter systems are installed along the gas line, a few 
centimetres before the gas enters the instrument so that contaminants which may 
damage the analytical column or instrument can be detected. These protect both 
the instrument and the analyte by removing impurities and moisture before they 
reach the instrument.  Water can affect analytical column polarity and peak shape 
while the presence of oxygen may affect sensitivity and peak shape [113-115]. 
Contaminants may affect both instrument sensitivity and analyte purity. The GC in a 
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simplistic form is comprised of the injection port, column and detectors and is 
represented in figure 2.2. 
 
 
Figure 2.2 Schematic diagram of a GCMS [113] 
 
The injection port, also known as the sample inlet is where samples (liquid or gas) 
are introduced into the GC for analysis. Inlet temperatures are usually set higher 
than the boiling point of the least volatile component in the sample and maintained 
at high temperature so as to vaporise the sample as soon as it is injected [112].  
GC injections are undertaken either in the split or split-fewer modes [114, 115]. In 
split injection mode, only a portion of the vaporised sample is transferred onto the 
head of the column while the remainder of the vaporised sample is removed from 
the injection port via the split vent line [114, 115]. Split injections are only 
performed with highly concentrated samples which will still produce and maintain a 
good detector signal even after a portion of the sample has been discarded during 
the injection process [114]. On the other hand, a split-less injection is performed 
when target analyte concentrations are low in the sample such that splitting of the 
sample would not produce a sufficient signal within the detector [114]. The process 
of performing either mode of injection is controlled by changing both the flow path 
and rate of carrier gas through the injection port [114, 116]. In split injections, the 
flow rate is set high so that the sample is rapidly swept through the injection port 
liner, past the column and out the split vent [116]. This will result with only a 
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minimal amount of the sample being directed into the column for analysis.  While in 
split less injections, the flow rate is set relatively slow so that most of the sample is 
directed into the analytical column [116]. 
The analytical column is housed inside a temperature controlled oven. There are 
two types of GC columns, packed and capillary [110, 113-117] columns. Packed 
columns have a finely packed inert solid supporting material. These columns usually 
measure between 1.5 and 10 metres with a thickness of 2 to 4 mm and are suitable 
for the analysis of gas samples [114]. Capillary columns are usually very thin (± 
0.30mm i.d) and can either be wall coated open tubular (WCOT) or support coated 
open tubular (SCOT) [114].  WCOT columns walls are coated with liquid stationary 
phase whereas the stationery phase of the SCOT column is lined with a thin layer of 
solid support on to which liquid phase is adsorbed [113, 114]. SCOT columns have a 
better separation efficiency compared to WCOT columns because of the increased 
surface area of the stationary phase coating [113, 114]. Capillary columns are 
suitable for most analytes including drug screening 
 
2.4.1 Column Efficiency Test 
The assessment of column packing efficiency is used to provide valuable 
information on column performance and deterioration throughout the entire 
analysis [111, 113]. The efficiency of a column can be determined by the Number of 
Theoretical Plates present [113-115]. One way of doing so is by applying equation 
3.1; 
 
 
  Where t is retention time and W is peak 
width [7]  
 
Equation 3.1 Calculation of theoretical plate [110] 
 
Columns with high plate numbers are considered more efficient than those with a 
lower plate count. However, literature does not give any specific numbers for 
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reference. High efficiency columns are very desirable because they are thought to 
produce narrower peaks which are easy to resolve [112, 113, 115]. 
Chromatography theory also states that doubling the length of a column increases 
the resolving power only by the square root of 2 – i.e. ~ 1.4 times [89]. The 
efficiency can be normalized with the length of the column to give the height 
equivalent theoretical plate, called HETP or H [89]. The Van Deemter equation 
describes the various factors influencing H, and is divided into eddy diffusion, 
longitudinal diffusion, and mass transfer terms. The relative importance of these 
factors varies with mobile phase velocity. Particle size and morphology contribute 
to H, along with a variety of other factors. Understanding the van Deemter 
equation allows the determination of the optimum mobile phase velocity [89]. 
Stationery phase particle size is one of the factors contributing to the efficiency of 
the column and therefore very important in the Van Deemter equation. For a given 
column length, the plate number (Nth) of a column is inversely related to the 
particle size of the column packing; the smaller the particles, the higher the plate 
number and the separation power [89]. The plate number is also dependent on the 
flow rate (F) of the mobile phase. Optimum velocity is the velocity at which the 
plate number is highest (and H is lowest). A lower or a higher flow rate provides 
fewer plates (higher H) [89, 90].  The equation describes the various contributions 
to plate height (H) in three terms:  
HETP =A+B/u+Cu [90]  
Where H is equivalent to a theoretical plate height (length of 
column/number of theoretical plates)  
A = Eddie diffusion term and only applies to packed columns 
B = longitudinal column length/ordinary molecular diffusion term; this is 
only observed in tendency of sample peaks to broaden at low flow rate in the 
column [90] 
C= resistance to mass transfer term resulting from pushing a peak through a 
column at high flow rates or when using thicker films. This limits sample interaction 
with the stationery phase [90] 
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Eddie diffusion can be minimised through the use of well packed columns, smaller 
stationery phase or using particles with a narrow size distribution. Effects of 
longitudinal diffusion can be minimised by using higher mobile phase flow rates, 
short and narrower system tubing and the use of correct nuts, ferrules and fittings 
wherever possible. Mass transfer can be minimised by using smaller (diameter) 
stationary phase particles, lower mobile phase flow rates and heating the column 
(at higher temperatures the diffusion processes are speeded up and the differences 
in elution time from the particle pore are reduced) [90].  
There are a range of detector systems available and commonly used with a GC 
system.  Within this research work the detection of the samples was performed 
using a mass spectrometer. 
  
2.5 Mass Spectrometry (MS) 
A mass detector analyses the pattern of molecular ions produced when a molecule 
is broken down during ionisation to generate a mass spectrum of the compound 
[113, 115, 116]. Ionisation can be achieved through either the creation of a radical 
cation (also known as Electron Ionisation, EI) or through charge transfer (Chemical 
Ionisation, CI) [117, 118]. Charge transfer involves the removal or addition of 
electrons to molecules or atoms to produce ions [118]. For EI, a sample is ionised by 
bombarding it with a beam of electrons. This results in the loss of electrons and 
creation of a molecular ion [112]. When the molecular ion is detected by the mass 
detector, its representative peak is displayed together with its molecular weight.  
Molecular ions are usually the heaviest ions and their mass is usually used to 
identify the parent compound [112]. Molecular ions are very unstable and often 
fragment further into smaller ions (called daughter ions) and are sorted within the 
mass spectrometer according to their mass to charge ratio [112]. The sequence of 
fragmentation can be very specific to the individual compound and the specificity of 
the mass spectrum generated upon ionisation of an analyte provides a ‘signature’ 
for its molecular structure. This information may then be used to identify the 
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compounds of interest and help construct the structure of unknown components of 
a mixture [112, 113].  
For chemical ionisation, methane or another suitable gas is first ionised to create a 
free radical which in turn can ionise the sample molecules to produce (M+H) 
molecular ions [108, 113]. This type of ionisation is less energetic than EI and gives 
less structural information about a compound. The two ionisation techniques can 
be used to complement each other, particularly where the presence of a compound 
molecular ion is critical in establishing the identity of the compound. EI does not 
always yield molecular ions while CI does [113].    
The mass spectrometer also has limitations.  The salt and free base forms of certain 
compounds cannot be distinguished and similarly, it is not always possible to 
differentiate isomers of the same compound from each other [119, 120]. Certain GC 
columns have the capacity to differentiate between related compounds and so the 
combination of GC coupled to MS provide significant characterisation ability [121].  
 
2.5.1 Sample inlet/Interface 
If the MS is already interfaced with a GC, then a transfer line/interface will be used 
to transport separated analyte molecules from the GC column into the MS for 
identification [113].  The interface is heated to allow the analytes to remain in their 
vaporised form. Heating also prevents the introduction of water molecules into the 
instrument [113].  In cases of stand-alone instruments, samples are introduced via 
an MS inlet, heated and vaporised before being swept into the ionising chamber 
[113]. 
 
2.5.2 Ionisation chamber/Ion source 
For GC-MS in EI mode the ionisation chamber comprises of an electron gun and an 
electron collector. Analyte molecules are ionised by being continuously showered 
with a beam of electrons from an electron gun (electron ionisation) [108, 111, 112]. 
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This results in the creation of a charged molecule and the associated loss of 
electrons. Electrons generated during ionisation are collected in an electron 
collector [113, 114]. 
 
2.5.3 Mass analyser 
The movement of charged analyte molecules through the analyser is controlled by 
placing different electrodes with different charges in the analyser [113, 119]. An 
electric field created by electrodes causes charged sample molecules to behave 
different from each other due to their mass where the rate of deflection is based on 
the mass and charge of the molecule [119]. This means that larger molecules reach 
the detector first because they are deflected less than those with lower mass. Some 
instruments have mass filters which dictate the order of molecules arriving at the 
detector and in these instruments smaller molecules may be detected first [113].  
There are different mass analysers in the market; for this research a quadruple 
mass analyser was used. 
 
2.5.3.1 Quadrupole mass analyser. 
Fragmented molecular ions and parent ions from the ionisation chamber pass 
through the quadrupole to reach the detector. The quadruple is made of four metal 
rods arranged in a cylinder conformation (figure 2.3) [111, 119].  
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Figure 2.3 Schematic diagram of a MS quadruple [113] 
 
An alternating radio frequency (RF) is used to generate an electric potential across 
the rods during which acts to separate positively and negatively charged ions as 
they are carried into the mass analyser [8, 14]. The application of radio frequency 
also causes the ions to separate further according to their size. Smaller particles will 
be deflected to a greater extend as they move through the quadruple and will reach 
the detector later than heavier particles [113, 119]. The application of direct 
current (DC) to the system favours the selection of smaller particles only and larger 
particles are deflected to a greater extent than smaller ones [119]. Smaller particles 
are refocused quicker and as a result reach the detector earlier [119]. By balancing 
the application of both the radio frequency and direct current to the mass analyser, 
the separation of the various fragments created from a given sample can be 
optimised. 
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2.5.4 Detector 
Electrons received from the mass analyser are picked up by the detector and 
amplified to become electrical signals [114, 116]. Information about the sample can 
be acquired both in the Selective Ion Monitoring (SIM) mode which targets the 
analytes and/or scan modes [122].  
In SIM mode, the GCMS is set only to gather data on ions masses of interest. The 
advantages of this mode are that it enhances instrument sensitivity; helps eliminate 
sample matrix interferences facilitating lower analyte limits of detection and 
quantitation [122]. The scan mode is used for the identification of chemical 
components, quantitative analysis and also for the determination of some 
parameters for SIM analysis [122].   The scan mode was applied during the analysis 
of all samples for this research. 
Signals produced by the detector are sent to a computer where a record of all data 
generated is produced [117, 118]. Information about each chromatogram can be 
searched and obtained from electronic libraries within the computer software. A 
plot of signals will reveal information about the sample such as analyte 
concentration (peak area) and composition [116-118]. 
 
2.6 Gas Chromatography Mass Spectrometry (GCMS) 
GCMS is a combination technique comprising Gas Chromatography and Mass 
spectrometry through which complex substances are separated, identified and 
quantified [110, 113]. The basic layout of a typical GCMS instrument is presented in 
figure 2.4.  A requirement for GCMS analysis is that samples should be both volatile 
and thermally stable [113]. Samples are usually analysed as organic solutions which 
are volatilised upon entry into the injection block of the instrument.  As a result, 
materials of interest have to be solvent extracted and occasionally subjected to a 
series of wet chemistry techniques before analysis is possible [113]. Functionalised 
compounds may need to be derivatised before analysis; in order to minimise or 
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eliminate unwanted adsorption effects that may otherwise affect the quality of 
data obtained [113].  
 
Figure 2.4 Schematic diagram of a GCMS [113] 
 
2.7 High performance Liquid Chromatography (HPLC) 
High Performance Liquid Chromatography is a separation technique which involves 
the injection of a small volume of a liquid sample into a column packed with 
particulate material (diameter size normally between 3 to 5 µm) [114, 115]; these 
make the stationery phase inside the column. Individual components of the sample 
are moved down the column as the liquid mobile phase is forced down the column 
by pressure from the instrument pump [114]. The liquid, which is may also be used 
as the sample solvent, serves as the mobile phase. Separation of the components of 
the sample in the column involves various chemical and /or physical interactions 
between their molecules and the packing particles [123, 124]. The separated 
components are detected as they elute from the column based either on the 
fluorescence, refractive index or spectroscopic information [113, 114, 123, 124]. 
The time each component spends in the column is called its retention time; 
components with high affinity to the column will spend longer than those with less 
affinity [123]. A typical liquid chromatogram is shown in figure 2.5 below. 
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Five major components of a HPLC are the pump, injector, column, detector and 
computer. 
 
Figure 2.5 Schematic diagram of a HPLC [124] 
 
The HPLC pump is used to drive the mobile phase through the column at a specific 
rate (usually in mL/min). The normal flow rates for HPLC are in the 1 - 2mL/min 
range. Pumps are normally operated in pressure ranges of between 5800-7000 
[110, 123]. HPLC pumps can either be isocratic or gradient based depending on the 
type of work under analysis [124]. The injector introduces the sample into the flow 
stream of the mobile phase; sample volumes are usually between 5 and 20µL [112]. 
Sample can be injected into the system manually via a syringe or automatically 
through the use of an auto sampler. 
The data system which controls all the modules of the instrument and is also 
responsible for recording the retention times and amounts of individual 
components of the sample is usually run via dedicated software on a computer 
connected to the instrument [112, 123, 124].  
Individual components of the sample that elute from the column are captured by 
the instrument detector. The detector response is sent to a recorder/computer 
where is it recorded as a chromatogram [124]. 
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2.7.1 Gradient and Isocratic elutions 
Gradient elutions employ two or more solvent systems. After the elution has begun, 
the ratio of the solvents is varied in a programmed way, sometimes in a series of 
steps. This mode enhances separation efficiency. Isocratic elutions employ a single 
solvent or solvent mixture of constant composition. They are best suited for simple 
separations and often used in quality control applications while gradient conditions 
are normally used for complex samples such as unknown mixtures or during 
method development [112].  
 
2.7.2 Separation modes of the HPLC 
Separation of the injected component mixture occurs within the analytical column 
using various physical and chemical parameters [113].  The nature of the stationery 
phase is responsible for causing the high backpressure at normal flow rates [124].  
The pump must push hard to move the mobile phase across the column and 
therefore creates resistance increasing the pressure inside the system [123]. 
The HPLC uses four separation modes for most components which are reversed 
phase, normal phase, ion exchange and size exclusion chromatography [112, 113, 
124].  
Reversed phase chromatography is the most commonly encountered stationary 
phase mode mostly due to its versatility; it can be used for polar, non-polar, 
ionisable and ionic molecules. Column packaging for this mode is non-polar and the 
mobile phase is normally a buffer and a water miscible organic solvent like 
acetonitrile or acetone [112, 123, 124]. Samples containing a wide range of 
components can easily be separated via gradient elution with this mode. 
The stationery phase for normal phase chromatography is polar (e.g. silica gel) 
while the mobile phase is non-polar. These are less common and used for the 
analysis of water sensitive compounds, chiral compounds, separation of various 
lipid classes, as well as cis-trans isomers [119].  
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The column packing for ion exchange chromatography contains ionic groups and 
the mobile phase is an aqueous buffer [110]. This mode is mostly suitable for the 
separation of organic and inorganic ionic compounds and cations in aqueous 
solutions [110]. It is also suitable for the separation of ionic dyes. Separation of 
proteins can also be achieved with ion exchange chromatography. The last 
separation mode for HPLC is size exclusion chromatography. In this mode, the 
sample and the column packing materials do not interact; instead molecules diffuse 
into the pores of a porous medium [110, 123]. Separation is based on the relative 
size of the sample molecules to the pores of the medium. This mode is mainly used 
for polymer characterisation and for protein analysis [123]. 
 
2.7.3 HPLC detection systems – Ultra Violet (UV) and Diode Array Detector (DAD) 
There are many detection modes used for HPLC but the three most common are 
spectroscopic, refractive index and fluorescence detections [18-20]. The detection 
system used for this research was the Diode Array Detector (DAD).  
Spectroscopic (UV or UV/UV-VIS) detectors are most frequently used to measure 
components showing an absorption spectrum in the ultraviolet or visible region 
[112, 124]. These employ a deuterium discharge lamp (D2 lamp) as a light source, 
with the wavelength of its light ranging from 190 to 380 nm. Measurement of 
sample components at wavelengths longer than this uses a UV-VIS detector which 
employs an additional tungsten lamp with wavelength range of 320- 1100nm [124]. 
When using these detectors, light from the lamp is shone onto a diffraction grating 
and dispersed according to the wavelength at which measurement is required 
[124]. For instance, when the measurement is performed with a wavelength of 320 
nm, the angle of the diffraction grating is adjusted so that 320 nm light is shone on 
the flow cell [124]. Comparison of the differences in light intensity between light 
emerging from the flow cell after interacting with the sample and the reference 
light which has not interacted with the sample can be determined and output as 
absorbance [124] (figure 2.6). In some cases a UV spectrum will also be generated 
and can be used to identify the compound (s) [112, 123, 124].  
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Figure 2.6 Illustration of a UV-VIS detector optical system [124] 
 
While a UV-VIS detector has only one sample-side light-receiving section, a Diode 
Array Detector (DAD) has multiple (1024 for L-2455/2455U) photodiode arrays to 
obtain information over a wide range of wavelengths concurrently [124]. Spectra 
are measured at intervals of 1 second or less during separation by HPLC with 
continuous eluate delivery. If the measurement is performed at a fixed wavelength, 
components are identified from only their retention time; thus, a minor deviation in 
retention time can make identification of components difficult [124]. In such a case, 
the DAD can be used to identify components by a comparison of the spectrum 
[124].  
The difference between DADs and UV-VIS detectors is that light from the lamps is 
shone directly onto the flow cell, light that passes through the flow cell is dispersed 
by the diffraction grating, and the amount of the dispersed light is estimated for 
each wavelength [124] (figure 2.7). Noise can be a feature in DAD output because 
the amount of light is small; the DAD is also susceptible to various changes, such as 
lamp fluctuations, because the reference light cannot be received [124-128].  
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Figure 2.7 Schematic diagram of Diode Array detector [124] 
 
2.8 HPLC detection systems – relating signal to concentration  
When light passes through the compound, energy from the light is used to promote 
an electron from a bonding or non-bonding orbital into one of the empty anti-
bonding orbitals [126] (figure 2.8).  
 
 
 
Figure 2.8 Energy level diagram [127] 
 
Possible electron jumps that light might cause is shown in figure 2.9.  
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Figure 2.9 Different electron excitation possibilities [127] 
 
In each possible case, an electron is excited from a full orbital into an empty anti-
bonding orbital. Each jump takes energy from the light, and a larger jump obviously 
needs more energy than a small one. Each wavelength of light has a particular 
energy associated with it, if that particular amount of energy is just right for making 
one of these energy jumps, then that wavelength will be absorbed - its energy will 
have been used in promoting an electron [127]. 
 
An absorption spectrometer works in a range from about 200 nm (in the near ultra-
violet) to about 800 nm (in the very near infra-red). Only a limited number of the 
possible electron jumps absorb light in that region. In order to absorb light in the 
region from 200 - 800 nm (where the spectra are measured), the molecule must 
contain either pi bonds or atoms with non-bonding orbitals [127]. 
 
2.9 Chromophores 
Many compounds absorb ultraviolet (UV) or visible (Vis.) light. These are called 
chromophores; the characteristic feature of chromophores to absorb light of UV 
and visible wavelengths from 200 nm to 400 nm and from 400 nm to 800 nm 
respectively can be used to determine their concentration by absorption 
photometry. The method measures the decrease in light intensity when light passes 
through a coloured solution. The distance which the light has to pass through a 
solution is called the path length. With a linearly rising concentration of the 
chromophore solution, the intensity of the emergent beam of light falls off 
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exponentially [127]. The amount of radiation absorbed may be measured in a 
number of ways:  
 
i. Transmittance, T = P / P0 
% Transmittance, %T = 100 T  
 
ii. Absorbance,  
    A = log10 P0 / P 
A = log10 1 / T  
A = log10 100 / %T 
A = 2 - log10 %T  
Where: 
I = intensity of transmitted light 
I0 = intensity of incident light 
T = I/I0 = transmittance 
Equation 2.2 Equation for absorbance [128] 
Using the last equation, A = 2-log10 %T, absorbance can be easily calculated from 
percentage transmittance data, but this is not normally used because the 
relationship between the two variables is not linear. The Beer Lambert equation 
2.3] is mostly preferred. With the equation, the relationship between absorbance is 
linear to the concentration and the path length. If the molar absorption coefficient 
of a chromophore in solution is known then its concentration can be calculated 
using the Lambert-Beer’s law equation:  
 
A = ε x c x d  
Where 
A = absorbance (dimensionless) 
c = concentration (mol/L)  
d = path length (cm) 
ε = molar absorptivity coefficient (L/mol x cm) 
Equation 2.3 Lambert-Beer’s law [128] 
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A plot of absorbance against concentration using the Lambert-Beer’s law yields a 
straight line passing through the origin. However the Beer-lambert’s law is limited 
since it is only valid for highly diluted solutions [128]. 
 
2.10 Quantification methods using GCMS and HPLC 
Quantitation of samples using both the GC-MS and HPLC instruments uses 
chromatographic data to determine the amount of a given component in a mixture. 
The data can be in the form of either peak height or peak area obtained from an 
integrated chromatogram [129]. Data used should be gathered accurately; peak 
resolution should be ensured to accurately determine the size or height. Several 
types of quantitation methods exist; but commonly used ones are area percent, 
single point external standard, multiple point external standard, single point 
internal standard, and multiple point internal standard [129]. Multi point external 
standard quantitation method was used for this research.  
 
2.10.1 Multi point external standard Method 
Multi-level calibration can be used when it is not sufficiently accurate to assume 
that a component shows a linear response or to confirm linearity of the calibration 
range, otherwise a single point external standard method is applied [130]. A sample 
containing a known amount of analyte or analytes is first analysed, followed by 
calculation of its response. Equation 2.4 is used to calculate the response factor 
[129, 130].  
Response factor = Peak area/standard amount  
Equation 2.4 Calculation of analyte response factor [129] 
 
This is followed by the analysis of a sample with an unknown concentration and 
recording of the peak area. The amount of the analyte in the sample is then 
calculated using equation 2.5 [129].  
 
Analyte amount = Peak area/response factor 
Equation 2.5 Calculation of analyte concentration [129] 
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After calculating concentrations for each analyte at different calibration levels, a  
line fitting algorithm such as point to point, linear least squares, or quadratic least 
square is used to produce a calibration curve [129] (figure 2.10).  
 
 
Figure 2.10 Typical calibration curve [131] 
 
Linear regression attempts to model the relationship between two variables by 
fitting a linear equation to observed data. One variable is considered to be an 
explanatory variable, and the other is considered to be a dependent variable [132].  
Linear regression calculates the equation that minimises the distance between the 
fitted line and all data points [132]. From the calibration curve, a regression analysis 
will yield an equation which describes the best fit of the line through the data 
points, with the form:  
Y = mx +c 
Where:   
 Y = peak area 
   m = the slope of the regression line  
c = intercept of the regression line with the y-axis [132] 
 
The slope of the calibration line is often used to determine the sensitivity of the 
analytical method while the intercept indicates the degree of systematic error 
within the method and is the direct result of ‘background’ response [132].  
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2.10.2 Least-Squares Regression 
The most common method for fitting a regression line is the method of least-
squares. This method calculates the best-fitting line for the observed data by 
minimizing the sum of the squares of the vertical deviations from each data point to 
the line. Because the deviations are first squared, then summed, there are no 
cancellations between positive and negative values [133].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
Chapter 3:  METHOD DEVELOPMENT AND VALIDATION STUDIES 
 
 
3.0 Gas Chromatography Mass Spectroscopy methods for efavirenz   (EFV) 
 
There are no available gas chromatographic analytical methods reported in the 
literature for efavirenz (EFV). As a consequence a new GC method was developed 
and validated. This process was divided into two phases; the first phase included the 
determination of initial instrument conditions, sample preparation, system 
suitability and selectivity. The second phase was involved with the validation of the 
developed method. Since cannabis is one of the alleged ingredients of nyaope, a 
GC-MS protocol developed by Cadola [134] for the analysis of cannabis was used as 
an initial starting point.   
 
3.1 Chemicals and reagents 
Efavirenz reference standard was purchased from Sigma Aldrich (Gillingham, 
Dorset, UK). Caffeine, Nevirapine and 2-(4-Isobutylphenyl) propanoic acid 
(Ibuprofen) reference standards were all also purchased from Sigma Aldrich 
(Gillingham, Dorset, UK). The Grob test mix was purchased from Restek, UK.   
Efavirenz tablets (600mg) were donated by Pharma South Pharmacy (Gaborone, 
Botswana). 
 
3.2  Determination of initial operational conditions for GCMS 
An Agilent 7890A gas chromatograph interfaced with an Agilent 5977E mass 
selective detector was used. Separation was achieved on a standard non-polar DB-1 
column, (15 m length, 0.32 mm i.d and 0.25 µm film thickness).  Sample injections 
were made in a split mode using a general purpose split/split-less liner packed with 
glass wool. The GC oven temperature program started at 1000C, held for 1 minute 
and increased to 2600c at a rate of 100C min-1 and held for 10 minutes resulting in a 
total run time of 27 minutes. Sample volumes of 1µL were injected into the 
instrument at a split ratio of 10:1 using helium as a carrier gas. The flow rate of the 
helium was set at a constant flow of 20µL min-1. Other temperature settings were 
as follows; the injector was set at 2800C, transfer line at 2500C, ion source at 2300C 
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and the quadruple at 1500C. Data acquisition was performed in full scan mode. 
Compounds were identified using both the NIST 2014 mass spectral database and 
data from available literature [134- 138]. Tuning of the MS was performed once a 
month using PFTA.  
 
For identification purposes, a standard solution of 1mg/mL EFV in methanol was 
prepared. Three replicate injections of the solution were performed using the 
above settings. Efavirenz was detected at 16.96 minutes and the mass spectrum 
(figure 3.1) reveals the main ions identified at m/z 315, 246, 243, 224, 180 and 167. 
 
 
 
Figure 3.1 efavirenz mass spectrum 
 
Column efficiency test and instrument precision were then performed to establish 
system suitability for analysis of the target analyte. A comprehensive, standardised 
quality test for column efficiency was proposed by Grob and Grob in 1978 [142] 
testing. For this study, a commercial test mix based on that proposed by the Grobs 
[142] was used to test the GC column efficiency. The test mix comprised a total of 
13 hydrocarbon components at a concentration of 0.05% V/V each in methyl 
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chloride. Six GC replicate injections of 1µL test mix were performed. A 
chromatogram obtained from the test mix is presented in figure 3.2.
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Figure 3.2 Grob mixture chromatogram  
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The peak width at half height was calculated for each component across the six 
injections. The number of theoretical plates for each component was then 
calculated using equation 1 and results used as a true representation of the total 
number of plates that each component. The results (table 3.1) show high 
theoretical number plate values for most components with the exception for p-
xylene and octane. 
 
Table 3.1 Theoretical plate number for components of the Grob test mix 
Assigned 
number on 
chromatogram Component Theoretical Plate number 
1 Eicosane 5231 
2 Octadecane 3657 
3 Hexadecane 8361 
4 Tetradecane 4869 
5 Dodecane 6475 
6 1,3 ethyl methyl benzene 2458 
7 1,3,5 tri methyl benzene 5034 
8 1 ethyl 3 methyl benzene 9769 
9 Decane 20585 
10 P-xylene 896 
11 Octane 646 
12 Toluene 1757 
 
 
3.2.1  Instrument precision 
The International Conference on Harmonization (ICH) defines precision as “the 
closeness of agreement between a series of measurements obtained from multiple 
sampling of the homogenous sample under a set of prescribed conditions” [144]. 
Precision can also be defined as a measure of random errors in a method [145]. 
 
There are three levels at which precision may be expressed and these are; 
(i) Repeatability - defined as a measure of the closeness of the agreement 
between reciprocally independent test results obtained using the same 
method, on identical test material in the same laboratory, performed by 
the same operator using the same equipment on the same day [145].   
64 
 
(ii) Variations in the conditions for repeatability when performed within the 
same laboratory results with intermediate precision. 
 
(iii) Reproducibility is used to assess the closeness of agreement between 
results obtained with the same method on identical test material in 
different laboratories with different operators using different equipment 
[144-146].  
 
Precision is concentration dependent and therefore should be measured at 
different concentrations within the working range, typically at the lower, mid and 
upper parts [146] 
 
For this research, the repeatability factor was used to measure precision. Within 
day instrument repeatability was assessed by performing 5 replicate injections of 
both the Grob text mixture and a 1mg/mL of the efavirenz (EFV) standard in 
methanol. Mean, standard deviation and % relative standard deviation (%RSD) 
values of peak areas across the six injections were calculated and evaluated. Results 
obtained for both solutions were within ≤5% [147, 148] confirming a very good 
repeatability and that the instrument was suitable for the intended analytical work. 
The results are displayed in Table 3.2 and 3.3  
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Table 3.1 Analytical repeatability results for the test mix 
 
Test mix analyte 
 
 
 
 
Peak area 
 
 
Mean 
 
 
SD 
 
 
RSD % 
 
Injection 1 Injection 2 Injection 3 Injection 4 Injection 5 
Toluene 135866973 140852156 135866973 138147943 144716169 139090043 3755737.2 2.7 
Octane 46744731 48296183 46744731 47764416 49146908 47739394 1033252.7 2.16 
p-Xylene 186167822 189822620 186167822 188035602 193503239 188739421 3065488.8 1.62 
1,3 ethyl methyl benzene 222075119 223059097 222075119 221540433 229634987 223676951 3375513.9 1.53 
1 Ethyl -2 methyl benzene 236155881 236015369 236155881 235279186 243069521 237335168 3226188.6 1.36 
1,3,5 ethyl methyl benzene 226859436 225603633 226859436 224831466 233078876 227446569 3265253 1.44 
Decane 93691629 93986694 93691629 93413314 96811353 94318924 1407986.7 1.49 
Dodecane 140225119 140225119 140225119 140228653 146292923 116205387 57162176 1.89 
Tetradecane 176181129 176819773 176181129 176594897 183121330 177779652 2998711.7 1.69 
Hexadecane 202413224 202048768 202413224 203686965 209227344 580567133 845069770 1.48 
Octadecane 216779465 214487216 216779465 215977681 221716745 217148114 2720040.7 1.25 
Eicosane 
 
234546438 232060443 234546438 233434373 239989219 234915382 3014967.9 1.28 
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                Table 3.3 EFV analytical repeatability test results 
 
 
 
 
 
3.3. GCMS Method Validation 
A method validation is performed to ensure that data generated from instrumental 
analysis can be relied upon forming an important part of any good laboratory 
practice [144]. The process of validating a method can also be described as 
“establishing documented evidence that provides a high degree of assurance that a 
specific method, and ancillary instruments included in the method, will consistently 
yield results that accurately reflect the quality characteristics of the product tested” 
[145].  Many reasons can be advanced towards the validation of analytical 
methods; the most important one being to meet the requirements and validation 
characteristics included in both the ISO/IEC 17025 standard and the International 
Conference on Harmonization (ICH) guidelines on method validation.  
 
 The ISO/IEC 17025 is the most relevant standard for chemical analytical 
laboratories including forensic science laboratories [149]. ICH is interested and 
involved with the harmonisation of technical requirements for the registration of 
products among the European Community, Japan and the United States of America 
[145, 146]. Typical validation parameters considered for qualitative method 
validation include linearity, specificity/selectivity, precision, limit of detection, limit 
of quantification, accuracy, and range and analyte stability  
 
Replicate efavirenz peak area 
1 118117451 
2 125124730 
3 120992717 
4 116694158 
5 123852796 
6 111606910 
Sum 716535468 
Average 119422578 
SD 11203696 
RSD% 4.18% 
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3.3.1 Method Linearity 
The linearity of a method is defined as its ability to obtain test results that are 
directly proportional to the amount of analyte in the sample within a specified 
range. It is used to study the relationship between the target analyte concentration 
and the mass detector response [145].  A linear response will therefore allow for its 
quantification of the analyte through either the peak area or height.  
 
To assess linearity, three standard stock solutions of 1mg/mL of efavirenz (EFV) in 
methanol were prepared. Aliquots of these solutions were further diluted with 
methanol to make six different solutions with concentrations ranging from 100-600 
µg/mL. Three replicate injections of these solutions were performed and their 
response (table 3.4). Data obtained from these were subjected to regression 
analysis using the least squares method to construct a calibration curve (figure 3.3). 
 
Table 3.4 Peak areas and %RSD values for three EFV replicate injections across the chosen 
calibration range 
EFV 
standard 
replicate 100µg/mL 200µg/mL 300µg/mL 400µg/mL 500µg/mL 600µg/mL 
1 71607690 117284724 225903704 284391686 364589472 440701756 
2 67930993 118878740 205618390 285863720 364376878 444748825 
3 69177128 121851640 215573165 282997920 362940605 443778088 
Average 69571937 119338368 215698419.7 284417775 363968985 443076223 
SD 1869875 2317892.116 10143237.04 1433078.1 896924.26 2112854.2 
RSD% 2.69 1.94 4.70 0.50 0.25 0.48 
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Figure 3.3 GCMS efavirenz calibration curve 
 
The correlation coefficient (R2) of efavirenz in methanol was found to be 0.995, 
confirming a linear relationship between the analyte and concentration. %RSD 
values for linearity concentrations ranged between 0.2-4.7percent (Table 3.4). 
 
3.3.2  Analytical Range 
The range of an analytical method is the interval from the upper to the lower levels 
(including these levels) that have been demonstrated to be determined with 
precision, accuracy and linearity using the method as written. Analytical range is 
normally expressed in the same units as the test results obtained by the analytical 
method [140, 144, 147]. Based on the instrument calibration results, the developed 
method demonstrates linearity between EFV concentrations of 100-600µg/mL.   
 
3.3.3 Method Selectivity 
A selective method is said to be the one in which the presence of other components 
in the sample mixture does not affect the identification and/or quantification of the 
analyte of interest. The other components may include impurities, degradation 
products, sample matrix and/or other components with similar behaviour [150-53].  
y = 753756x - 1E+07 
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To assess the selectivity, stock solutions of efavirenz, 2-[4-(2-
methylpropyl)phenyl]propanoic acid (ibuprofen), caffeine and nevirapine were 
prepared by weighing 5mg of each standard and dissolving in 5mL of methanol to 
yield 4 standard solutions, each with a concentration of 1mg/mL.  The two 
standards of caffeine and ibuprofen were chosen based on the consideration that 
they likely to be present in most human biological samples as they are thought to 
be  used by most people. Nevirapine on the other hand is an anti-retro viral drug 
which, in most cases, has been observed to be taken in combination with or in place 
of EFV.  
 
Following the preparation of the three stock solutions, a laboratory standard 
mixture was prepared by mixing together 1mL each of the prepared stock solutions. 
6 replicate injections of the prepared standard were analysed.  The standard 
mixture was very well separated (figure 3.4) with RSD values <5% for each 
compound in the mixture (Table 3.5). None of the components eluted at the 
retention time of efavirenz, confirming that the method was selective for this target 
analyte. 
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Figure 3.4 Chromatogram of the laboratory standard mixture 
 
 
Table 3.5 %RSD values of peak area for EFV mixed with 3 standards (ibuprofen, caffeine and 
nevirapine) using GCMS 
Injection Ibuprofen Caffeine efavirenz Nevirapine 
1 25328192 108613924 118264157 258845222 
2 25373055 11973163 125124730 272723489 
3 26121465 112011811 120992717 265649888 
4 25724251 110381326 116694158 258998759 
5 24426022 123094098 123852796 279989405 
6 23010254 105742316 111606910 249006997 
Mean 24997206.5 111969440 119422578 264202293 
SD 1124063.73 5938324.541 4989540.793 11050893.3 
%RSD 4.50% 5.30% 4.18% 4.81% 
 
 
3.3.4 Analyte stability 
Potential analytical bias during method development can be eliminated by 
investigating the stability of the target analytes and standards used [152, 153]. Bias 
can arise at the start of an analytical investigation due to 
degradation/decomposition of chemical compounds during sample preparation 
Ibuprofen 
Caffeine 
EFV 
Niverapine 
0
1000000
2000000
3000000
4000000
5000000
6000000
7000000
8000000
9000000
10000000
9 10 11 12 13 14 15 16 17 18 19 20
A
b
u
n
d
an
ce
 
Retention time (minutes) 
Plot of test mix for analyte peak area vs retention time 
71 
 
procedures and storage of prepared aliquots or while awaiting analysis in 
instrument auto samplers [150].   
Analyte stability can be defined as the measure of the capacity of an analyte to 
remain within established specifications (identity, concentration and quality) 
throughout the whole analytical procedure [144-146] and is mainly dictated by 
analyte storage conditions (before, during and after analysis). Stability tests are 
carried out by comparing freshly prepared analyte solutions of known 
concentration with similar samples retained for different periods of time under 
various conditions [146].  
 
Stability was assessed by analysing two sets of EFV standard solutions at 
concentrations 200, 300 and 500µg/mL over 9 consecutive days. One set of 
standard solutions were maintained at room temperature (19OC) while the other 
was kept in the fridge (2.5OC) for the duration of the test period (9 days). Three 
replicate injections were performed daily of each sample. Daily mean peak areas at 
each concentration were calculated from which graphs of peak area vs number of 
days were generated. Percentage relative standard deviations for each 
concentration across the three replicate injections were calculated. The results 
obtained are presented in tables 3.6, 3.7 and figures 3.5. 
 
 
 
 
   
72 
 
 
 
Table 3.6 %RSD results for analyte stability test at room temperature performed over 5 days 
Standard 
solution 
concentration 
 
 Average peak area (n=3) 
 
Day 1 Day 2 Day 3 Day 4 Day 5 Mean SD %RSD 
500µg/mL 
 
371884643 368948416 365096057 352547121 337714249 359238097 14111930 3.93 
300µg/mL 
 
276296770 270024795 263645980 260245309 259729836 265988538 7074507 2.66 
200µg/mL 
 
202513340 198893706 190580607 188145291 180410062 192108601 8791966 4.58 
 
Table 3.7 %RSD results for average analyte stability for samples stored in the fridge over 5 days 
Standard 
solution 
concentration 
 
 Average peak area (n=3) 
 
Day 1 Day 2 Day 3 Day 4 Day 5 Mean SD %RSD 
500µg/mL 
 
192840944 191814446 188040105.7 179230230.7 178152602 186015666 6199654 3.33 
300µg/mL 
 
90350795.33 899949994.67 88014750.3 87775070 86494363 88516995 1435970 1.62 
200µg/mL 
 
73089827 17000950 69555841 69459549 65881877 69597609 2288482 3.29 
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*Key: green =500µg/mL, blue = 300µg/mL, red = 200µg/mL 
 
 
 
Figure 3.5 Plot of EFV stability at a) room temperature  and b) samples kept in the fridge for 
different concentrations (200, 300 and 500µg/mL) of  methanol 
*Key: green =500µg/mL, red = 300µg/mL, blue = 200µg/mL 
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The data reveal that both room temperature and fridge samples remained 
relatively stable for five days. Stability was determined by the %RSD for the average 
peak area where all three solutions remained within the ≤ 5% range.   
 
3.3.5 Limit of Detection (LOD) and Limit of quantitation (LOQ) 
The limit of quantification is the lowest concentration of analyte detectible and 
quantifiable with certainty of precision and accuracy using the analytical method. 
LOD is the lowest amount of analyte that can be detected without being necessarily 
quantified as an exact value. It can also be described as the lowest concentration 
that can be distinguished from the background noise with a certain degree of 
confidence [144, 146, 150].  LOQs are normally used as a measure of the amount of 
impurities and/or degradation products in a sample [147, 148].   
 
The LOD and LOQ were derived from the standard deviation of the response and 
slope of the calibration curve using Equations 3.2 and 3.3 below; 
 
LOD = 3.3 x (Standard Deviation of the analyte response /slope of the 
Calibration curve for the analyte). 
Equation 3.2 LOD calculations [147] 
 
 
LOQ = 10 x (Standard Deviation of the analyte response /slope of the 
Calibration curve for the analyte). 
Equation 3.3 LOQ calculations [147] 
   
Based on equation 3.2 the LOD for EFV was calculated as:   
3.3*5494506/743247 = 24 µg/mL. 
The LOQ for EFV (base on equation 3.3) was found to be:  
10*5494506.47/743247 = 74µg/mL 
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3.3.6 Method accuracy 
Accuracy is used to estimate how close the method test results are to the true 
response value of the analyte in the sample [145]. Disagreements between the two 
results may arise from either systematic or random errors or both [150]. 
 
Accuracy can be obtained through several ways; 
(i) By comparing the results from the method with those obtained from an 
established reference method, assuming that the uncertainty of the 
reference method is known [147].  
 
(ii) By injecting known concentrations of sample (either a control sample or 
certified reference material) and comparing the measured value with 
the true value. If neither of these is available then a spiked blank sample 
matrix can be used [144, 145, 147]. 
 
(iii) By comparing the response of the extract with the response of the 
reference material dissolved in a pure solvent (percentage recovery).  
This can also be used to assess the effectiveness of sample preparation 
[144, 145, 147] 
 
The accuracy of the new method was estimated by injecting known concentrations 
of sample certified reference material and comparing the measured value with the 
true value. The accuracy of the new method was found to be 99.4 ± 6.3%. 
Percentage analyte recovery using the new method developed for this study was 
found to be very good (over 85%) (Table 3.8 and 3.9) 
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Table 3.8 Method analyte recovery at each calibration level -EFV standard sample 
Actual  sample 
concentration 
(µg/mL) Peak  Area 
calculated 
concentration 
(µg/mL) 
Calculated accuracy (based 
on peak area) (%) 
100 71607690 110 110 
100 67930993 105 105 
100 69177128 107 107 
200 117284724 171 87 
200 118878740 173 87 
200 121851640 177 89 
300 225903704 317 106 
300 205618390 290 97 
300 215573165 304 101 
400 282997920 396 99 
400 284391686 398 100 
400 285863720 394 99 
500 364589472 504 101 
500 364376878 504 101 
500 362940605 502 100 
600 440701756 606 101 
600 444748825 612 102 
600 443778088 611 102 
Mean recovery 99.4% 
SD 6.3 
 
 
Table 3.9 calculated %RSD for recovery studies 
Replicate 100µg/mL 200µg/mL 300µg/mL 400µg/mL 500µg/mL 600µg/mL 
1 100 86 106 99 101 101 
2 105 87 97 100 101 102 
3 107 89 102 100 100 102 
Mean 107 87 101 99 101 102 
SD 2.52 1.56 4.55 0.48 0.24 0.47 
%RSD 2.34 1.79 4.49 0.49 0.24 0.47 
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Summary of GCMS method validation results is presented in table 3.10 below 
 
Table 3.9 Summary of GCMS method validation results 
Parameter Results 
 
Linearity 100-600µg/mL 
Cor. Co-efficient 0.99 
Precision (%RSD): intraday repeatability 1-4% 
Method specificity (%RSD) efavirenz 
with three other drugs 
4-6% 
Method accuracy 99-105% 
LOD 24µg/mL 
LOQ 74µg/mL 
Analyte stability (%RSD) fridge (5 days) 
Room temperature (5 days) 
 
1-4 % 
4-5% 
 
These combinations of results provide confidence that the chosen Gas 
Chromatography Mass Spectrometry method for the detection of EFV was 
appropriately validated.  
 
3.4.0 HPLC Method adoption and validation  
An analytical method developed by Veldkamp et al [154] for the analysis of EFV in 
biological fluids was adopted. A method revalidation was performed due to the 
differences in the sample matrices (biological fluids vs EFV powdered tablet). As 
with the GCMS validation, the process was divided into two phases which included 
the establishment of instrumental conditions, sample preparation, system and 
selectivity optimization followed by validation of the developed method.  
 
3.4.1 Chemicals and reagents 
Efavirenz reference standard was purchased from Sigma Aldrich (Gillingham, 
Dorset, UK). Efavirenz 600mg tablets (Mylan Laboratories Limited, Maharashtra, 
India) were kindly supplied by the Princess Marina Hospital in Botswana.  
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Acetonitrile and HPLC water (both HPLC supra-gradient) were purchased from VWR 
International LTD (Lutterworth, Leicestershire UK).  Na2HPO.12H20 and KH2PO4 
were purchased from Sigma Aldrich (Gillingham, Dorset, UK). The pH meter 
calibration standards of pH 4 and 7 were purchased from Mettle Toledo, 
Switzerland. 
 
3.4.2 Chromatography conditions 
An Agilent HPLC 1200 series (Waldbronn, Germany) equipped with a degasser, 
binary pump, an auto sampler, column oven and diode array detector (DAD) was 
used. Separation was achieved on an Agilent ZORBAX SB C18 column (4.6 mm x 
150mm x 3.5μm) and detection at wavelength of 246 nm. The mobile phase 
consisted of phosphate buffer (25mM)-acetonitrile (53:47, v/v). The pH of mobile 
phase was adjusted to 7.5 using a diluted 2M solution of potassium hydroxide. The 
analysis was performed at room temperature with the flow rate maintained at 1.5 
mLmin-1 and injection volume of 50μL. The run time was initially set for 25 minutes 
but was adjusted to 15 minutes after establishing the RT of other alleged 
components in the nyaope. Analytical results were processed by Agilent Openlab 
Chromatography Data System/Chemstation/windows 7 Pro computer version 
A.02.01 (1.3.3). 
 
3.4.3 Preparation of buffer solutions 
A 25mM phosphate buffer solution was prepared by dissolving 0.09g 
Na2HPO.12H20 and 0.34g KH2PO4 in 100mL of HPLC grade water.  The buffer was 
then mixed with acetonitrile at ratio 53:47. The resultant mixture was adjusted to 
pH 7.5 with dilute 2M KOH solution. The KOH solution was diluted 1:5 with 
deionised water before use. The pH meter was calibrated with a pH 4 and 7 
calibrating standards before use.  
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The retention time for EFV was first established by preparing a standard solution of 
1mg/mL EFV in methanol; three replicate injections of this solution were made and 
efavirenz was detected at 10.961minutes (figure 3.6).  
 
Figure 3.6 HPLC chromatogram showing caffeine just before 2 minutes and EFV at 10.961 minutes  
 
3.5. HPLC Method revalidation parameters 
3.5.1 Preparation of standards 
Stock solutions of efavirenz, 2-(4-Isobutylphenyl) propionic acid, caffeine and 
nevirapine were prepared by weighing the appropriate amount of each standard 
and dissolving it in the corresponding amount of mobile phase to yield 
concentrations of 1mg/mL each. 
 
3.5.2 Method Linearity 
Standard stock solutions containing 1 mg/mL of efavirenz were prepared in 
triplicate. Aliquots of these solutions were diluted with methanol to make standard 
solutions of concentrations ranging from 100-500µg/mL. Data obtained from these 
were subjected to regression analysis using the least squares method to construct a 
calibration curve for the different concentrations versus peak area (table 3.10 and 
figure 3.7). 
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Table 3.10 Calibration data and %RSD results for the five HPLC calibration points 
                          
Replicate 100µg/mL 200µg/mL 300µg/mL 400µg/mL 500µg/mL 
1 6856.489 12794.3 16694.6 24310.5 29996.8 
2 6831.031 12778.5 16573.4 24488.4 30659.1 
3 6819.571 12756.3 16569.4 24326.5 29928.7 
Mean 6835.697 12776.37 16612.47 24375.13 30194.87 
SD 18.89605 19.08961 71.15767 98.4175 403.4772 
%RSD 0.276432 0.149413 0.428339 0.403762 1.336244 
 
 
 
Figure 3.7 EFV calibration curve for the HPLC analysis 
 
The correlation coefficient (R2) of efavirenz in methanol was found to be 0.993, 
confirming a linear relationship between the analyte and concentration. %RSD 
values for linearity concentrations (Table 3.4) ranged between 0.1-0.28%  
 
3.5.3 Analytical Range 
Based on the instrument calibration results, the method demonstrated linearity for 
EFV concentrations ranging between 100-600µg/mL.   
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3.5.4 Limit of Detection (LOD) and Limit of quantitation (LOQ) 
The LOD and LOQ were derived from the standard deviation of the response and 
slope of the calibration curve and calculated using equations 3.2 and 3.3 
(mentioned earlier in section 3.2.5). They were found to be 29 µg/mL and 88 µg/mL 
respectively. 
 
3.5.5  Accuracy of the method 
The accuracy of the HPLC method was determined by injecting known 
concentrations of certified reference material and comparing the measured value 
with the true value. Percentage analyte recoveries for the method (table 3.11) were 
found to be ≥ 90% (tables 3.10). %RSD for all analyte recoveries was found to be 
<5%.  
 
 
Table 3.11 HPLC method accuracy -analyte recoveries at different concentrations 
Actual sample 
concentration 
(µg/mL) Peak area 
Calculated 
concentration 
(µg/mL)  
Calculated 
accuracy (based 
on peak area) (%) 
100 6856.5 105 105 
100 6831.0 105 105 
100 6819.6 105 105 
200 12794.3 206 103 
200 12778.5 206 103 
200 12756.3 206 103 
300 16694.6 273 91 
300 16673.4 271 90 
300 16569.4 270 90 
400 24310.5 402 101 
400 24488.4 405 101 
400 24327.5 402 101 
500 29996.8 499 100 
500 30659.1 510 102 
500 29928.4 498 100 
   Mean recovery 99.91% 
   SD 5.23 
   LOD 29 
   LOQ 88 
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Table 3.12 Calculated %RSD for recovery at each calibration level 
Replicate 100µg/mL 200µg/mL 300µg/mL 400µg/mL 500µg/mL 
1 105 103 91 101 100 
2 103 103 90 101 102 
3 105 103 90 101 100 
Mean 105 103 90 101 100 
SD 0.32 0.16 0.40 0.42 1.37 
%RSD 0.31 0.16 0.45 0.42 1.37 
 
3.5.6 Method precision 
The repeatability factor was used to test for the method precision. To do this, 6 
replicate injections of the 200µg/mL and 300µg/mL of EFV standard solutions into 
the HPLC. The mean, standard deviation and %relative standard deviation (%RSD) of 
peak areas across the six injections were calculated and evaluated. Results obtained 
(table 3.12) were found to be ≤5%, confirming excellent repeatability.  
 
Table 3.13 Results for HPLC method precision 
Replicate injection 200µg/mL EFV standard  300µg/mL EFV standard  
1 12794 166945 
2 12779 16573 
3 12756 16569 
4 12776 16612 
5 12794 166956 
6 12788 160382 
Mean 12781 16634 
SD 14.45 57.12 
%RSD 0.11 0.34 
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3.5.7 Method selectivity 
Method selectivity was investigated by performing 6 replicate injections of the 
laboratory standard into the instrument and calculating the %RSD values of each 
component across the resultant 6 peak areas. The standard was modified to contain 
only 1mg/mL EFV and 1mg/mL nevirapine. There was no need to include caffeine 
since it was used as an internal standard earlier (section 3.3.3), where it was found 
to elute at retention time different from that of EFV. The %RSD values of the two 
analytes were found to be within the acceptable level of ≤ 5% (figure 3.8) (table 
3.13) 
 
 
Figure 3.8 HPLC chromatogram showing nevirapine (1.427 minutes) and EFV (9.93 minutes) 
 
The standard mixture was very well separated and the two components of the 
mixture did not elute at the same retention time, demonstrating good selectivity. 
Calculated %RSD values for peak areas for each sample were found to be ≤5% (table 
3.14) 
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Table 3.14 %RSD results for HPLC method selectivity 
Replicate injection 1mg/mL EFV   1 m/mL nevirapine   
1 4734 16812 
2 4728 16445 
3 4745 16732 
4 4617 15907 
5 4724 16836 
6 4712 16583 
Mean 4701 16552.56 
SD 55.12 349.03 
%RSD 1.19 2.11 
 
 
3.5.8 Analyte stability 
Analyte stability was tested by preparing two sets of EFV standard solutions at 
different concentrations of 200, 300 and 500 µg/mL and analysing them for 9 
consecutive days. One set of solutions was kept in the fridge (2.5OC) while the other 
was kept at room temperature (19OC). Three replicate injections were made for 
each sample on daily basis. Daily mean peak areas at each concentration were 
calculated and used to generate graphs of peak area vs number of days (figures 
3.9a and b) (table 3.15). Percentage relative standard deviations for each 
concentration were calculated. Even though all samples remained stable over the 
five day period, it was observed that those stored in the fridge were more stable. 
Calculated %RSDs values (table 3.15 and 3.16) for the three solutions at both 
temperatures were less than 5%.  
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Table 3.15 %RSD results for analyte stability test at room temperature over 5 days 
Standard 
solution 
concentration 
 
 Average peak area (n=3) 
 
Day 1 Day 2 Day 3 Day 4 Day 5 Mean SD %RSD 
500µg/mL 
 
10119.9 10131 10152.6 10136.4 10303.4 10168.66 76.239 0.74 
300µg/mL 
 
4267.292 4250.081 4149.219 4178.729 4180.900 4205.24 50.732 1.21 
200µg/ml 
 
3595.359 3576.821 3513.994 3419.070 3418.934 3504. 83 83.96 2.39 
 
Table 3.16 %RSD results for samples stored in the fridge over 5 days 
Standard 
solution 
concentration 
 
 Average peak area (n=3) 
 
Day 1 Day 2 Day 3 Day 4 Day 5 Mean SD %RSD 
500µg/mL 
 
10119.9 10100.70 10066.50 10040.5 9981.8 10061.88 54.23 0.54 
300µg/mL 
 
4267.29 4250.08 4180.90 4149.22 4180.90 4205.68 50.46 1.20 
200µg/mL 
 
3576.82 3576.82 3513.99 3419.07 3418.93 3501.13 79.24 2.26 
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Figure 3.9 Plot of EFV stability at a) room temperature  and b) samples kept in the fridge for 
different concentrations (200, 300 and 500µg/mL) of  methanol 
*Key: green =500µg/mL, red = 300µg/mL, blue = 200µg/mL 
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A summary of HPLC method validation results is presented in table 3.17 
 
                                        Table 3.17 Summary of HPLC method validation results 
Parameter Results 
 
Linearity 100-500µg/mL 
Cor. Co-efficient 0.99 
Precision (%RSD): intraday repeatability 0.1-0.3% 
Method specificity (%RSD) efavirenz 
with three other drugs 
1-2% 
Method accuracy 99 ±5% 
LOD 30µg/mL 
LOQ 88µg/mL 
Analyte stability (%RSD) fridge (5 days) 
Room temperature (5 days) 
 
1-4 % 
4-5% 
 
The various conditions tested for the High Performance Liquid Chromatography 
detection of the target analytes demonstrated validity of the method. 
 
3.6 Generation of pyrolysed EFV samples in the absence and presence of other 
drug compounds. 
A number of different methods for abuse of EFV in combination with other drugs 
(cannabis, opium, heroin and methamphetamine) are known.  All these involve 
heating the drug in the presence of EFV either indirectly by the application of a 
flame (for example using a flame to heat a spoon containing heroin or 
methamphetamine) or in combination with tobacco as a ‘joint’.    
As a consequence, a method for the generation of the pyrolysis products from EFV 
on its own and in combination with the other drugs commonly encountered was 
required in order to correctly simulate case samples.   Two methods were needed, 
one involving the pyrolysis and combustion of a joint containing EFV and one where 
EFV was added to a sample of solid material (opium, heroin or methamphetamine) 
and heated. 
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3.6.1 The pyrolysis process 
Pyrolysis is a process involving molecular breakdown of larger molecules into 
smaller volatile molecules in the presence of heat without interaction with oxygen 
or any other oxidants. The process is necessary for almost all solids (or liquids) to 
burn [155, 156]. Every molecule within a substrate experiences some form of 
molecular vibration at any given temperature; the frequency at which it vibrates is 
directly proportional to its temperature [155]. During pyrolysis molecules are 
subjected to very high temperatures leading to very high molecular vibrations. At 
these high molecular vibrations, every molecule is stretched and shaken to such an 
extent that they start breaking down into smaller molecules [155]. Pyrolysis 
reactions causing molecular stretching vibrations have been reported [157].  
 
Pyrolysis has also been described as a process which involves molecular 
fragmentation [157]; however this type of fragmentation is different from that of 
mass spectrometry as the resultant fragments are not charged. 
 
When a substrate is freely burned, most of the pyrolysis products released by the 
substrate will be fuelling the flame. However, some will be adsorbed onto the 
substrate and may later be recovered during the extraction procedure [156]. 
 
Examples of pyrolysis processes include those observed in polymers where 
decomposition occurs through main chain reactions of cross linking and chain 
scission or side chain /substitutions reactions of side chain elimination or cyclization 
[158].  
 
 
3.6.2 Environment inside a smoked cigarette  
The environment inside a burning cigarette is hydrogen-rich and oxygen deficient 
and this allows the processes of combustion and pyrolysis/distillation to take place 
[159, 160, 161].   Several simultaneous chemical processes take place during the 
smoking of a cigarette, including pyrolysis and aerosol formation [156]. Combustion 
occurs around the tip of a cigarette and is mostly characterised by the presence of 
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an ember. The carbonised environment inside a cigarette consumes oxygen as soon 
as it is drawn into the cigarette during a ‘puff’, causing combustion to occur. Carbon 
monoxide, carbon dioxide and water together with the heat released during 
combustion sustain the burning process [157]. Immediately next to the combustion 
zone is a pyrolysis/distillation zone, which has relatively low oxygen levels and 
generally reaches temperatures of between 200°C and 600 °C. The majority of 
smoke products are generated in this region by a variety of mechanisms, essentially 
driven by the heat released from the preceding combustion zone [159]. During a 
‘puff’, supersaturated vapour created by the smoke products are drawn down the 
tobacco rod as the mainstream of smoke and inhaled by the smoker. Taking a ‘puff’ 
in this way causes the air from outside the cigarette to enter through the paper 
line. This air dilutes and rapidly cools the generated mainstream smoke as it is 
drawn out of the pyrolysis zone [156, 161]. Cooling of the main stream smoke 
quickly brings vapours of less volatile compounds to their saturation point causing 
them to condense into ``a dense aerosol consisting of growing droplet particles of 
condensed pyrolysis products (smoke) which can be trapped and analysed [161].  
 
 
Figure 3.10 Schematic diagram for the combustion of a cigarette [161] 
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3.6.3 Passive Headspace Extraction 
When substances are heated, pyrolysis products are released from the sample 
matrix into the air above the surface of the heated material. If this were to take 
place inside a controlled environment, the released gases would be pre-
concentrated onto the surface of a porous material and later desorbed with a 
suitable solvent for analysis. This is the basic principle of passive headspace 
sampling.  The captured pyrolysis products (fig. 3.11) can be desorbed and then 
analysed using a GCMS or any other suitable instrumental method [101-106].  
 
 
Figure 3.11 Schematic representation of the principle of passive headspace extraction technique [161] 
 
The use of activated charcoal strips (ACS) as adsorbents has been known for many 
years [94, 95], however other adsorbents including DEFLEX and C-bags have also 
been used [96-99]. ACS has been viewed as an effective extraction method for fire 
debris by the American Society for Testing Materials (ASTM) in their ASTM-E1412-
12 standard [94, 102] and, as a consequence, many forensic science laboratories 
have adopted them as adsorbents for fire debris analysis [95, 103, 104]. The effects 
of temperature (in the adsorption phase), strip size and adsorption time have all 
been investigated [94]. It has been recommended that temperatures above 90oC 
degrees are avoided when using ACS as degradation of substrates are likely to 
occur. The recommended adsorption time is between 12-16 hours at temperatures 
ranging between 60oc and 90oC [95, 104].  
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3.6.4 ACS experimental set up for capturing pyrolysis products. 
3.6.4.1 Materials and methods 
EFV reference material was purchased from Sigma Aldrich, UK. 600mg EFV tablets 
were purchased from Pharma South, Gaborone Botswana. K type Thermocouple 
and cables, the Picolog data logger and software (Pico Technology, UK), ACS strips 
(3M), paper clips and small round magnets were all available within University of 
Dundee or purchased locally. Tin cans and lids were purchased from VWR Products, 
UK.  
The methodology used was based on a design developed by Agu [163] which was 
adapted from the ASTM E1412 [32] guidelines. Activated carbon strips were placed 
inside a clean tin can lid and held in place using a paper clip and a magnet. This was 
to ensure that the ACS remained suspended above the material while it is being 
pyrolysed.  
EFV tablets and any other samples which were not already in powder form were 
individually homogenised by crushing each into fine powder using a mortar and 
pestle. An amount corresponding to half the weight of the EFV tablet was used for 
each test. After weighing, the powder was heated to ensure pyrolysis occurred 
inside the tin can.  The tin was capped during heating.  
Once the desired pyrolysis temperature, (monitored using the thermocouple) had 
been reached the tin was removed from the heat source and the lid replaced with 
one onto which the ACS strips had been attached. The can was then incubated in an 
oven at 80oC for 16 hours. Following this, the ACS were removed and placed inside 
a GC vial containing 0.5mL of pentane. A 1mg/mL solution of caffeine standard was 
used as the internal standard.  The heating temperatures were monitored and 
recorded using the picolog data recorder (figure 3.12)  
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Figure 3.12 Experimental setup for the ACS pyrolysis experiment 
 
 
Figure 3.13 shows a typical plot of temperature vs time generated from the picolog data 
during a pyrolysis experiment  
 
 
Figure 3.13 Plot of pyrolysis temperature vs time 
 
0
50
100
150
200
250
300
350
400
0 100 200 300 400 500
T
e
m
p
e
ra
tu
re
 (
0
C
) 
Time (seconds) 
Plot of pyrolysis temperature vs time 
93 
 
3.6.5 Determination of the pyrolysis temperature for EFV. 
In order to determine the optimum EFV Pyrolysis temperature range, a tablet of 
EFV was ground into a powder using a mortar and pestle and the powder (0.5g) was 
then heated to between 280oC and 450oC to cause thermal decomposition and the 
generation of pyrolysis products. The adsorption and desorption procedure 
described in section 3.5.4.1 was then followed.  
3.6.5.1 Pyrolysis products of EFV 
Only one pyrolysis product of EFV was identified by GCMS analysis presenting at 
11.79 minutes. A library search did not reveal the identity of the product (Product 
1; m/z 270, 252, 235, 210, 201, 185, 167).  The mass spectrum of both EFV and 
product 1 are presented in figure 3.13a and figure 3.13 b. 
 
 
 
Figure 3.13 Mass spectra for (a) EFV and (b) EFV product 1 
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A tentative explanation of fragmentation suggests that the base peak of product 1 
(m/z 270) could have resulted from the loss of CO2 during ionisation; m/z 201 could 
resulted from the loss of CHF3 while m/z 167 could have been due to loss of 
C7H11OF. Additional loss of H2O, HCL and HF resulted with ions m/z 185, 210, 235 
and 245. 
 
3.6.5.2 ACS Repeatability for EFV 
To assess repeatability, 0.5g EFV tablet powder was placed inside each of 6 tin cans 
and each can heated.  All heating temperatures were based on the literature 
relating to pyrolysis and combustion of a cigarette (section 3.4.2) as this is a 
common form of how the material is consumed. The boiling and flash points (340OC 
and 159.8OC respectively) of EFV were also taken into consideration. Each tin can 
contained 6 ACS strips suspended within the tin giving a total of n=36 strips to 
assess the within can repeatability of the pyrolysis generation and extraction 
process.  
Can 1 was heated to 175OC, can 2 to 353OC, can 3 at 355 OC, can 4 at 3740C while 
can 5 and 6 were at 378OC and 386OC respectively. Each ACS strip within each can 
was removed, placed into a clean GC-MS sample vial and extracted by adding 0.5mL 
of the pentane. Six replicate injections were performed for each desorbing solution 
for each ACS strip. The peak areas and %RSDs were calculated across the six 
injections for each strip demonstrating excellent within tin repeatability for the 
production and extraction of the pyrolysis product and are presented in table 3.18 
and figures 3.14 and 3.15.   
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Table 3.18 EFV pyrolysis product peak area vs pyrolysis temperature 
 
ACS 
strip 
 
Pyrolysis temperatures and average peak areas for each 
175
O
C 353
O
C 355
O
C 374
O
C 378
O
C 386
O
C 
1 7124520 1492438981 1423165240 958400994 883354598 2278462 
2 7533409 1484723831 1434838802 958400994 883502169 2203772 
3 7009784 1449681288 1491337756 958400994 888739443 2209059 
4 7192589 1472867832 1445515087 958400994 894182859 2243810 
5 7029019 1430724088 1483872522 959423895 889595852 2141265 
6 7244520 1430724080 1473872522 959423895 88959852 2141265 
average 7177864 1466087204 1455745881 958605574 888161796 2215274 
SD 212061 25531456 30253771 457455 4556681 51126 
%RSD 2.95 1.74 2.08 0.05 0.51 2.31 
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Figure 3.14 Plot of EFV pyrolysis temperature vs EFV pyrolysis product peak area. 
 
 
 
Figure 3.15 Expanded plot of EFV pyrolysis temperature vs pyrolysis product amount 
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The results obtained suggest that the largest peak areas representing the highest 
concentration of pyrolysis product were obtained between 3530C and 355OC. 
Heating either below or above these temperatures led, either to poor generation of 
the pyrolysis product or to degradation of the pyrolysis product.  Based on these 
findings, it was decided that EFV samples and all other samples containing EFV 
would be heated between 3530C and 355OC.  
 
3.7 Adaptation of GCMS method for the analysis of EFV 
The use of pentane as a desorbing agent for ACS was abandoned, because  while it 
worked very well for the desorption of EFV on its own, it was not successful when 
used for other thermal decomposition products of drugs combined with EFV which 
would be expected to be encountered within the nyaope mixture.  Pentane was 
initially the preferred solvent out of a number of those available for ACS desorption 
in the literature; because of its better desorption efficiency (meaning the ability to 
extract different classes of samples) and also that it is relatively safe to work with in 
the laboratory.   Massey et al [98] 33, suggested that dichloromethane (DCM) was 
also an excellent solvent for ACS desorption, with high adsorption efficiency, 
particularly for alcohols and ketones which are commonly present in some illicit 
drug compounds [98].  
Ultimately a combination of MeOH:DCM was required to ensure full sample 
desorption and two ratios were chosen (MeOH:DCM; 90:10 and 50:50) for further 
evaluation for GCMS analysis. A mini GCMS validation of both solvents was carried 
out to establish linearity, product stability, recovery, LOD and LOQ for each of the 
desorption solvent. 
3.7.1 GCMS mini validation for EFV using MeOH: DCM 90:10 solvent 
Five calibration standard solutions of 100 – 500µg/mL were prepared in the same 
manner as previously described. Three replicate injections of each solution were 
performed. Data obtained from these (Table 3.19) was subjected to regression 
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analysis using the least squares method to draw a calibration curve (figure 3.16). 
Correlation coefficient (R2) of efavirenz was found to be 0.992.  
 
Table 3.19 GCMS calibration data for EFV in MeOH-DCM 90:10  
 
 
 
 
 
 
 
Figure 3.16 GC-MS calibration data of EFV for 90:10 MeOH-DCM  
 
Calculated %RSD values for linearity concentrations (table 3.18) ranged between 
0.4-2.5% confirming that the method was linear between the concentrations of 
100-500µg/mL. LOD and LOQ were found to be 44µg/mL and 133µg/mL 
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Calibration curve for EFV 90:10 (MeOH:DCM)   
Replicate 100µg/mL 200µg/mL 300µg/mL 400µg/mL 500µg/mL 
1 5760354 16539579 32270348 47717734 64273757 
2 5983685 16639589 31842348 47919989 64069912 
3 5832825 16949576 31019867 47525841 67019434 
Mean 5858955 16709581 31710854 47721188 65121034 
SD 113935.3 213772.3 635526.3 197096.7 1647219 
%RSD 1.94 1.28 2.00 0.41 2.53 
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respectively. Accuracy of the method was found to be 99 ± 6 % while the 
percentage analyte recovery was between 88- 106% (table 3.20 and 3.21). 
 
Table 3.20 Percentage recoveries, LOD and LOQ for extractions in MeOH-DCM 90:10  
Actual conc. 
(µg/mL) Peak area 
Calculated 
concentration 
(µg/mL)   
Calculated  % 
recovery 
100 5760354 105 105 
100 5983685 107 107 
100 5832825 106 105 
200 16539579 177 89 
200 16639589 178 89 
200 16949576 180 90 
300 32270348 283 94 
300 31842348 280 93 
300 31019867 274 91 
400 47717734 386 96 
400 47919989 387 97 
400 47525841 385 96 
500 64273757 497 99 
500 64069912 495 99 
500 67019434 515 103 
  
mean recovery 97 
  
SD 6 
  
LOD 44 
  
LOQ 134 
 
Table 3.21 %RSD for analyte recovery extracted in MeOH-DCM 90:10  
% analyte 
recovery 
 
 
CONC.(µg/mL) 
 
100 200 300 400 500 
105 89 94 96 99 
107 89 93 94 99 
106 90 91 96 103 
Mean 106 89 93 97 100 
SD 0.76 0.71 1.42 0.33 2.20 
%RSD 0.7 0.8 1.5 0.3 2 
 
 
100 
 
3.7.2 Analyte stability for MeOH:DCM 90:10  
Samples for establishing stability were prepared like described earlier using EFV 
reference material of 100 and 300µg/mL concentrations. Injections were also 
performed in duplicates and daily mean peak areas at each concentration and are 
presented in Tables 3.22, 3.23 and figures 3.17a and b. Relative standard deviations 
for each concentration were also calculated. This experiment was performed for 
only 5 days because the calculated daily %RSD for samples stored at room 
temperature (table 3.21 and 3.22) remained within the set limit of ≤ 5 for only that 
period.  
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Table 3.22 %RSD results analyte stability at room temperature over five days 
Standard 
solution 
concentration 
 
 Average peak area (n=2) 
 
Day 1 Day 2 Day 3 Day 4 Day 5 Mean SD %RSD 
200µg/mL 
 
5206062 4809994 4711489 4684408 4654389 4813268 227213.5 5 
300µg/ml 
 
31840365 31738377 30133259 30410831 28917854 30608137 1216277 4 
 
 
Table 3.23 %RSD results for analyte stability in the fridge over five days 
Standard 
solution 
concentration 
 
 Average peak area (n=2) 
 
Day 1 Day 2 Day 3 Day 4 Day 5 Mean SD %RSD 
200µg/mL 
 
5206061 5192987 4997791 4985532 4981497 5072774 115954.4 2 
300µg/mL 
 
35691125 34459171 33398453 33953559 32834294 34184537 1032199 3 
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*Key: green = 300µg/mL, blue = 100µg/mL 
 
 
Figure 3.17 Plot of EFV stability at (a) room temperature and (b) fridge samples for different 
concentrations (100 and 300µg/mL) in MeOH-DCM 90:10 v/v 
*Key: red = 100µg/mL, blue = 300µg/mL 
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3.7.3  Establishing GCMS linearity using MeOH:DCM 50:50 v/v solvent 
Five calibration standard solutions of 100 – 500µg/mL were prepared in the same 
manner as previously described. Three replicate injections of each solution were 
performed. Data obtained from these (table 3.24) were subjected to regression 
analysis using the least squares method to draw a calibration curve (figure 3.18). 
The correlation coefficient (R2) of efavirenz was found to be 0.99. Calculated %RSD 
values for linearity testing were between 0.4 -3%. The analytical range at which the 
method was linear was between 100-500µg/mL. LOD and LOQ were found to be 95 
and 107µg/mL respectively. Obtained analyte percentage recoveries were between 
95 -107µg/mL and are presented in Table 3.25.  
 
Table 3.24 %RSD results for HPLC calibration using the MeOH-DCM 50:50 
 
 
 
 
 
 
Table 3.25 %RSD for percentage recoveries using MeOH-DCM 50:50  
Replicate 100µg/mL 200µg/mL 300µg/mL 400µg/mL 500µg/mL 
1 7277336 25939117 44800749 64206227 82090428 
2 7275648 25638198 42772571 64857321 82425991 
3 7212933 24926501 44924472 60844263 82722333 
Mean 7255306 25501272 44165931 63302604 82412917 
SD 36705.51 520009 1208270 2153732 316155.3 
%RSD 1 2 3 3 0.4 
 
% found 
recovery 
 
 
Concentration (µg/mL) 
 
100 200 300 400 500 
96 101 99 99 98 
96 99 103 102 99 
95 107 99 102 100 
Total 287 307 301 302 298 
mean 95.66 102.19 100.18 101 99.25 
SD 0.50 4.63 2.42 1.28 0.87 
%RSD 0.5 5 2 1 1 
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Figure 3.18 EFV calibration curve using 50:50 MeOH-DCM v/v 
 
3.7.4 Analyte stability for the MeOH-DCM 50:50 solvent 
In order to be consistent with the stability experiment for the other solvent, this 
experiment was also performed across 5 days; however the test was stopped after 
only 4 days for room temperature samples because the analyte stability proved to 
be very unstable. Samples for establishing stability were prepared as previously 
described using EFV reference material. Injections were performed in triplicate. 
Daily mean peak areas at each concentration were calculated and used to generate 
graphs of peak area vs number of days (figure 3.19a and b). Relative standard 
deviations for each concentration were calculated. Calculated %RSD for samples 
kept in the fridge (table 3.26 were found to be within the acceptable range of ≤ 5 
while those at room temperature (table 3.27) were outside the acceptable level. 
Following this, %RSD values for samples stored at room temperature were 
recalculated for the first two days (table 3.28), and were found to be within the ≤ 
5%.   
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Table 3.26  %RSD results for analyte stability test at room temperature over five days 
Standard 
solution 
concentration 
 
 Average peak area (n=2) 
 
Day 1 Day 2 Day 3 Day 4 Day 5 Mean SD %RSD 
200µg/mL 
 
27602172 273121064 26897992 26735798 26728859 27132502 397497.7 1 
300µg/mL 
 
47454950 471953328 45937491 43633490 43020113 45592103 1800933 3 
 
 
Table 3.27 %RSD results for analyte stability for fridge samples over five days 
Standard 
solution 
concentration 
 
Average peak area (n=2) 
 
Day 1 Day 2 Day 3 Day 4 Mean SD %RSD 
200µg/mL 
 
48549452 46113476 37930360 35598256 42047886 6254362 15 
300µg/mL 
 
53613194 51289760 36409333 29881667 42798489 11499640 27 
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Figure 3.19 Plot of EFV stability at a) room temperature and b) fridge samples for different 
concentrations (200 and 300µg/mL) in MeOH-DCM 50:50 v/v 
*Key: red = 300µg/mL, blue = 200µg/mL 
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Table 3.28 %RSD results for analyte stability for first two days at room temperature extracted in 
MeOH-DCM 50:50 
Day 200 µg/mL 300  µg/mL 
1 48549452 53613194 
2 46113476 51289760 
mean 47331464 52451477 
SD 1722495 1642916 
%RSD 4 3 
 
 
3.8   Determination of HPLC repeatability for the ACS method. 
Six replicate injections were performed for each extracted strip; mean peak areas 
and %RSDs were calculated across the six injections for each strip. The repeatability 
of each ACS sample set (within each tin can) was demonstrated excellently by 
within tin repeatability, as confirmed by the %RSD results (table 3.28). 
 
Table 3.29 %RDS results for inter-can analytical repeatability 
Replicate Mean peak area can 1 Mean peak area can 2 
1 97.22958 153.71959 
2 98.33775 158.543 
3 98.8492 156.81042 
4 101.04742 159.88846 
5 99.75414 161.09944 
6 97.43099 159.73824 
Mean 99 158 
SD 1.45 2.67 
%RSD 1 1 
 
3.8.1 Establishing the HPLC linearity using 90:10 solvents 
Five calibration standard solutions of 100 – 500µg/mL EFV were prepared in the 
same manner as previously described. Three replicate injections of each solution 
were performed. Data obtained from these (table 3.29) were subjected to 
regression analysis using the least squares method to draw a calibration curve 
(figure 3.20). The correlation coefficient (R2) of efavirenz was found to be 0.99. 
Calculated %RSD values for linearity test were found to be between 0.1 -2.8.  
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The method is linear between the ranges of 100-500µg/mL. LOD and LOQ were 
found to be 9 and 28µg/mL respectively. Obtained analyte percentage recoveries 
were between 98 -105µg/mL (table 3.30 and 3.31). 
 
Table 3.29 %RSD for HPLC calibration using the MeOH-DCM 90:10 v/v/ solvent 
Replicate 100µg/mL 200µg/mL 300µg/mL 400µg/mL 500µg/mL 
1 2028 3899 5800 7749 9753 
2 2045 3899 5808 7756 9741 
3 2131 4002 5812 7797 9672 
Mean 2067.88 3934 5807 7768 9722 
SD 55.0247 59.414 5.810 25.92 43.91 
%RSD 3 2 0.1 0.3 0.5 
 
 
 
Figure 3.20 HPLC calibration curve for EFV in MeOH-DCM 90:10  
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Table 3.30 HPLC results for percentage recoveries, LOD and LOQ in the MeOH-DCM 90:10  
Actual 
concentration(µg/mL) Peak area 
Calculated 
concentration 
(µg/mL) %Recovery 
100 2027.7 100 100 
100 2045.4 101 101 
100 2130.6 105 105 
200 3899.4 196 99 
200 3899.4 198 99 
200 4002.3 203 101 
300 5800.3 297 99 
300 5811.7 297 99 
300 5807.9 297 99 
400 7749.4 399 100 
400 7756.4 399 100 
400 7797.4 401 100 
500 9753.5 503 101 
500 9742.0 503 101 
500 9672.3 499 100 
  
 
Mean  100 
  
SD 1.60 
  
LOD 8.9 
  
LOQ 27.9 
 
 
Table 3.31 %RSD results for recovery studies of the MeOH-DCM 90:10 
Found conc. 
Replicate 
 
 
Concentration (µg/mL) 
100 200 300 400 500 
1 100 99 99 100 101 
2 101 99 99 100 101 
3 105 101 99 100 100 
Mean 102 100 99 100 100 
SD 2.87 1.55 0.10 0.34 0.46 
%RSD 3 2 0.1 0.3 0.5 
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3.8.2 Establishing the HPLC linearity using MeOH:DCM 50:50 solvent 
Five calibration standard solutions of 100 – 500µg/mL were prepared as previously 
described. Upon inspection of the chromatograms, it was observed that use of the 
50:50 (MeOH:DCM) solvent caused EFV to decompose. A double peak was observed 
at 8.973 and 9.4915 minutes in all samples (figure 3.21). This was not the case when 
using the 90:10 MeOH:DCM mixture or the mobile phase.   
 
 
 
Figure 3.21 Chromatogram of 100 µg/mL EFV in 50:50 MeOH-DCM 
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A summary of ACS method validation results for both techniques is presented in 
table 3.32 below 
 
Table 3.32 Summary of validation results for the GCMS and HPLC ACS method  
Parameter GCMS MeOH-DCM 
90:10 
HPLC  MeOH-
DCM 90:10 
GCMS  MeOH-
DCM 50:50 
Linearity 100 -  500µg/mL 100 -  500µg/mL 100 -  500µg/mL 
Cor.co-efficient 0.99 0.99 0.99 
Precision 
(%RSD):repeatability 
0.4-3% 0.1-3% 0.4-3% 
Selectivity (%RSD) 
Laboratory test mix 
1-2% 1±0.2% 1-2% 
Method accuracy 99±6% 100±2% 99±1% 
LOD 44µg/mL 8.9µg/mL 95µg/mL 
LOQ  133µg/mL 28µg/mL 107µg/mL 
Analyte stability (% srd): 
 Fridge  (5 days) 
Room temp. (2 days) 
 
2-3% 
4-5% 
 
n/a 
n/a 
 
1-3% 
3-4% 
 
The various conditions tested for the GCMS and HPLC detection of the target 
analytes in both solvents demonstrated validity of the method 
 
3.9 Conclusions. 
A validated approach to the generation of pyrolysis products of the target analyte, 
efavirenz, and its analysis by both GCMS and HPLC was undertaken.  As a result of 
this, the analytical methodology and workflows for the analysis of the simulated 
nyaope mixture involving EFV and a variety of target illicit drugs were structured 
and are presented in figure 3.22. 
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Figure 3.22 Solvent strategies for the extraction of pyrolysis products of EFV and other drug 
mixtures 
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CHAPTER 4:  EFFECTS OF EFAVIRENZ ON THE SYNTHETIC DRUGS ALLEDGEDLY 
USED IN THE NYAOPE MIXTURE. 
 
4.1 Introduction 
As previously discussed, the South African street drug nyaope, is allegedly made of 
a cocktail of many illegal substances ranging from heroin, cannabis, 
methamphetamine, opium to pain killers, where in each case the material also 
includes anti-retroviral drugs. The anti-retro viral drug, efavirenz, is believed to be 
the main ingredient in each case as it is thought to prolong the effects of other 
narcotic drugs in the mixture. The tablets are reportedly crushed into the mixture 
for smoking. There are various ways of smoking the nyaope; some people prefer to 
prepare joints while others prefer inhaling its vapours after heating over a flame on 
a piece of aluminium foil. The latter is a replica of a method developed in the 1950’s 
by heroin smokers known as chasing the dragon [164]. 
In this chapter, the pyrolysis products of EFV in its mixture with methamphetamine, 
amphetamine and heroin were investigated. The experiment was carried out by 
first heating each drug on its own followed by heating a mixture of each with EFV 
and comparing the two analytical results. All pyrolysis products were trapped with 
activated carbon strips and analysed using both the GCMS and HPLC.  
The reasons for the presence of impurities in illicit drugs which are clandestinely 
manufactured vary; impurities may be generated as by-product during drug 
manufacture, they may already be present in starting materials, reagents and/or 
solvents and may be carried over unchanged  to the final product; or they may arise 
from reactions of original impurities in starting materials [165]. The relative amount 
of impurities in methamphetamine for instance, may show large variations, 
attributed to the exact nature of the starting materials, the synthetic route, actual 
manufacturing conditions used by the ‘cook’, the cutting agent added, storage 
conditions and methods of distribution [165]. Route specific impurities are those 
which, when present in an illicit substance, indicate the use of a specific synthetic 
pathway [165].  Studies of pyrolysis products of different drugs including 
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methamphetamine, amphetamine, heroin, opium and cannabis, exist [71, 81-87]. 
According to these studies, the word ‘pyrolysis products’ can mean either: 
(i) Impurities arising from synthetic pathways or from elsewhere (chemicals or 
other sources), for example benzaldehye and phenyl-2-propanone as 
starting materials for amphetamine type stimulant drugs.  
(ii)  Main pyrolysis products. These may arise from the breakdown of the parent 
drug or breakdown of intermediate products from synthetic routes and are 
usually used to determine the synthetic methods/routes applied during the 
manufacturing, for example acetyl-morphine for heroin or N-
formylmethamphetamine as intermediate product of methamphetamine 
synthesis.  
Similar pyrolysis products were obtained during this study and a similar strategy 
was applied.  
 
4.2. Experimental   
4.2.1 Chemicals and reagents 
Efavirenz (600mg) tablets were kindly supplied by the Princess Marina Hospital in 
Botswana. These were obtained from the supplies bought by the Botswana 
government for the Anti-retroviral therapy (ART) programme. The same type of EFV 
is also used by the South African government. Methamphetamine samples were in-
house samples synthesised for research purposes. Opium, heroin and cannabis 
resin samples were available from completed forensic case samples. Acetonitrile 
(ACN), methanol (MeOH) and deionised water (all HPLC supra-gradient) were also 
purchased from VWR International LTD (Lutterworth, Leicestershire UK).  Potassium 
hydroxide (KOH), Disodium hydrogen phosphate dodecahydrate (Na2HPO.12H2O) 
and Potassium phosphate monobasic (KH2PO4) were all purchased from Sigma 
Aldrich (Gillingham, Dorset, UK). Dichloromethane (DCM) and methanol were 
analytical grade reagents and purchased from VWR International LTD (Lutterworth, 
Leicestershire UK).  The pH meter calibration standards of pH 4 and 7 were 
purchased from Mettler Toledo, Switzerland. HPLC reference materials were 
purchased from Sigma Aldrich (Gillingham, Dorset, UK).  
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4.2.2 Instrumentation/Techniques 
4.2.2.1 Pyrolysis procedure 
All samples were heated using the apparatus described by Agu [163]. It consisted of  
a Picolog data logger and software (Pico Technology Ltd, Eaton Socon, United 
Kingdom), activated carbon strips (3M, United Kingdom), stainless steel paper clips 
and small round magnets (Amazon online), tin cans and lids (VWR Products, United 
Kingdom). The Sony laptop and hot plate were property of Dundee University.  All 
individual drugs except EFV were heated at three different temperatures of 315OC, 
354OC and 398OC. Samples in mixtures with EFV were heated to 354OC. The 
pyrolysis products were trapped using activated carbon strips. To ensure that the 
strips remained suspended above the sample headspace, they were first secured 
into a paper clip, put inside the tin can lid and a small magnet placed on top of the 
lid to hold them in place (figure 4.1).  
 
 
Figure 4.1 Presentation of a prepared tin can lid with the suspended ACS 
 
Heating temperatures were monitored and recorded using the picolog data 
recorder  
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4.2.2.2 Pyrolysis product extraction procedure and ACS sampling strategy 
For analysis with the GCMS, one strip (out of the four in a can) was extracted using 
0.5mL methanol-dichloromethane (MeOH/DCM) 90:10 v/v and the other with 
0.5mL MeOH/DCM 50:50v/v. The remaining two strips were analysed with the HPLC 
where one was extracted with the mobile phase and the other with 0.5mL 
MeOH/DCM (90:10 v/v). Six replicate injections were performed for each extract 
using each analytical instrument. Figure 4.2 summarises the sampling strategy.  
.  
 
Figure 4.2 Overall ACS sampling strategy for each technique 
 
4.2.2.3 GCMS conditions 
Pyrolysis products were identified using an Agilent 7820A gas chromatograph 
interfaced with an Agilent 5977E mass selective detector, operated under 
conditions described in Chapter 3.1.2. Compounds were identified using both the 
NIST 2014 mass spectrum database and data from gathered literature. 
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4.2.2.4. HPLC conditions 
An Agilent HPLC 1200 series (Waldbronn, Germany) equipped with a degasser, 
binary pump, an auto sampler, column oven and diode array detector (DAD) was 
used for the analysis of all samples. Operating conditions and settings for the HPLC 
were set as described earlier in Chapter 3.2.3. The mobile phase was prepared and 
the pH adjusted as discussed in Chapter 3.2.4.  
 
 4.3 Isolation of pyrolysis products of EFV and analysis with GCMS 
Six replicate EFV samples were prepared following the protocol described in 
chapters 4.2.2.1 where EFV tablets (600mg) were first homogenised by crushing 
them into fine powder using a mortar and pestle. 0.5g of the tablet powder was 
then weighed into 6 separate tin cans, heated and pyrolysis products extracted and 
trapped using four ACS in each tin can.  Following this, the analysis sampling 
strategy in Chapter 4.2.2.2 was applied where one of the four ACS strips was 
extracted with MeOH-DCM 90:10 and the second one with MeOH-DCM 50:50.  
 
4.3.1 Results and discussions 
Only one EFV pyrolysis product (figure 4.3) was revealed in all analysed samples.  
The product was detected at 11.09 minutes and presented a fragmentation pattern 
with main four molecular ions of m/z 270, 201, 167, 245 and 235. The product was 
labelled as EFV pyrolysis product 1. The results were verified against those obtained 
from the EFV standard sample during the GCMS method validation. 
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Figure 4.3 Chromatogram for EFV pyrolysis product 1 
 
 
 
Figure 4.4 Mass spectrum of EFV pyrolysis product1 
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The mass spectrum of the pyrolysis product was compared with that of EFV and it 
was confirmed that only one molecular ion (m/z 167) was common to both.  A 
superimposed image of both spectra is shown in figure 4.5 and a proposed 
structure of EFV pyrolysis product 1 presented in figure 4.6. 
 
 
 
Figure 4.5 Superimposed mass spectral images of (a) EFV (b) EFV pyrolysis product 1 
 
4.4 Isolation of pyrolysis products of EFV and analysis with the HPLC  
EFV samples used for the HPLC analysis were the two remaining ACS strips from the 
four prepared earlier in section 4.3. As per the project sampling strategy in section 
4.2.2.2, one strip was extracted with the MeOH-DCM 90:10 while the other with 
the mobile phase. Negative control samples were prepared by running fresh ACS 
through the same sample preparation and analysis procedure. Reference materials 
were also analysed in the mobile phase and the MeO:DCM 90:10. 
 
4.4.1 Results and Discussions 
4.4.1.1 Results obtained from the pyrolysis of fresh ACS samples 
The results obtained from the pyrolysis of fresh ACS (figure 4.7a and b) showed the 
presence of one product in each solvent; these were detected at 0.792 and 0.742 
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minutes for the mobile phase and MeOH:DCM 90:10 respectively. Analysis of both 
solvents also did not reveal the presence of any pyrolysis product, and as such the 
two products observed were considered to be artefacts from the activated carbon 
strips.  
 
  
Figure 4.7 HPLC results showing ACS artefacts observed in the ( a) mobile and  (b) MeOH:DCM 
90:10 
 
4.4.1.2 Results for the analysis of pyrolysis of EFV using the HPLC 
The results obtained (figure 4.8 (a) for extraction of the analyte using the mobile 
phase and 4.8 (b) for extraction of the analyte using MeOH-DCM 90:10 v/v) 
revealed the presence of only EFV and its pyrolysis product 1. The pyrolysis product 
was detected at 1.431 minutes in the mobile phase and at 1.423 minutes using the 
MeOH-DCM 9010 v/v.  These results were verified against those obtained from the 
EFV standard sample during the HPLC method validation (table 4.1) 
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Table 4.1 Results for the HPLC reference materials in the mobile phase and MeOH:DCM 90:10 
Reference material Retention time (minutes)  
with  mobile phase 
Retention time (minutes) 
with  MeOH:DCM  90:10 
Benzaldehyde 
Allylbenzene 
1,2 Dimethyl -3-
phenylaziridine,trans 
P2P 
Methamphetamine 
di-methyl amphetamine 
N-formyl methamphetamine 
N-acetylamphetamine 
1.26 
1.60 
2.39 
2.45 
3.26 
3.81 
11.46 
11.74 
11.92 
1.67 
2.40 
2.52 
3.38 
3.97 
12.29 
12.61 
12.02 
Morphine 
Meconin 
Noscapine 
Papaverine 
Codeine 
Thebaine 
1.35 
1.72 
2.85 
8.45 
2.29 
5.82 
1.40 
1.91 
2.75 
7.90 
2.98 
4.80 
Cannabinol 
Cannabidiol 
 
 
5.43 
3.28 
5.43 
3.28 
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Figure 4.8 HPLC chromatogram for the pyrolysis of EFV in (a) the mobile phase and (b) MeOH-DCM 
90:10 
 
4.5 Isolation of pyrolysis products of methamphetamine and analysis with the 
GCMS 
4.5.1 Sample preparation 
Six replicate methamphetamine samples were prepared following the protocol 
described in section 4.2.2.1.  Methamphetamines were sourced in-house from 
samples previously prepared under known synthetic conditions. A mixed 
methamphetamine sample containing samples from more than one synthetic 
method was used to better simulate real life conditions.  In this case samples 
prepared using the Leuckart, Emde] and Nagai synthetic routes [166-176] were 
within the mixed sample. 
 
The methamphetamine samples were first homogenised by crushing them into fine 
powder using a mortar and pestle. 0.5g of the powdered material was weighed into 
6 separate into tin cans. Each tin can was covered with a lid, heated to the desired 
temperature and removed from the hot plate. The covering lid was replaced with 
the one with prepared CAS strips (section 4.2.2.1) and incubated for 16 hours at 
800C to trap the pyrolysis products. The products were trapped using four ACS in 
each of the six tin cans.  Following this, the analysis sampling strategy in section 
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4.2.2.2 was applied.  For GCMS analysis one of the four ACS strips was extracted 
with MeOH-DCM 90:10 and the other with MeOH-DCM 50:50.  
 
4.5.2 Results and discussions 
Results obtained from samples extracted with the two different solvents ratios are 
displayed in table 4.2. Typical chromatograms for pyrolysis products obtained from 
the pyrolysis of methamphetamine at 3540C (extracted using MeOH-DCM 90:10 and 
MeOH-DCM 50:50) is displayed in figure 4.9 and 4.10. Detected pyrolysis products 
in both cases have been reported as impurities from various chemicals and 
reactions used during the synthesis of methamphetamine [168, 169], and, given 
their survival of the pyrolysis process have the potential to be used to assist in the 
determination of methamphetamine synthetic routes. Four main pyrolysis products 
of methamphetamine are displayed in figure 4.11. 
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Table 4.2 Pyrolysis products of methamphetamine extracted with the two MeOH-DCM solvent ratios at 3 different temperatures 
 
 
ACS 
extracting solvent 
 
 
 
Pyrolysis Temperature (0C) 
315 354 396 
MeOH:DCM 50:50 
 
 
 
 
 
 
 
 
 
N-Formylmethamphetamine 
N-Methylbenzamide 
trans 1,2 Dimethyl -3-phenylaziridine 
Allybenzene 
Benzaldehyde 
 
N-Formylmethamphitamine 
N-Methylbenzamide 
 norephedrine 
Deoxyephedrine 
1-Phenyl-1-Propane 
Trans 1,2-dimethyl-3-phenyl 
Aziridine 
1-propenyl benzene 
Benzaldehyde 
N-Formylmethamphitamine 
norephedrine 
Methoxyphenamine 
1-Phenyl-2-Propanone 
trans 1,2-dimethyl-3-phenyl Aziridine  
1-propenyl- benzene 
Cyclopropyl-benzene 
Benzaldehyde 
MeOH:DCM 90:10 
 
N-Methylbenzamide 
trans 1,2 Dimethyl -3-phenylaziridine 
Methamphetamine 
Amphetamine 
Cyclopropylbenzene 
Benzoic acid 
Allylbenzene 
Benzaldehyde 
Ephedrine 
N-acetylmethamphetamine 
di-methylamphetamine 
N-methylamphetamine 
 Methamphetamine 
1-Phenyl-2-Propanone 
1-Propenylbenzene 
Benzaldehyde 
cyclopropylbenzene 
N-acetylmethamphetamine 
di-methylamphetamine 
N-acetylmethamphetamine 
Ephedrine 
Deoxyephedrine 
Ethyl phenyl ketone 
Trans 1,2-dimethyl-3-phenyl Aziridine   
1-Propenylbenzene 
Benzaldehyde 
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Figure 4.8 Chromatogram for pyrolysis products of methamphetamine extracted in MeOH-DCM 90:10 at 354
0
C 
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Figure 4.10 Chromatogram for the pyrolysis products of methamphetamine extracted in MeOH-DCM 50:50 at 3540C  
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 (a)    (b)  
 
(c)   (d)  
Figure 4.11 Chemical structures and mass spectra of four main pyrolysis products of methamphetamine (a) N-formylmethamphetamine (b) N-acetylmethamphetamine 
(c) dimethyl methamphetamine (d) methamphetamine 
128 
 
4.5.3 Evaluation of the method repeatability for pyrolysis products of 
methamphetamine 
The repeatability of the method for the production of pyrolysis products of 
methamphetamine was evaluated to determine the analytical repeatability for 
desorbed samples. This was performed in two steps; the first was involved with the 
establishment of repeatability of results within one sampling tin (within-can 
repeatability) and the second was for the repeatability  between the 6 six tin  cans.  
 
4.5.3.1 General procedure for the evaluation of the method repeatability for 
pyrolysis products of nyaope street drug. 
Six replicate samples of the drug were prepared by weighing 0.5g of the powder 
material into six different tin cans and each sample pyrolysed. Each tin can 
contained 6 ACS strips. Overlays of chromatographic profiles of detected pyrolysis 
products were plotted and compared for retention time, peak shape, peak height as 
well as any differences in overall chemical profile. %RSD of peak areas for pyrolysis 
products from each tin can were calculated and used to represent analytical 
repeatability of products within each can (within-can repeatability). Analytical 
reproducibility was calculated using %RSD for average peak areas (n=6) of pyrolysis 
products detected within each can compared across all 6 tin cans to generate the 
between can reproducibility (n=36). 
 
4.5.4 Results and Discussions 
Typical chromatographic profiles of the detected pyrolysis products obtained from 
the 6 injections in  tin can 1, (extracted using both MeOH-DCM 90:10 and MeOH-
DCM 50:50 solvents at 3540C) are displayed in figures 4.12 and 4.13.  They all show 
similar retention times, similar pyrolysis products and quantities as well as a large 
methamphetamine peak at 5.922 minutes. Table 4.3 and table 4.4 show calculated 
%RSDs for tin can 1 using MeOH-DCM 90:10 and MeOH-DCM 50:50 respectively. 
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Calculated %RSD for the analysis ranged between 0.8-5%, indicating excellent 
repeatability.  
Chromatographic profiles of pyrolysis products generated across the six different 
tin cans were also compared. This was followed by the calculation of %RSDs across 
these samples.  Figure 4.14 shows chromatographic profiles of methamphetamine 
pyrolysis products generated at different temperatures for the MeOH-DCM 50:50.  
Profiles revealed similar retention times but calculated %RSD values (table 4.5 and 
4.6) were all ≥5%, indicating that repeatability was considerably more challenging. 
Plots of pyrolysis product versus product peak area (appendix 1; figures 4.15 and 
4.16) for methamphetamine pyrolysis products also revealed variations in product 
quantities.  This is not unreasonable given the nature of the pyrolysis event and 
that some variation would be expected to occur.  The data is analogous to other 
between sample extraction data for synthetic drugs (for example extractions for 
different drug samples [177]. 
 
Chromatographic profiles from both solvents extracts revealed a large 
methamphetamine at 5.22 minutes; a tentative explanation for the existence of the 
peak was that the methamphetamine might have undergone decomposition in the 
injection port of the GCMS where temperatures (2800C) were much higher that it’s 
melting point of 1700C.  
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Figure 4.12 Overlay of chromatographic profile of pyrolysis products of methamphetamine extracted in MeOH-DCM 50:50 at 354
0
C, showing highlighted methamphetamine peak  
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Figure 4.13 Overlay of chromatographic profile of pyrolysis products of methamphetamine extracted in MeOH-DCM 90:10 at 354
0
C, also showing the methamphetamine peak 
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Figure 4.14 Overlay of chromatographic profile of pyrolysis products of methamphetamine extracted in MeOH-DCM 50:50 at different temperatures 
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Table 4.3 %RSD results for pyrolysis products of methamphetamine for within-can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1  
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average stdev %RSD 
 
 
Benzaldehyde 5935732 5905670 5808374 5945662 5976632 5953273 5920891 59801.78 1.0 
 
Cyclo propyl benzene 187202 187667 179201 192113 186632 186421 186539 4162.94 2.2 
 
Benzyl methyl ketone 2438910 2454461 2499620 2400371 2679335 2388356 2476842 106901 4.3 
 
Phenyl-1,2 propanedione 6015307 6002503 5937219 6015307 6321003 6221007 6085391 150035.7 2.4 
 
N,alpha-dimethyl benzeneethanamine 
 
142421300 143257324 152100037 156222871 142654922 139611784 14600000 6542687 4.4 
Benzoin 6015307 6021151 6103208 6000366 6116201 6014287 6045087 50682.62 0.8 
 
N-formylmethamphetamine 
 
19274238 23797551 20357559 18999534 19573560 22887621 21148344 1086695 5.4 
N-acetylmethamphetamine 
 
8595102 9126062 8699452 9003245 7981503 7960622 8727664 425634.1 4.9 
Trans 1,2- phenyl-dimethyl Aziridine 142421300 140539771 138750026 
 
141538382 127755024 142260025 139000000 5613718 4.0 
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Table 4.4 %RSD results for pyrolysis products of methamphetamine for within-can analytical repeatability extracted in MeOH-DCM 90:10 at 3540C 
Pyrolysis product Pyrolysis product average peak area from the six replicate injections in each ACS in tin can 1 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
Benzaldehyde 1050792 1050795 1049115 1050563 1056665 1066672 1054100 6691 1 
Cyclo propyl benzene 65821 64823 65779 68255 65773 66653 66184 1168 2 
1 phenyl 1,2 propanedione 94159 94237 94144 96511 93674 95632 94726 1097 1 
Benzeneethanamine, N, alpha-dimethyl 3356342 3276001 3354212 3610110 3346778 3330089 3378922 117114 3 
Benzoin 362394 364577 357782 362001 359912 365446 362019 2857 1 
N-formylmethamphetamine 81975 81972 79834 81432 79229 82411 81142 1299 2 
N-acetylmethamphetamine 15502 14502 16221 14324 15443 14456 15075 762 5 
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Table 4.5 %RSD results for pyrolysis products of methamphetamine for inter-can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
 
Benzaldehyde 5935732 1365941 10206219 764771 15636920 5591527 6583518 5613780 85 
Cyclo propyl benzene 187202 290689 295616 515748 882807 247752 403302.33 259900.80 64 
Benzyl methyl ketone 2438910 2042030 25448383 14552407 76495875 5631814 21101569.83 28569877.98 135 
Phenyl-1,2 propanedione 6015307 1149236 11607074 22464220 17791319 3523059 10425035.83 8411001.75 81 
N,alpha-dimethyl 
benzeneethanamine 
142421300 22135588 33848492 36081781 25701954 25571440 47626759.17 46746264.30 98 
Benzoin 6015307 370282 5407958 7196611 1137748 2674340 3800374.33 2798132.99 74 
N-formylmethamphetamine 19274238 287069 815823 838411 41867032 4131266 11202306.5 16672809.37 149 
N-acetylmethamphetamine 8595102 149025 80713 377955 6130425 916748 2708328 3700260.68 137 
Trans 1,2- phenyl-dimethyl Aziridine 142421300 6629139 12204525 18005572 19868903 11719515 35141492.33 52770250.46 150 
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Table 4.6 %RSD results for pyrolysis products of methamphetamine of inter-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product peak area 
 
 can1  can2  can3  can 4  can 5  can 6 Average Stdev %RSD 
 
Benzaldehyde 1050792 605269 ND 1564535 991098 ND 1052924 394110 37 
Cyclo propyl benzene 65821 ND ND 138001 ND ND 101911 51039 50 
1 phenyl 1,2 propanedione 94159 178230 23506 266167 ND 30880 118588.4 103280 87 
Benzeneethanamine, N, alpha-dimethyl 3356342 5137359 1778845 759036 497962 457002 1997758 1892539 95 
Benzoin 362394 257226 69615 513619 548879 55895 301271.3 212580 71 
N-formylmethamphetamine 81975 49855 14474 104293 115067 22656 64720 42222 62 
N-acetylmethamphetamine 15502 11348 2299 17148 18313 ND 12922 6498 50 
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4.6 Determination of methamphetamine synthetic routes from detected pyrolysis 
products 
The detection of methamphetamine amongst its pyrolysis products indicates the 
possibility of incomplete hydrolysis or a breakdown product from the intermediate 
product N-Formylmethamphetamine[166]. Other products, Dimethyl 
amphetamine, Acetyl-methamphetamine, amphetamine, N-methylamphetamine 
and N-formylmethamphetamine are main pyrolysis products of methamphetamine 
produced via reactions of N-formylation, N-acetylation and N-demethylation. These 
have been previously reported [178-186].  
 
The detection of benzaldehyde and ally benzene in all samples is indicative of their 
use in the synthesis of 1–phenyl-2-propanone (P2P), a starting material for the 
production of methamphetamine via the Leuckart route [5] (figure 4.17-18). As an 
internationally monitored chemical, P2P has become increasingly difficult for illicit 
amphetamine laboratories to secure, which means alternative routes for its 
manufacture have become increasingly important. New synthetic route impurities 
are therefore highly likely. A variety of P2P manufacturing chemicals in 
methamphetamine samples have been reported [6]. 
 
 
 
Figure 4.17 Methamphetamine synthesis through the Leuckart route [169] 
 
138 
 
 
Figure 4.18 P2P synthesis using benzaldehyde [170] 
 
The reaction between P2P and N-methylformamide produces an intermediate, N-
formylmethamphetamine [170], which was detected in all samples extracted with 
Methanol-dichloromethane 50:50 v/v. Allyl benzene (propenyl benzene) can be 
used as a precursor for the Leuckart methamphetamine synthesis through its 
treatment hydrogen bromide. The reaction produces an intermediate, 1-phenyl-2-
bromopropane, which can be converted to methamphetamine [167,171]. Even 
though this intermediate was not detected, allyl benzene was detected in all 
samples, suggesting that it was used as a starting material for P2P.  
The presence of the methamphetamine isomer suggests the use of ephedrine or 
pseudoephedrine or norephedrine as starting materials via the Emde or Nagai 
routes [172-174] (figure 4.19a and b).  
 
(a)  
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(b)   
Figure 4.19 Methamphetamine synthesis via the two routes of (a) Nagai and (b) Emde 
 
Both (+)-ephedrine and (+)-norephedrine were also detected. The two synthesis 
methods are both associated with the production of aziridine type impurities [170, 
173-175]; trans 1,2 dimethyl-3-phenylaziridine was detected in all samples. Since 
these impurities are common to both methods, their presence cannot be 
considered as being route specific, unless they accompanied by other products 
which are thought to be more specific, for example, dimethyl naphthalene for the 
Nagai route [170, 171]. Only the ephedrine and aziridine type impurities were 
detected in this study. Studies involving the determination of pyrolysis products of 
methamphetamine have been performed in the past; amongst these were some 
which revealed the presence of chemicals from precursor materials, intermediate 
or by-products of chemical reactions used during the synthesis. The types of 
products produced were largely dependent on the synthetic route employed [171-
179]. Some studies even went further to use the detected pyrolysis products to 
discriminate between synthetic routes with common starting materials [174, 180]. 
Based on the results obtained, it was concluded that there is a possibility that the 
methamphetamine samples used for this research were synthesised via the 
Leuckart, Emde or Nagai synthetic routes. Similar pyrolysis products have also been 
reported from methamphetamine samples synthesised via the three synthetic 
routes [165, 181]  
A side by side comparison of commonly encountered pyrolysis products of 
methamphetamine (table 4.7) was performed against detected pyrolysis products 
(table 4.8) to confirm possible synthetic routes for samples used in this research. 
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Table 4.7 Commonly encountered synthetic impurities for three methamphetamine synthetic routes [177]  
 
Emde synthetic route 
 
Nagai synthetic route 
 
Leuckart route 
 
Benzaldehyde 
Cis/trans-1,2 –dimethyl -3-
phenylaziridine 
Dimethylamphetamine 
Ephedrine 
Chloroephedrine 
N-formylamphetamine 
N-acetylmethamphetamine 
Benzylmethamphetamine 
N-benzoylmethamphetamine 
Methylamphetamine dimer 
3,4 Dimethyl-5-
phenyloxazolidine 
 
 
 
 
 
 
 
 
Amphetamine 
Dimethylamphetamine 
N-formylmethamphetamine 
N-formylamphetamine 
N-acetylamphetamine 
Benzylmethamphetamine 
N-benzoylamphetamine 
Benzylmethnaphthalene 
Bibezyl 
Cis/trans-1,2 –dimethyl -3-
phenylaziridine 
N-benzoylmethamphetamine 
Trans/cis-3,5-Dipheny-3-
buten-one 
Dimethylphenylaphthalenel  
Ephedrine 
Chloroephedrine 
 
 
Amphetamine 
Dimethylamphetamine 
N-formylamphetamine 
Dimethylamphetamine 
Bibezyl 
N-acetylmethamphetamine 
N-formylamphetamine 
Dibenzylketone 
Benzylmeththylamphetamine 
trans 3.4-Diphenyl-3-buten-2-
one 
N-benzoylamphetamine 
Benzaldehyde 
1-phenyl-2-propanone 
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Table 4.8 Detected pyrolysis products of methamphetamine matched with three possible 
synthetic routes  
 
 
ACS 
extracting 
solvent 
 
 
 
Pyrolysis Temperature (
0
C) 
315 354 396 
MeOH:DCM 
50:50 
 
 
 
 
 
 
 
 
 
N-
Formylmethamphetamine 
N-Methylbenzylamide 
trans 1,2 Dimethyl -3-
phenylaziridine 
Allybenzene 
Benzaldehyde 
 
N-
Formylmethamphetamine 
N-Methylbenzylamide 
norephedrine 
Deoxyephedrine 
1-Phenyl-1-Propane 
Trans 1,2-dimethyl-3-
phenyl Aziridine 
1-propenyl benzene 
Benzaldehyde 
N-
Formylmethamphetamine 
norephedrine 
Methoxyphenamine 
1-Phenyl-2-Propanone 
trans 1,2-dimethyl-3-
phenyl Aziridine  
1-propenylbenzene 
Cyclopropylbenzene 
Benzaldehyde 
MeOH:DCM 
90:10 
 
N-Methylbenzylamide 
trans 1,2 Dimethyl -3-
phenylaziridine 
Methamphetamine 
Amphetamine 
Cyclopropylbenzene 
Benzoic acid 
Allylbenzene 
Benzaldehyde 
Ephedrine 
N-
acetylmethamphetamine 
Dimethylamphetamine 
N-methylamphetamine 
Methamphetamine 
1-Phenyl-2-Propanone 
1-Propenylbenzene 
Benzaldehyde 
cyclopropylbenzene 
N-
acetylmethamphetamine 
Dimethylamphetamine 
 
Ephedrine 
Deoxyephedrine 
Ethyl phenyl ketone 
Trans 1,2-dimethyl-3-
phenyl Aziridine   
1-Propenylbenzene 
Benzaldehyde 
 
Colour key:  yellow = Leuckart route, green = common to Emde and Nagai routes, blue = common to all three 
synthetic routes 
 
4.7 Isolation of pyrolysis products of EFV and methamphetamine, and analysis 
with the GCMS.  
Six replicate samples of EFV and methamphetamine were prepared by weighing 
0.5g of each drug and mixing the two drugs into 6 separate tin cans. The mixture 
was heated to 3540C and pyrolysis products extracted according to the protocol 
described chapters 4.2.2.1. The products were trapped using four ACS in each of 
the six tin cans.  The analysis sampling strategy in Chapter 4.2.2.2 was applied 
where one of the four ACS strips was extracted with MeOH-DCM 90:10 and the 
other with MeOH-DCM 50:50. Methamphetamine samples were in-house samples 
synthesised for research purposes. 
142 
 
 4.7.1 Results and Discussions 
The results obtained (table 4.9) revealed the presence of benzaldehyde, 
cyclopropylbenzene, 1-phenyl-1,2–propanedione, N, alpha–dimethyl 
benzeneethanamine (methamphetamine), Benzoin, N-formylmethamphetamine, N-
acetyl methamphetamine, EFV pyrolysis product 1 and EFV. Typical 
chromatographic profiles of pyrolysis products obtained from the pyrolysis of the 
mixture with both solvent ratios are displayed in figures 4.20 and 4.21. Detected 
pyrolysis products have been reported as impurities arising from various chemicals 
and intermediate products of reactions used during the synthesis of 
methamphetamine. Similar pyrolysis products have been reported [167, 168] 
 
Table 4.9  Pyrolysis products of EFV and methamphetamine extracted in the two solvents of MeOH-DCM  
 
 
ACS 
extracting solvent 
 
 
Pyrolysis Temperature (
0
C) 
315 354 
 
 
MeOH:DCM 50:50 
 
 
 
 
 
 
 
 
 
Methamphetamine 
N-Formylamphetamine 
N-Acetylamphetamine 
2-furan methanol 
 
Benzaldehyde 
Cyloproyplbenzene 
1-phenyl-1,2,-propanedione 
N-alpha-dimethyl-
benzeneethanamine 
Benzoin 
N-formylmethamphetamie 
N-acetylmethamphetamine 
EFV 
EFV pyrolysis product 1 
MeOH:DCM 90:10 
 
methamphetamine 
1,2-Propanediol, 1 –phenyl 
Benzaldehyde N-
Acetylamphetamine 
N-Formylamphetamine 
2-furan methanol 
 
 
Benzaldehyde 
Cyloproyplbenzene 
1-phenyl-1,2,-propanedione 
N-alpha-dimethyl-
benzeneethanamine 
Benzoin 
N-formylmethamphetamie 
N-acetylmethamphetamine 
EFV 
EFV pyrolysis product 1 
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Figure 4.20 Chromatogram for pyrolysis products of EFV and methamphetamine extracted in MeOH-DCM 50:50 at 354
0
C 
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Figure 4.21 Chromatogram for pyrolysis products of EFV-methamphetamine extracted in MeOH-DCM at 354
0
C  
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4.7.2 Evaluation of method repeatability for EFV and methamphetamine 
The repeatability of the method for the production of pyrolysis products of EFV and 
methamphetamine was evaluated to determine the analytical repeatability for 
desorbed samples. This involved the establishment of analytical repeatability of 
results within one sampling tin (within-can repeatability) and between 6 six tin cans 
(inter-can repeatability). For within-can repeatability, two sets of 6 replicate 
samples were prepared as described previously in section 4.5.6, desorbing the ACS 
using the appropriate solvent. Each resultant extract was analysed six times to 
facilitate the calculation of repeatability within a desorption and analysis event. 
Chromatographic profiles of pyrolysis products generated from each of the six 
replicate injections in each sample can were plotted and compared for similarities 
in retention time, peak shape, peak height as well as any differences in overall 
chemical profile.  
Within-can repeatability was evaluated through %RSDs values calculated from 
average peak areas of pyrolysis products detected from the 6 replicate injections 
performed on each of the 6 strips in each tin can using both solvents and ratios.    
%RSD results for within-can repeatability for each pyrolysis product obtained from 
the 6 cans were compiled (average peak areas of pyrolysis products detected from 
the 6 injections in each of the 6 tin cans (n=36); their %RSDs values calculated and 
used to establish repeatability.   
 
4.7.2.1 Repeatability results 
Typical chromatographic profiles of the detected pyrolysis products obtained from 
the 6 injections in  tin can 1, (extracted using both MeOH-DCM 90:10 and MeOH-
DCM 50:50 solvents at 3540C) are displayed in figures 4.22 and 4.23.  They all show 
similar retention times, similar pyrolysis products and quantities.  Table 4.10 and 
table 4.11 show calculated %RSDs for tin can 1 using MeOH-DCM 90:10 and MeOH-
DCM 50:50 respectively. Calculated %RSDs for the analysis was all ≤5%, indicating 
excellent repeatability.  
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Chromatographic profiles of pyrolysis products generated across the six different 
tin cans were also compared. This was followed by the calculation of %RSDs across 
these samples.  Figure 4.24 and 4.25 shows chromatographic profiles of 
methamphetamine pyrolysis products generated at 3540C for the MeOH-DCM 
50:50 and 90:10 solvents respectively.  Profiles revealed similar retention times but 
calculated %RSD values (table 4.12 and 4.13) were all ≥5%, indicating that 
repeatability was not achievable. Plots of pyrolysis product versus product peak 
area (figures 4.25 and 4.26) for EFV-methamphetamine pyrolysis products also 
revealed variations in product quantities.  This was expected given the nature of the 
pyrolysis event and that some variation was probable.   
 
Chromatographic profiles from both solvents extracts revealed a large 
methamphetamine peak at 5.22 minutes; a tentative explanation for the existence 
of the peak was that the methamphetamine might have undergone decomposition 
in the injection port of the GCMS where temperatures (2800C) were much higher 
that it’s melting point of 1700C.  
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Figure 4.22 Overlay of chromatographic profile of pyrolysis products of EFV-methamphetamine extracted in MeOH-DCM 50:50 at 354
0
C, showing EFV pyrolysis product 
1 at 11 minutes and EFV at 16 minutes 
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Figure 4.23 Overlay of chromatographic profile of pyrolysis products of EFV-methamphetamine extracted in MeOH-DCM 90:10 at 354
0
C, showing EFV pyrolysis product 1 at 11 minutes 
and EFV at 16 minutes 
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Table 4.10 %RSD results for pyrolysis products of EFV a and methamphetamine for within-can analytical repeatability extracted in MeOH-DCM at 354
0
C 
 
Pyrolysis product 
 
 
Average abundance 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS  5 ACS 6 Average Stdev RSD% 
 
2-Furan carboxaldehyde-5 methyl 2851396 2846775 2956734 2855942 2854937 2858657 2870740 42327.75 1.47 
Benzaldehyde 2573923 2550275 2497332 2518932 2815465 2836651 2632096 152652 5.80 
Cyclo propyl benzene 486615 489769 491022 149673 157108 485698 4894918 4079.33 0.83 
2-furan methanol 2900269 2981700 2914634 2932105 2944837 2897553 2928516 31802.84 1.09 
1,2-propanedione ,1-phenyl 1571980 1577231 1518731 1581627 1541354 1551380 1557051 24417.48 1.57 
Benzeneethanamine, N, alpha-dimethyl 3825507 3762834 3857710 3951127 3960392 3944002 3883595 80913.32 2.08 
Benzoin 284996 294226 283353 296007 294326 297644 291759 6029.15 2.07 
1-Dodecanol 1489188 1474117 1477756 1567110 1403954 1572892 1497503 63696.22 4.25 
N-Formylmethamphitane 1493846 1554567 1576433 1540475 1622712 1645290 1572221 55440.55 3.53 
methamphetamine acetylated 60946 65731 69302 67533 68619 69445 66929 3237.79 4.84 
EFV product 1 1571366 1558265 1473425 1576835 1567562 1496767 1540703 44118.64 2.86 
Trichlorocetic acid pentadecyl ester 26239 27301 25787 27722 28736 26986 27129 1056.14 3.89 
EFV 1191516 1176214 1136774 1267129 1139856 1125640 1172855 52663.33 4.49 
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Table 4.11  %RSD results for EFV-methamphetamine pyrolysis product vs peak area for within-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Average peak area 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 average Stdev %RDS 
 
Benzaldehyde 1050792 1050792 1050700 1050699 1052792 1050789 1051094 833.05 0.08 
cyclopropylbenzene 65821 65707 65722 65800 65820 65819 65781.5 52.691 0.08 
Benzyl methyl ketone 145351 145366 145356 145344 145319 145366 145350.3 17.580 0.01 
1-phenyl-1,2 propanedione 94159 94150 94146 94146 94148 94152 94150.17 4.92 0.01 
N, alpha-dimethyl Benzeneethanamine 3356342 3356771 3356317 3356364 3361223 3366212 3358872 4075.19 0.12 
N-formylmethamphetamine 362394 362393 362394 363212 362336 355895 361437.3 2735.63 0.76 
N-acetylmethamphemtamine 81975 81973 81935 81987 81974 81988 81972 19.31 0.02 
EFV 15502 15503 15521 15491 15511 15507 15505.83 10.01 0.06 
EFV pyrolysis product 1 89254 89253 89255 89253 89249 89253 89252.83 2.04 0.002 
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Table 4.12  %RSD results for EFV- methamphetamine pyrolysis products vs peak area for inter-can analytical repeatability extracted in MeOH-DCM at 354
0
C 
 
 Pyrolysis product  
  
  
Average abundance  
   
 
can 1 can 2 can 3 can 4 can 5 can 6 Average Stdev RSD% 
 
2-Furan carboxaldehyde-5 methyl 2851396 9046785 322984 10486912 7754939 2858657 5553612 4081906 73.5 
Benzaldehyde 2573923 8450286 731102 9331353 5815533 2.863 4483670 3970897 88.6 
Cyclo propyl benzene 486615 769299 153622 1230140 767158 174098 596822 411612 68.9 
2-furan methanol 1500269 3981700 294634 4330285 2444837 1475213 2337823 1568688 67.1 
1,2-propanedione ,1-phenyl 1571980 2811710 201873 3610286 3254230 930380 2161696 1505955 69.67 
Benzeneethanamine, N, alpha-dimethyl 3825507 628129 3554710 2119527 3960392 3221012 2696754 1343514 49.82 
Benzoin 284996 907596 132253 1161703 942164 236103 675964 460857 68.18 
1-Dodecanol 1489188 4746496 50308 8110480 4618354 2502892 4005706 2986507 74.56 
N-Formylmethamphitane 1493846 1615700 1258572 1504758 1302490 1645290 1465362 177353 12.10 
methamphetamine acetylated 60946 274051 33220 238822 189619 55074 158157 108586 68.66 
EFV product 1 1571366 8558683 207415 3019014 2892068 702031 3075842 3315170 107.78 
Trichlorocetic acid pentadecyl ester 26239 109062 2470 129922 71673 26986 680236 53643 78.86 
EFV 1191516 2124485 539686 2448129 1061881 1685140 1571864 776456 49.40 
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Table 4.13  %RSD results for EFV-methamphetamine vs peak area for inter-can analytical repeatability extracted in MeOH-DCM at 354
0
C 
Pyrolysis product Average peak area 
Can 1 Can 2 Can 3 Can 4 Can5 Can 6 average Stdev %RDS 
Benzaldehyde 1050792 605269  1564535 991098 - 1052923.5 394109.89 37.43 
cyclopropylbenzene 65821 - - 138001 - - 101911 51038.97 50.08 
Benzyl methyl ketone 145351 79167 - 224942 - 38659 - - - 
1-phenyl-1,2 propanedione 94159 178230 23506 266167  30880 118588.4 103279.96 87.09 
N, alpha-dimethyl Benzeneethanamine 3356342 5137359 1778845 759036 497962 457002 1997757.67 1892538.88 94.73 
N-formylmethamphetamine 362394 257226 69615 513619 548879 55895 301271.33 212579.99 70.56 
N-acetylmethamphemtamine 81975 49855 14474 104293 115067 22656 64720 42222.24 65.24 
EFV 15502 11348 2299 17148 18313 - 12922 6498.15 50.29 
EFV pyrolysis product 1 89254 120374 3672 121302 75984 18024 71435 50327.95 70.45 
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4.8 GCMS conclusions about the pyrolysis of EFV and methamphetamine  
The results obtained from the analysis of pyrolysis products of methamphetamine 
and from a mixture of the two drugs revealed the presence of products from 
various chemicals used as starting materials and in the making of other chemicals 
for the manufacture of methamphetamine. The detected pyrolysis products in this 
case were used to establish possible synthetic routes for the samples used. It is 
thought the detected products only survived the pyrolysis process because they 
were in access quantities or due to incomplete chemical reactions (where they 
were detected as intermediate products). Product quality is usually compromised in 
clandestine laboratory settings because most chemicals used are controlled. It was 
also discovered that analytical repeatability of desorbed pyrolysis products was only 
achievable for products produced within one tin can and not between two or more 
different tin cans. This is as a result of the unpredictability of the generation of 
pyrolysis products and was to be expected.   
The presence of EFV in the mixture did not interfere with the pyrolysis patterns of 
methamphetamine and vice versa. The overall conclusion relating to the smoking of 
the two drugs together as mixture is that the pyrolysis products will contain a 
mixture of products from both drugs. 
 
4.9 Isolation of pyrolysis products of methamphetamine and analysis with the 
HPLC 
4.9.1 Sample preparation 
Methamphetamine samples used for the HPLC analysis were the two remaining ACS 
strips from the four prepared earlier in section 4.3 where six replicate 
methamphetamine samples were homogenised and prepared following the 
protocol described in chapters 4.2.2.1; 0.5g of the powdered material was weighed 
into 6 separate tin cans, heated and pyrolysis products extracted. The products 
were trapped using four ACS in each of the six tin cans.  Following this, the analysis 
sampling strategy in Chapter 4.2.2.2 was applied where two of the strips were used 
for GCMS analysis and two by the HPLC. One of the two strips was extracted with 
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the MeOH-DCM 90:10 while the other with the mobile phase. Methamphetamine 
samples were in-house samples synthesised for research purposes. 
 
4.9.2 Results and discussions 
Results obtained from extractions using the mobile phase are displayed in table 
4.14 and figure 4.26 while figure 4.27 and Table 4.15 shows results for the MeOH-
DCM 90:10. Both results revealed the detection of the same pyrolysis products 
being a mixture of benzaldehyde, propenyl benzene, P2P, methamphetamine, 
dimethyl amphetamine, N-formylmethamphetamine, N-acetylmethamphetamine 
and trans-1, 2-dimethyl-3-phenylaziridine. All the detected pyrolysis products have 
been discussed in the previous section where they were discovered to be chemicals 
used as starting materials in the different synthetic routes mentioned earlier or 
intermediate products from chemical reactions involved.  
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Table 4.14 Pyrolysis products of methamphetamine detected following extraction the mobile phase at 354
0
C 
 
 
Pyrolysis Temperature ( in degrees 
Celsius) 
 
HPLC  methamphetamine 
Mobile phase  25Mm buffer-ACN (53:47) Retention time  (minutes) 
315 Benzaldehyde 
Allylbenzene 
1,2 Dimethyl -3-phenylaziridine,trans 
P2P 
Methamphetamine 
di-methyl amphetamine 
N-formyl methamphetamine 
N-acetylmethamphetamine 
1.261 
1.641 
2.349 
2.458 
3.256 
3.810 
11.468 
11.748 
354 Benzaldehyde 
Allylbenzene 
1,2 Dimethyl -3-phenylaziridine,trans 
P2P 
Methamphetamine 
di-methyl amphetamine 
N-formyl methamphetamine 
N-acetylmethamphetamine 
1.261 
1.641 
2.349 
2.458 
3.256 
5.483 
11.468 
11.748 
358 Benzaldehyde 
Allylbenzene 
1,2 Dimethyl -3-phenylaziridine,trans 
P2P 
Methamphetamine 
di-methyl amphetamine 
N-formyl methamphetamine 
N-acetylmethamphetamine 
1.261 
1.641 
2.349 
2.458 
3.256 
5.483 
11.468 
11.748 
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Table 4.15 Results for pyrolysis products of methamphetamine extracted in MeOH-DCM 90:10 at 354
0
C 
 
 
Pyrolysis Temperature 
(in degrees Celsius) 
 
HPLC  methamphetamine 
MeOH-DCM 9010 v/v Retention time  (minutes) 
315 Allylbenzene 
Trans 1,2 dimethyl -3-phenylaziridine 
P2P 
Methamphetamine 
di-methyl amphetamine 
N-formyl methamphetamine 
N-acetylmethamphetamine 
1.67 
2.40 
2.52 
3.38 
3.97 
12.29 
12.61 
354 Allylbenzene 
Trans 1,2 Dimethyl -3-phenylaziridine 
P2P 
Methamphetamine 
di-methyl amphetamine 
N-formyl methamphetamine 
N-acetylmethamphetamine 
1.67 
2.40 
2.52 
3.38 
3.97 
12.29 
12.61 
358 Allylbenzene 
Trans 1,2 Dimethyl -3-phenylaziridine 
P2P 
Methamphetamine 
di-methyl amphetamine 
N-formyl methamphetamine 
N-acetylmethamphetamine 
1.67 
2.40 
2.52 
3.38 
3.97 
12.29 
12.61 
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Figure 4.26 Chromatogram for pyrolysis products of methamphetamine in the mobile phase at 354
0
C 
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Figure 4.27 Chromatogram for pyrolysis products of methamphetamine extracted in MeOH-DCM at 354
0
C 
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The presence of all the detected products of methamphetamine was discussed in 
detail in the previous sections. Some products indicated the involvement of the 
synthetic routes of Leuckart, Emde and Nagai. Other products, di-
methylamphetamine, acetyl-methamphetamine, methamphetamine and N-
formylmethamphetamine are main pyrolysis products of methamphetamine via 
reactions of formylation, acetylation and di-methylation [169, 185].  
 
4.9.3 Evaluation of method repeatability 
The repeatability of the method for methamphetamine pyrolysis products was 
evaluated through calculation of %RSDs from peak areas. Peak areas for all the 6 
replicate injections in tin can 1 were used to represent the within-can repeatability. 
The results obtained from the mobile phase are presented in table 4.16 while those 
from the MeOH-DCM are in table 4.17. Both results revealed %RSD values of ≤5%, 
indicating very good repeatability 
 
The repeatability of inter-can results was also evaluated. This was obtained from 
%RSDs values calculated from average peak areas of pyrolysis products generated 
from the 6 injections in each of the 6 tin cans. The results obtained using the mobile 
phase are presented in table 4.18 while those for the MeOH-DCM are in table 4.19 
Both results revealed %RSD values of ≥5%, indicating that repeatability was not 
achieved. Plots of peak area versus pyrolysis (figures 4.28 and 4.29) also revealed 
variations in the quantities of pyrolysis products. 
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Table 4.16 %RSD for methamphetamine pyrolysis product vs peak area for within-can analytical repeatability extracted in the mobile phase at 354
0
C 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
ACS 1  ACS 2  ACS 3 ACS 4  ACS 5  ACS 6 Average Stdev %RSD 
 
Benzaldehyde 26.24 23.98 25.38 26.24 26.24 26.33 25.74 0.93 3.61 
allyl benzene 35.54 35.54 35.55 35.26 35.54 35.56 35.50 0.12 0.33 
1 phenyl 1,2 propanedione 144.80 144.79 144.81 144.79 144.81 144.80 144.8 0.008 0.01 
Trans 1,2 dimethyl phenyl aziridine 657.26 657.44 657.22 657.23 657.11 657.22 657.25 0.12 0.02 
P2P 144.80 144.78 144.76 144.80 144.79 144.86 144.80 0.03 0.02 
methamphetamine 144.80 144.88 144.76 144.76 144.73 144.78 144.79 0.05 0.04 
N-formylmethamphetamine 42.56 42.54 42.57 42.65 42.57 42.56 42.58 0.04 0.09 
N-acetylmethamphetamine 32.69 32.76 32.65 32.56 32.56 32.57 32.63 0.08 0.25 
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Table 4.17 %RSD results for methamphetamine pyrolysis product vs peak area for within-can analytical repeatability extracted in the MeOH-DCM at 35
40
C 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
Allylbenzene 5.123 5.123 5.122 5.233 5.220 5.234 5.18 0.06 1.13 
Trans 1,2 Dimethyl -3-phenylaziridine 91.370 91.370 91.33 91.36 91.35 95.360 92.02 1.63 1.78 
P2P 5.920 5.910 5.910 5.940 5.910 5.910 5.92 0.01 0.20 
Methamphetamine 10.371 10.344 10.365 10. 557 10.345 10.358 10.36 0.01 0.12 
di-methyl amphetamine 29.960 29.468 29.676 29.923 29.983 29.656 29.78 0.21 0.70 
N-formyl methamphetamine 29.123 29.123 29.121 29.124 29. 129 29.211 29.14 0.04 0.14 
N-acetylmethamphetamine 44.263 44.362 44.331 44.232 44.452 45.213 44.48 0.37 0.83 
   
   
   
   
   
   
   
   
162 
 
 
 
 
 
Table 4.18 %RSD results for methamphetamine pyrolysis products vs peak area for inter-can analytical repeatability extracted in the mobile phase 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
ACS 1  ACS 2  ACS 3 ACS 4  ACS 5  ACS 6 Average Stdev %RSD 
 
Benzaldehyde 26.243 23.901 25.384 27.973 26.260 28.271 26.34 1.63 6.19 
allyl benzene 35.540 55.142 114.58 65.799 78.354 99.543 74.83 29.04 38.81 
1 phenyl 1,2 propanedione 657.262 376.62 425.716 465.234 491.562 397.072 468.91 101.54 21.65 
Trans 1,2 dimethyl phenyl aziridine 144.802 20.301 36.900 352.221 243.121 234.44 171.96 129.18 75.12 
P2P 144.801 140.94 119.61 410. 543 210.322 103.367 143.81 40.79 28.36 
methamphetamine 42.561 22.162 26.772 26.786 47.342 43.343 34.83 10.76 30.90 
N-formylmethamphetamine 32.691 33.049 49.741 44.226 44.243 45.354 41.55 7.02 16.91 
N-acetylmethamphetamine 26.243 23.901 25.384 27.973 26.26 28.271 26.34 1.63 6.19 
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Table 4.19 %RSD results for methamphetamine pyrolysis product vs peak area for inter-can analytical repeatability extracted in the MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
Allylbenzene 5.123 19.465 6.002 15.302 6.333 7.112 9.90 5.99 60.53 
Trans 1,2 Dimethyl -3-phenylaziridine 91.37 87.244 98.222 82.345 95.102 129.001 97.21 16.56 17.03 
P2P 5.92 11.23 12.111 15.444 6.772 5.145 9.44 4.12 43.52 
Methamphetamine 10.371 10.564 17.3 17.243 13.992 13.221 13.78 3.06 22.18 
di-methyl amphetamine 29.96 37.224 56.356 32.998 76.243 36.898 44.95 17.90 39.82 
N-formyl methamphetamine 29.123 28.098 45.434 24.339 16.993 36.843 30.14 9.90 32.86 
N-acetylmethamphetamine 44.263 78.254 45.981 44.9 42.132 65.879 53.57 14.91 27.838 
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4.10 Isolation of pyrolysis products of EFV and methamphetamine and analysis 
with the HPLC. 
Six replicate samples of EFV and methamphetamine were prepared by weighing 
0.5g of each drug and mixing the two drugs into 6 separate tin cans. The mixture 
was heated to 3540C and pyrolysis products extracted according to the protocol 
described chapters 4.2.2.1. The products were trapped using four ACS in each of 
the six tin cans.  Following this, the analysis sampling strategy in Chapter 4.2.2.2 
was applied where two of the strips were used for GCMS analysis and two by the 
HPLC. One of the two strips was extracted with the MeOH-DCM 90:10 while the 
other with the mobile phase. Methamphetamine samples were in-house samples 
synthesised for research purposes 
 
 
 4.10.1 Results and Discussions 
The results obtained (Table 4.20) (figure 4.31) for mobile phase extractions and 
(Table 4.21) (figure 4.32) for the MeOH-DCM 9010 v/v revealed the presence of 
benzaldehyde, propenyl benzene, aziridines, methamphetamine, dimethyl 
amphetamine, N-acetylmethamphetamine, EFV pyrolysis product 1 and EFV. The 
first three products from recovered list are all impurities from chemicals used for 
the manufacture of starting materials for methamphetamine synthesis while 
methamphetamine may have been detected as the main product or as product 
from incomplete hydrolysis of the intermediate N-formyl methamphetamine. 
Dimethyl amphetamine and N-acetyl methamphetamine are main pyrolysis 
products of methamphetamine formed through acetylation and dimethylation 
reactions. 
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Table 4.20 Pyrolysis products of EFV and methamphetamine extracted in the mobile phase at 354
0
C 
 
Pyrolysis Temperature ( in 
degrees Celsius) 
 
HPLC  methamphetamine 
MeOH-DCM 9010 v/v Retention time  (minutes) 
315 EFV product 1 
Allylbenzene 
1,2 dimethyl -3-phenylaziridine,trans 
Methamphetamine 
di-methyl amphetamine 
EFV 
N-acetylmethamphetamine 
1.428 
1.302 
2.386 
3.318 
3.858 
10.208 
11.772 
354 EFV product 1 
Allylbenzene 
1,2 dimethyl -3-phenylaziridine,trans 
Methamphetamine 
di-methyl amphetamine 
EFV 
N-acetylmethamphetamine 
1.428 
1.302 
2.386 
3.318 
3.858 
10.208 
11.772 
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Table 4.21 Pyrolysis products of EFV-methamphetamine extracted in MeOH-DCM 90:10 at 354
0
C 
 
Pyrolysis Temperature ( in 
degrees Celsius) 
 
HPLC  methamphetamine 
MeOH-DCM 9010 v/v Retention time  (minutes) 
315 Benzaldehyde 
EFV product 1 
Allylbenzene 
1,2 dimethyl -3-phenylaziridine,trans 
Methamphetamine 
di-methyl amphetamine 
EFV 
N-acetylmethamphetamine 
1.24 
1.42 
1.65 
2.35 
3.28 
3.84 
10.20 
11.74 
354 Benzaldehyde 
EFV product 1 
Allylbenzene 
1,2 dimethyl -3-phenylaziridine,trans 
Methamphetamine 
di-methyl amphetamine 
EFV 
N-acetylmethamphetamine 
1.24 
1.42 
1.65 
2.35 
3.28 
3.84 
10.20 
11.74 
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Figure 4.31 Chromatogram for pyrolysis products of EFV and methamphetamine extracted in the mobile phase at 354
0
C 
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Figure 4.32 Chromatogram for pyrolysis products of EFV and methamphetamine extracted in the MeOH-DCM at 354
0
C 
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4.10.2 Evaluation of the repeatability of the method for pyrolysis products of EFV-
methamphetamine 
The repeatability of the method for the EFV-methamphetamine pyrolysis products 
was evaluated through the calculation of %RSDs of product peak areas extracted 
using both solvents. The peak areas for all the 6 replicates in tin can 1 were used as 
the overall representation of within-can repeatability. The results obtained from 
extractions with the mobile phase are presented in table 4.22 while those from the 
MeOH-DCM are in table 4.23. Both results revealed %RSD values of ≤5%, indicating 
very good repeatability 
 
The repeatability of inter-can results was also evaluated. This was obtained from 
%RSDs values calculated from average peak areas of pyrolysis products generated 
from the 6 injections in each of the 6 tin cans (n=36). The results obtained from the 
mobile phase are presented in table 4.24 while those from the MeOH-DCM are in 
table 4.25. Both results revealed %RSD values of ≥5%, indicating that repeatability 
was challenging. This was as expected given the conditions of the pyrolysis 
experiment settings.  
Plots of peak area versus pyrolysis (figures 4.33 and 4.34) also revealed variations in 
the quantities of detected pyrolysis products. It was also discovered from these 
plots that a larger quantity of detected pyrolysis products was recovered from 
extractions involving the MeOH-DCM 90:10 solvent. Trans-1,2-dimethyl-3-
phenylaziridinewas found to be detected in higher amounts than other products 
(figure 4.35). 
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Table4.22 %RSD results for EFV-methamphetamine pyrolysis product vs peak area for within-can analytical repeatability extracted in the mobile phase at 354
0
C 
 
 
 
 
 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
Benzaldehyde 396.146 396.164 403.115 396.656 399.9 399.434 398.57 2.77 0.70 
allylbenzene 119.43 119.43 115.743 114.904 114.86 109.543 115.65 3.66 3.17 
Trans 1.2 dimethyl-3-phenylaziridine 574.711 574.712 588.443 576.876 587.432 588 981 580.43 6.92 1.19 
Methamphetamine 54.565 54.564 66.755 56.987 59.138 58.321 87.10 4.51 5.13 
di-methyl amphetamine 52.586 52.586 56.876 56.641 56.665 57.331 55.45 2.23 4.02 
EFV1 419.468 419.468 374.031 396.373 387.35 426.37 403.84 21.03 5.21 
EFV 141.696 141.696 134.765 145.745 147.61 145.705 142.87 4.63 3.24 
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Table 4.23 %RSD results for EFV-methamphetamine pyrolysis product vs peak area for within-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
benzaldehyde 236.44 236.44 236.421 236.443 236.411 235.411 236.261 0.42 0.18 
allylbenzene 42.901 42.94 42.91 42.91 42.902 42.931 42.92 0.02 0.04 
Trans 1,2 dimethyl-3-phenyl aziridine 351.22 351.22 351.21 352.11 351.2 351.22 351.36 0.37 0.10 
Methamphetamine 26.021 26.18 26.011 26.181 26.111 26.21 26.12 0.09 0.33 
di-methyl amphetamine 17.24 17.24 17.221 17.211 17.221 17.221 17.23 0.01 0.07 
EFV 1 226.373 226.373 226.37 226.65 226.374 226.37 226.42 0.11 0.05 
EFV 105.751 105.66 105.75 105.751 105.751 105.752 105.74 0.04 0.44 
N-acetylmethamphetamine 30.95 30.95 30.93 30.91 30.92 30.95 30.935 0.02 0.06 
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Table 4.24 %RSD results for EFV-methamphetamine pyrolysis product vs peak area for inter-can analytical repeatability extracted in the mobile at 354
0
C 
 
 
 
 
 
 
 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
Can 1 Can 2 can 3 can 4 can 5 can 6 Average Stdev %RSD 
 
benzaldehyde 396.146 396.164 403.115 236.436 329.9 236.440 333.03 79.44 23.85 
allylbenzene 119.43 119.43 115.743 42.904 114.86 99.543 101.99 29.87 29.29 
Trans 1,2 dimethyl-3-phenylaziridine 574.711 574.712 708.572 351.267 901.754 351.223 577.04 211.10 36.74 
Methamphetamine 54.565 54.564 66.755 26.095 99.138 26.011 54.52 27.43 50.315 
di-methyl amphetamine 52.586 52.586 38.496 17.241 73.216 17.243 41.89 22.08 52.69 
EFV 1 419.468 419.468 374.031 226.373 317.35 226.370 330.51 88.10 26.92 
EFV 141.696 141.696 227.112 105.745 217.094 105.745 156.51 53.38 34.12 
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Table 4.25 %RSD results for EFV-methamphetamine pyrolysis product vs peak area for inter-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
Can 1 Can 2 Can  3 Can 4 Can  5 can 6 Average Stdev %RSD 
 
benzaldehyde 236.44 236.44 236.421 236.443 256.4 115.221 219.53 47.23 21.51 
allylbenzene 42.901 42.94 42.91 22.91 52.902 42.931 41.249 9.83 23.83 
Trans 1,2 dimethyl-3-phenyl aziridine 351.22 351.22 345.781 352.11 267.09 351.22 351.36 34.05 9.69 
Methamphetamine 26.021 26.18 58.023 26.181 26.111 15.56.21 26.12 14.27 54.62 
di-methyl amphetamine 17.24 17.24 17.221 39.711 17.221 23.201 17.23 9.01 52.32 
EFV 1 226.373 226.373 305.671 226.65 226.374 156.364 226.42 47.27 20.88 
EFV 105.751 105.66 115.75 95.751 105.751 115.752 105.74 7.531 7.12 
N-acetylmethamphetamine 30.95 30.95 29.113 36.231 30.92 91.95 30.935 24.74 79.98 
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Figure 4.35 Pyrolysis products of methamphetamine detected when it was heated (a) alone and 
extracted in the mobile phase   (b) heated with EFV and extracted with the mobile phase  
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(a) HPLC plot of pyrolysis product vs amount for methamphetamine 
in MeOH-DCM 90:10 v/v 
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From figure 4.35 it can be seen that a larger quantity of pyrolysis products was 
recovered when methamphetamine was heated in the presence of the EFV. It was 
also noted that a smaller number of products were recovered from the same 
extraction. The presence of both drugs in the pyrolysis mixture did not affect either 
drug.  
 
4.11 Isolation of pyrolysis products of amphetamine and analysis with the GCMS  
4.11.1 Sample preparation 
Six replicate amphetamine samples were prepared following the protocol described 
in section 4.2.2.1.  The samples were sourced from finished forensic cases. The 
amphetamine samples were first homogenised by crushing them into fine powder 
using a mortar and pestle. 0.5g of the powdered material was weighed into 6 
separate into tin cans. Each tin can was covered with a lid, heated to the desired 
temperature and removed from the hot plate. The covering lid was replaced with 
the one with prepared CAS strips (section 4.2.2.1) and incubated for 16 hours at 
800C to trap the pyrolysis products. The products were trapped using four ACS in 
each of the six tin cans.  Following this, the analysis sampling strategy in section 
4.2.2.2 was applied.  For analysis with the GCMS, one of the four ACS strips was 
extracted with MeOH-DCM 90:10 and the other with MeOH-DCM 50:50.  
 
4.11.2. Results and Discussions 
The results obtained (table 4.26) show the detection of different amphetamine 
synthetic route impurities. They revealed the presence of known intermediate 
products from various chemical reactions involved during synthesis of the 
amphetamine samples; they included N-formylamphetamine and N-
acetylamphetamine. N-formylamphetamine may suggest the involvement of the 
Leuckart amphetamine synthesis route, as illustrated on figure (4.36) while N –
acetyl amphetamine while may be indicative of the use of the reductive amination 
synthetic route (figure 4.37). Amphetamine may have been detected as the main 
product or as a breakdown product from the intermediate product N-
formylamphetamine. Typical chromatograms obtained from the pyrolysis of 
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amphetamine are displayed in figures 4.38 for products extracted with the MeOH-
DCM 90:10 and figure 4.41 for the MeOH-DCM 50:50. The four main detected 
pyrolysis products of amphetamine are displayed in figure 4.42. 
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Table 4.26 Pyrolysis products of amphetamine extracted in the two MeOH-DCM solvent ratios solvents at three different temperatures of 315, 354 and 398
0
C 
 
 
ACS 
extracting solvent 
 
 
Pyrolysis Temperature (
0
C) 
315 354 
 
 
394 
MeOH:DCM 50:50 
 
 
 
 
 
 
 
 
 
Amphetamine 
N-Formylamphetamine 
N-Acetylamphetamine 
 
N-Formylmethamphetamine 
N-Acetylamphetamine 
N-Formylamphetamine 
2-Nitro-1-phenylpropene 
1-phenyl -1,2 – Propanedione 
alpha-methyl- Benzeneethanol 
Benzaldehyde 
5-Hydroxymethyl-2-
furancarboxaldehyde 
5 hydroxymethyl furfural 
N-Acetylamphetamine 
N-Formylamphetamine 
[1,3]Diazepan-2-4-dione 
1-phenyl -1,2 – Propanedione 
alpha-methyl-Benzeneethanol 
Benzaldehyde 
2-Propylbenzene 
1-Propylbenzene 
MeOH:DCM 90:10 
 
Amphetamine 
1,2-Propanediol, 1 –phenyl 
Benzaldehyde 
n- Acetylamphetamine 
N-Formylamphetamine 
Benzaldehyde 
alpha-methyl- Benzeneethanol 
 
N-Acetylamphetamine 
N-Formylamphetamine 
Benzyl methyl ketone 
Propylbenzene 
Benzaldehyde 
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Figure 4.36 Chromatogram for pyrolysis products of amphetamine extracted  in MeOH-DCM 50:50 at 354
0
C 
179 
 
 
 
 
Figure 4.37 Chromatogram for pyrolysis products of amphetamine extracted in MeOH-DCM 90:10 at 354
0
C 
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(a)  (b)  
 
 
 (c)   
Figure 4.38 Chemical structures and mass spectra of three main pyrolysis products of amphetamine (a) N-acetylamphetamine (b) amphetamine (c) N-formylamphetamine 
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The detection of benzaldehyde is suggestive of its use as a starting material in the 
reductive amination synthesis of  P2P [6] (figure 4.39), which itself is a starting 
material for amphetamine synthesis through the Leuckart route while 1-phenyl-2-
nitropropene is produced as an intermediate product in the same synthetic 
reaction. 
Various synthetic routes for amphetamine are displayed in figure 4.39 to 4.40 
below. 
 
 
Figure 4.39 Amphetamine synthesis through the reductive amination route [169] 
 
 
 
 
 
 
 
Figure 4.40 Amphetamine synthesis through the Leuckart route [184] 
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Figure 4.41 P2P synthesis using benzaldehyde [176] 
 
Both chemicals can also be used without involving P2P, where the reduction of 
nitro-1-phenylpropene with excess lithium aluminium hydride produces 
amphetamine [4, 6, 24] (figure 4.41-4.42)  
 
Figure 4.42 Amphetamine synthesis through via reductive amination [185] 
 
Based on the results obtained, the possibility of the involvement of the reductive 
amination synthetic route seems unlikely; the detection of N-formylamphetamine 
in all samples and the presence of the two breakdown products of P2P (1-phenyl -
1,2-Propanedione and 1 –phenyl-1,2-Propanediol) [183] supports the use of the 
Leuckart synthetic route for the synthesis of the samples used. Other products 
detected 2-propylbenzene, 1-propylbenzene and alpha-methyl-benzeneethanol 
were detected. The results also revealed the presence of amphetamine, and based 
on this it can be said that amphetamine does not undergo complete thermal 
decomposition when heated to temperatures below 315OC or it could have resulted 
from the breakdown of the intermediate product N-forymylamphetamine.  
Many methods are available for illicit amphetamine synthesis. The most common 
being the Leuckart reaction, favoured for its simplicity, rapidness, safety and good 
yield [22].  Since most chemicals used for illicit manufacture of amphetamine are 
controlled by law, the precursor chemicals are also manufactured in clandestine 
laboratories. Several impurities including benzyl methyl ketone, dibenzyl ketone, 
pheny-2-propanone (P2P), formic acid, formamide [169, 184, 185] and others were 
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observed within the pyrolysis products generated.  Intermediate products also 
observed within the pyrolysis products of the samples such as N-
formlyamphetamine and N-acetylamphetamine [169, 184] were also detected.  
 
4.11.3 Evaluation of the analytical repeatability for pyrolysis products of 
amphetamine 
The repeatability of the method for the production of pyrolysis products of 
amphetamine was evaluated to determine the analytical repeatability for desorbed 
samples. This was performed in two steps; the first was involved with the 
establishment of repeatability of results within one sampling tin (within-can 
repeatability) and the second was through the assessment of analytical 
repeatability  between the 6 six tin  cans. For within-can repeatability, two sets of 6 
replicate samples were prepared by weighing 0.5g of amphetamine into 6 tin cans 
per set, these were heated and pyrolysis products trapped and extracted as per the 
protocol in 4.2.2.1.  Each sampling tin can contained a total of 6 ACS strips. The 
trapped pyrolysis products from each set were desorbed using the appropriate 
solvent and ratio. Each resultant extract was analysed six times to facilitate the 
calculation of repeatability within a desorption and analysis event. 
Chromatographic profiles of pyrolysis products generated from each of the six 
replicate injections in each sample can were plotted and compared for similarities 
in retention time, peak shape, peak height as well as any differences in overall 
chemical profile.  
Within-can repeatability was evaluated through %RSDs values calculated from 
average peak areas of pyrolysis products generated detected from the 6 replicate 
injections performed on each of the 6 strips in each tin can using both solvents and 
different ratios.    
%RSD results for within-can repeatability for each pyrolysis product  obtained from 
the 6 cans were compiled (average peak areas of pyrolysis products detected from 
the 6 injections in each of the 6 tin cans (n=36);  their %RSDs values calculated and 
used to establish between-can repeatability.   
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4.11.3.1 Analytical repeatability results 
Typical chromatographic profiles of the detected pyrolysis products obtained from 
the 6 injections in  tin can 1, (extracted using both MeOH-DCM 90:10 and MeOH-
DCM 50:50 solvents at 3540C) are displayed in figures 4.43 and 4.44 (appendix A).  
They all show similar retention times, similar pyrolysis products and quantities. 
Tables 4.27 and table 4.28 (appendix B) show calculated %RSDs for tin can 1 using 
MeOH:DCM 90:10 and MeOH-DCM 50:50 respectively. Calculated %RSDs for the 
analysis were all ≤5%, indicating excellent repeatability.  
Chromatographic profiles of pyrolysis products generated across the six different 
tin cans were compared. This was followed by the calculation of %RSDs across 
these samples.  Figures 4.45 and 4.46 (appendix A) show typical chromatographic 
profiles of amphetamine pyrolysis products generated at 3540C for the MeOH-DCM 
50:50 and 90:10 solvents respectively.  Profiles revealed similar retention times but 
calculated %RSD values (tables 4.29 and 4.30) (appendix B) were all ≥5%, indicating 
that repeatability was considerably more challenging. Plots of pyrolysis product 
versus product peak area (figures 4.47 and 4.48) (appendix A) for amphetamine 
pyrolysis products also revealed variations in product quantities.  This is expected 
given the nature of the pyrolysis event and that some variation was likely.   
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4.12 Isolation of pyrolysis products of EFV in a mixture with amphetamine and 
analysis with the GCMS 
Six replicate samples of EFV and amphetamine were prepared by weighing 0.5g of 
each drug and mixing the two drugs into 6 separate tin cans. The mixture was 
heated to 3540C and pyrolysis products extracted according to the protocol 
described in chapter 4.2.2.1. The products were trapped using four ACS in each of 
the six tin cans.  The analysis sampling strategy in Chapter 4.2.2.2 was applied 
where one of the four ACS strips was extracted with MeOH-DCM 90:10 and the 
other with MeOH-DCM 50:50. Amphetamine samples were available from 
completed forensic case samples 
 
4.12.1 Results and Discussions 
Results obtained (table 4.31) revealed the detection of N-acetylamphetamine, N-
formylamphetamine, benzaldehyde, 1-phenyl-1,2-propanedione, isosorbide, 
dimethyl-benzaldehyde, alpha-methyl-benzeneethanol. The last four products are 
impurities from chemicals used in the manufacture of amphetamine and their 
detection suggest possible involvement of the Leuckart amphetamine synthetic 
route. N-acetylamphetamine and N-formylamphetamine are main pyrolysis 
products of amphetamine and can be used to assist with the determination of 
synthetic route. EFV and its pyrolysis product were also detected.  
Typical chromatograms for pyrolysis products obtained from the pyrolysis of the 
mixture of the two drugs (extracted using both solvents) are displayed in figures 
4.48 and 4.49.  
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Table 4.31 Pyrolysis products of EFV and amphetamine extracted in the two MeOH-DCM solvent ratios solvents at 354
0
C 
 
 
ACS 
extracting solvent 
 
 
Pyrolysis Temperature (
0
C) 
315 354 
 
 
MeOH:DCM 50:50 
 
 
 
 
 
 
 
 
 
Amphetamine 
N-Formylamphetamine 
N-Acetylamphetamine 
 
N-Acetylamphetamine 
N-Formylamphetamine 
2-furan methanol 
1-phenyl -1,2 – Propanedione 
alpha-methyl- Benzeneethanol 
Benzaldehyde 
5-Hydroxymethyl-2-
furancarboxaldehyde 
5 hydroxymethyl furfural 
EFV 
EFV pyrolysis product 1 
MeOH:DCM 90:10 
 
Amphetamine 
1,2-Propanediol, 1 –phenyl 
Benzaldehyde N-
Acetylamphetamine 
N-Formylamphetamine 
2-furan methanol 
 
 
N- Acetylamphetamine 
N-Formylamphetamine 
Benzaldehyde 
alpha-methyl- Benzeneethanol 
EFV 
EFV pyrolysis product 1 
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Figure 4.48 Chromatogram for pyrolysis products of EFV-amphetamine extracted in MeOH-DCM 90:10 at 354
0
C 
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Figure 4.49 Pyrolysis products of amphetamine extracted in MeOH-DCM 50:50 at 354
0
C 
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4.12.2 Analytical repeatability of the method for pyrolysis products of EFV-
amphetamine 
The repeatability of the method for the production of pyrolysis products of amphetamine 
was evaluated to determine the analytical repeatability for desorbed samples. The first 
evaluation involved the establishment of repeatability of results within one sampling tin 
(within-can repeatability) and the second was for the repeatability  of between the 6 six 
tin  cans. Samples for within-can repeatability were prepared as previously.  Pyrolysis 
products were extracted according to the protocol in 4.2.2.1, each sampling tin can 
contained a total of 6 ACS strips. The trapped pyrolysis products from each set were 
desorbed using the appropriate solvent and ratio. Each resultant extract was analysed six 
times to facilitate the calculation of repeatability within a desorption and analysis event. 
Chromatographic profiles of pyrolysis products generated from each of the six replicate 
injections in each sample can were plotted and compared for similarities in retention 
time, peak shape, peak height as well as any differences in overall chemical profile.  
Within-can repeatability was evaluated through %RSDs values calculated from average 
peak areas of pyrolysis products generated detected from the 6 replicate injections 
performed on each of the 6 strips in each tin can using both solvents and ratios.    
Average peak areas of pyrolysis products detected from the 6 injections in each of the 6 
tin cans (n=36) were compiled; their %RSDs values were calculated and used to establish 
between-can repeatability.   
 
4.12.2.1 Repeatability results 
Typical chromatographic profiles for the detected pyrolysis products obtained from the 6 
injections in  tin can 1, (extracted using both MeOH-DCM 90:10 and MeOH-DCM 50:50 
solvents at 3540C) are displayed in figures 4.50 and 4.51 (appendix A).  They all show 
similar retention times, similar pyrolysis products and quantities. Table 4.32 and table 
4.33 (appendix B)s how calculated %RSDs for tin can 1 using MeOH:DCM 90:10 and 
MeOH-DCM 50:50 respectively. Calculated %RSDs for the analysis were all ≤5%, indicating 
excellent repeatability.  
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Chromatographic profiles of pyrolysis products generated across the six different tin cans 
were also compared. This was followed by the calculation of %RSDs across these samples.  
Profiles revealed similar retention times but calculated %RSD values (table 4.34 and 4.35) 
(appendix B) were all ≥5%, indicating that repeatability was not achievable. Plots of 
pyrolysis product versus product peak area (figures 4.52 and 4.53) (appendix A) for 
amphetamine pyrolysis products also revealed variations in product quantities.  The 
results were not surprising as variation would be expected to occur due the nature of the 
pyrolysis event.  
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Figure 4.52 and 4.53 (appendix A) show variations in amounts of pyrolysis products 
obtained from both drugs across the six cans, with the highest quantities observed 
for benzaldehyde, 2-furan methanol, isosorbide and EFV pyrolysis product 1. 
According to the results, the presence of EFV in mixture with amphetamine does 
not alter the expected pyrolysis patterns of amphetamine or vice versa. The 
number of amphetamine pyrolysis products obtained from the mixture was 
however less than when amphetamine was heated on its own.  
 
4.13 Isolation of pyrolysis products of amphetamine and analysis with the HPLC 
4.13.1 Sample preparation 
Amphetamine samples used for the HPLC analysis were the two remaining ACS 
strips from the four prepared earlier in section 4.3 where six replicate 
amphetamine samples were homogenised and prepared following the protocol 
described in chapters 4.2.2.1; 0.5g of the powdered material was weighed into 6 
separate tin cans, heated and pyrolysis products extracted. The products were 
trapped using four ACS in each of the six tin cans.  Following this, the analysis 
sampling strategy in Chapter 4.2.2.2 was applied where two of the strips were used 
for GCMS analysis and two by the HPLC. One of the two strips was extracted with 
the MeOH-DCM 90:10 while the other with the mobile phase. The samples were 
sourced from completed forensic work.  
 
4.13.2 Results and discussions 
Results obtained from extractions using the mobile phase are displayed in table 
4.36 and figure 4.54 while figure 4.55 and Table 4.37 shows results for the MeOH-
DCM 90:10. Both results revealed the detection of the same pyrolysis products 
being a mixture of benzaldehyde, furan methanol, P2P, and dimethyl amphetamine 
and amphetamine. These have been discussed in the previous section where they 
were discovered to be chemicals used as starting materials in the different 
synthetic routes mentioned earlier or intermediate products from chemical 
reactions involved.  
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Table 4.36 Pyrolysis products of amphetamine extracted in the mobile phase at 354
0
C 
 
Pyrolysis Temperature ( in degrees 
Celsius) 
 
HPLC  methamphetamine 
Mobile phase  25Mm buffer-ACN (53:47) Retention time  (minutes) 
315 Benzaldehyde 
Furan methanol 
P2P 
Dimethyl amphetamine 
 
1.048 
1.448 
2.473 
3.479 
354 Benzaldehyde 
Furan methanol 
P2P 
Dimethyl amphetamine 
 
1.048 
1.448 
2.473 
3.479 
358 Benzaldehyde 
Furan methanol 
P2P 
Dimethyl amphetamine 
 
1.048 
1.448 
2.473 
3.479 
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Table 4.37 Pyrolysis products of amphetamine extracted in the MeOH-DCM 90:10 at 354
0
C 
 
Pyrolysis Temperature ( in degrees 
Celsius) 
 
HPLC  methamphetamine 
Mobile phase  25Mm buffer-ACN (53:47) Retention time  (minutes) 
315 Benzaldehyde 
2-Furan methanol 
P2P 
dimethyl amphetamine 
N-formyl amphetamine 
N-acetylamphetamine 
1.048 
1.448 
2.473 
3.479 
11.631 
11.922 
354 Benzaldehyde 
2-Furan methanol 
P2P 
dimethyl amphetamine 
N-formyl amphetamine 
N-acetylamphetamine 
1.048 
1.448 
2.473 
3.479 
11.631 
11.922 
358 Benzaldehyde 
2-Furan methanol 
P2P 
dimethyl amphetamine 
N-formyl amphetamine 
N-acetylamphetamine 
1.048 
1.448 
2.473 
3.479 
11.631 
11.922 
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 Figure 4.54 Chromatogram for pyrolysis products of amphetamine extracted in the mobile phase at 540C 
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Figure 4.55 Chromatogram for pyrolysis products of amphetamine extracted in the MeOH-DCM 90:10 at 354
0
C 
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The presence of all the detected pyrolysis products of amphetamine was discussed 
in detail in the previous sections. The presence of some products indicates the 
involvement of the synthetic routes of Leuckart or reductive amination synthesis 
reactions, where products like dimethylamphetamine, Acetyl-methamphetamine, 
amphetamine and N-formylamphetamine are main pyrolysis products of 
amphetamine via reactions of formylation, acetylation and di-methylation [169]  
 
4.13.3 Evaluation of analytical repeatability of the method for amphetamine 
pyrolysis products 
The repeatability of the method for amphetamine pyrolysis products was evaluated 
through the calculation of %RSDs from peak areas of detected pyrolysis products. 
Peak areas for all the 6 replicate injections in tin can 1 were used to represent the 
within-can repeatability. The results obtained from the mobile phase are presented 
in table 4.38 while those from the MeOH-DCM are in table 4.39. Both results 
revealed %RSD values of ≤5%, indicating very good repeatability 
 
The analytical repeatability of inter-can results was also evaluated. This was 
performed through the use of %RSDs values calculated from average peak areas of 
pyrolysis products generated from the 6 injections in each of the 6 tin cans  (n=36). 
The results for the mobile phase are presented in table 4.40 while those for the 
MeOH-DCM are in table 4.41 (appendix B). Both results revealed %RSD values of 
≥5%, indicating that repeatability not achievable. Plots of peak area versus pyrolysis 
(figures 4.56 and 4.57) (appendix B) also revealed variations in the quantities of 
pyrolysis products. 
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4.14 Isolation of pyrolysis products of EFV in its mixture with amphetamine and 
analysis with the HPLC. 
Amphetamine samples used for the HPLC analysis were the two remaining ACS 
strips from the four prepared earlier in section 4.3 where six replicate 
amphetamine samples were homogenised and prepared following the protocol 
described in chapters 4.2.2.1; 0.5g of the powdered material was weighed into 6 
separate tin cans, heated and pyrolysis products extracted. The products were 
trapped using four ACS in each of the six tin cans.  Following this, the analysis 
sampling strategy in Chapter 4.2.2.2 was applied where two of the strips were used 
for GCMS analysis and two by the HPLC. One of the two strips was extracted with 
the MeOH-DCM 90:10 while the other with the mobile phase. The samples were 
sourced from completed forensic work.  
 
 4.14.1 Results and Discussions 
The results obtained (Table 4.42) (figure 4.58a) for mobile phase extractions and 
(Table 4.43) (figure 4.58b) for the MeOH-DCM 9010 v/v revealed the presence of 
EFV pyrolysis product 1, EFV, benzaldehyde, dimethylamphetamine, P2P and 2-
Furan methanol and other amphetamine products which could not be identified 
because they didn’t correlate with the reference material used.  
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Table 4.42 Pyrolysis products from a mixture of EFV and amphetamine extracted in the mobile 
phase 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
HPLC  EFV 
 and amphetamine 
Mobile phase  25Mm buffer-ACN 
(53:47) 
Retention time  
(minutes) 
 
354 
 
EFV pyrolysis product 1 
EFV 
Benzaldehyde 
Dimethylamphetamine 
P2P 
2-furan methanol 
 
1.429  
10.369 
1.052, 2.392 and 3.33 
 
 
 
 
Table 4.43 Pyrolysis products from a mixture of EFV and amphetamine extracted in the MeOH-
DCM 90:10 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
HPLC  EFV and amphetamine 
DCM-MeOH 90:10 Retention time  
(minutes) 
354 EFV pyrolysis product 1 
EFV 
Benzaldehyde 
Dimethylamphetamine 
P2P 
2-furan methanol 
N-acetylamphetamine 
1.426 
10.284 
1.299, 1.496, 2.30 and 
3.310 
 
  
199 
 
 
 
 
Figure 4.58 Chromatograms for pyrolysis products of amphetamine extracted in the (a) mobile 
phase and (b) MeOH-DCM 90:10 
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The presence of all the detected pyrolysis products of amphetamine was discussed 
in detail in the previous sections. The presence of some products indicates the 
involvement of the synthetic routes of Leuckart or reductive amination synthesis 
reactions, where products like dimethylamphetamine, Acetyl-methamphetamine, 
amphetamine and N-formylamphetamine are main pyrolysis products of 
amphetamine via reactions of formylation, acetylation and di-methylation [169, 
185].  
 
4.14.2 Evaluation of analytical repeatability of the method for amphetamine 
pyrolysis products 
The repeatability of the method for amphetamine pyrolysis products was evaluated 
through the calculation of %RSDs from peak areas of detected pyrolysis products. 
Peak areas for all the 6 replicate injections in tin can 1 were used to represent the 
within-can repeatability. The results obtained from the mobile phase are presented 
in table 4.44 while those from the MeOH-DCM are in table 4.45 (appendix B). Both 
results revealed %RSD values of ≤5%, indicating very good repeatability 
 
The analytical repeatability of inter-can results was also evaluated. This was 
performed through the use of %RSDs values calculated from average peak areas of 
pyrolysis products generated from the 6 injections in each of the 6 tin cans  (n=36). 
The results for the mobile phase are presented in table 4.46 while those for the 
MeOH-DCM are in table 4.47 (appendix B). Both results revealed %RSD values of 
≥5%, indicating that repeatability not achievable. Plots of peak area versus pyrolysis 
(figures 4.59 and 4.60) (appendix A) also revealed variations in the quantities of 
pyrolysis products. 
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4.14.2.1 Analytical repeatability results 
The results obtained from the analysis of pyrolysis products of amphetamine from a 
mixture of the two drugs revealed that repeatability is easily achieved for multiple 
single injections from ACS strips within one tin can and within one strip, indicating 
overall stability of the pyrolysis to analysis method.  As expected the repeatability 
of analysis between sample cans varies much more widely.  One very useful result 
obtained, however is that the nature of the pyrolysis mixtures did not vary 
significantly within a specific temperature solvent ratio mix and this provides a 
considerable confidence to the methodology.  
It was observed that the presence of EFV in the mixture did not interfere with the 
pyrolysis of amphetamine; however the EFV was observed to have remained stable 
and did not undergo any transformation.  
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4.15 Summary of the pyrolysis of EFV and ATS drugs.  
The pyrolysis of EFV revealed the presence of only one pyrolysis product. The 
product was detected at 11.09 minutes with main four ions with m/z 270, 245, 235, 
201 and 167 with the GCMS technique and at 1.431 minutes with the HPLC mobile 
phase and 1.423 minutes with the MeOH-DCM 90:10 using the HPLC. A possible 
chemical structure of the EFV pyrolysis was proposed together with those of its 
main molecular ions. The pyrolysis of amphetamine type stimulant drugs revealed 
the formation of pyrolysis products through typical reactions of N-acetylation, N-
formylation, dimethylation, N-methylation. In addition to the products formed from 
the reactions listed above, the pyrolysis of the ATS drugs (methamphetamine and 
amphetamine) revealed the presence of chemical used as starting materials and by-
products of chemical reactions used during the various synthetic processes. Some 
of these products were used to determine possible synthetic routes for the 
manufacture of both methamphetamine and amphetamine samples used for this 
research. The results obtained from the pyrolysis of a mixture of EFV and the two 
ATS type drugs revealed that none of the three drugs interferes with the pyrolysis 
of another and that the quantities of the products produced will vary. The 
conclusion drawn from the pyrolysis of a mixture of these drugs was that when 
either of the two ATS drugs is smoked for abuse in its mixture with EFV, the inhaled 
pyrolysis products will likely comprise of products from both drugs.  
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CHAPTER 5:  EFFECTS OF EFAVIRENZ ON THE SEMI-SYNTHETIC DRUGS ALLEDGED 
TO BE USED IN THE NYAOPE MIXTURE. 
 
5.1 Isolation of pyrolysis products of heroin and analysis with the GCMS 
5.1.1 Sample preparation 
Six replicate heroin samples were prepared following the protocol described in 
section 4.2.2.1.  The samples were recovered from forensic case work samples.  
They were first homogenised by crushing them into fine powder using a mortar and 
pestle. 0.5g of the powdered material was weighed into 6 separate into tin cans. 
Each tin can was covered with a lid, heated to the desired temperature and 
removed from the hot plate. The covering lid was replaced with the one with 
prepared CAS strips (section 4.2.2.1) and incubated for 16 hours at 800C to trap the 
pyrolysis products. The products were trapped using four ACS in each of the six tin 
cans.  Following this, the analysis sampling strategy in section 4.2.2.2 was applied.  
For GCMS analysis one of the four ACS strips was extracted with MeOH-DCM 90:10 
and the other with MeOH-DCM 50:50.  
 
5.1.2 Results and discussions 
Results obtained from samples extracted with the two different solvents ratios are 
displayed in table 5.1 and they revealed the presence of papaverine, noscapine, 
diacetylmorphine, 6-monoacetylmorphine, morphine, caffeine, diacetamate, 
meconin and paracetamol. Typical chromatograms of pyrolysis products obtained 
from the pyrolysis of heroin at 3540C (extracted using MeOH-DCM 90:10 and 
MeOH-DCM 50:50) are displayed in figure 5.1 and 5.2 respectively.  Detected 
pyrolysis products in both cases have been reported as alkaloids of opium, cutting 
agents and breakdown products of some of the main alkaloids. Heroin street 
samples are known to contain morphine and other alkaloids from the opium plant; 
these include codeine, thebaine, noscapine, and papaverine [186-188]]. This 
therefore explains the presence of papaverine and noscapine in the analysed 
samples. Meconin and hydrocortanine were detected as breakdown of noscapine 
[189]. Paracetamol and caffeine are common cutting agents for street heroin [190] 
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and their presence in the samples suggests they were used for such purposes. 
Noscapine has also been implicated as a cutting agent for heroin [190]; especially 
where it was detected in larger quantities than normal.  
Codeine can present in the extract during the extraction of morphine, and as a 
result will be acetylated to acetyl codeine. This therefore explains why it was 
detected amongst the pyrolysis products for this experiment. 
Figure 5.3 shows different chemical transformations/reactions of diacetylmorphine. 
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Table 5.1 Pyrolysis products of heroin at different temperatures of 315, 354 and 398
0
C 
 
Pyrolysis 
Temperature ( in 
0
C) 
 
GCMS  heroin ACS 
DCM:MeOH 
50:50 
DCM:MeOH 
10:90 
315 acetaminophen 
Meconin 
Morphine 
Acetyl codeine 
6 Mono acetyl morphine 
papaverine 
acetaminophen 
Meconin 
Morphine 
Acetyl codeine 
6 Mono acetyl morphine 
papaverine 
354 acetaminophen 
Meconin lactone 
diacetamate 
caffeine 
hydrocortamine 
Acetyl codeine 
6-monocaetyl morphine 
diacetylmorphine 
papaverine 
acetaminophen 
Meconin lactone 
diacetamate 
caffeine 
hydrocortamine 
Acetyl codeine 
6-monocaetyl morphine 
diacetylmorphine 
papaverine 
noscapine 
394 acetaminophen 
Meconin lactone 
diacetamate 
caffeine 
hydrocatamine 
EFV 
Acetyl codeine 
6-monocaetyl morphine 
diacetylmorphine 
 
 
acetaminophen 
Meconin lactone 
diacetamate 
caffeine 
hydrocatamine 
EFV 
Acetyl codeine 
6-monocaetyl morphine 
diacetylmorphine 
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Figure 5.1 Chromatogram of pyrolysis products of heroin extracted in MeOH-DCM 90:10 
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Figure 5.2 Pyrolysis products of heroin extracted in MeOH-DCM at 354
0
C 
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Figure 5.3 Chemical transformations of diacetylmorphine [186]  
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5.1.3 Method repeatability test for the pyrolysis products of heroin 
 
The repeatability of the method for the production of pyrolysis products of heroin 
was evaluated to determine the analytical repeatability for desorbed samples. This 
involved the establishment of repeatability of results within one sampling tin 
(within-can repeatability) and between the 6 six tin cans. For within-can 
repeatability, two sets of 6 replicate samples each were prepared by weighing 0.5g 
of heroin into 6 tin cans per set, these were heated and pyrolysis products trapped 
and extracted as per the protocol in 4.2.2.1.  Each sampling tin can contained a 
total of 6 ACS strips. The trapped pyrolysis products from each set were desorbed 
using the appropriate solvent and ratio. Each resultant extract was analysed six 
times to facilitate the calculation of repeatability within a desorption and analysis 
event. Chromatographic profiles of pyrolysis products generated from each of the 
six replicate injections in each sample tin can were plotted and compared for 
similarities in retention time, peak shape, peak height as well as any differences in 
overall chemical profile.  
Within-can repeatability was evaluated through %RSDs values calculated from 
average peak areas of pyrolysis products detected from the 6 replicate injections 
performed on each of the 6 strips in each tin can using both solvents and ratios.    
To evaluate the in-between can repeatability, %RSD results for within-can 
repeatability for each pyrolysis product  obtained from the 6 cans were compiled 
(average peak areas of pyrolysis products detected from the 6 injections in each of 
the 6 tin cans (n=36);  their %RSDs values were calculated and used to establish 
between-can repeatability.   
 
5.1.4 Repeatability test results  
Typical chromatographic profiles of the detected pyrolysis products obtained from 
the 6 injections in tin can 1, (extracted using both MeOH-DCM 90:10 and MeOH-
DCM 50:50 solvents at 3540C) are displayed in figures 5.4 and 5.5 (appendix A).  
They all show similar retention times, similar pyrolysis products and quantities and 
a large paracetamol peak at 11.022 minutes. Tables 5.2 and 5.3 (appendix B) show 
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calculated %RSDs for tin can 1 using MeOH-DCM 90:10 and MeOH-DCM 50:50 
respectively. Obtained %RSD values for the both solvents were in the analytical 
range of 0.01-2.72, indicating excellent repeatability.  
Chromatographic profiles of pyrolysis products generated across the six different 
tin cans were also compared. This was followed by the calculation of %RSDs across 
these samples.  Figures 5.6 and 5.7 (appendix A) shows chromatographic profiles of 
heroin pyrolysis products generated at 3540C for the MeOH-DCM 50:50 and 90:10 
solvents respectively.  Profiles revealed similar retention times but calculated %RSD 
values (tables 5.4 and 5.5) (appendix B) were all ≥5%, indicating that repeatability 
was considerably more challenging.  This is not unreasonable given the nature of 
the pyrolysis event and that some variation would be expected to occur 
 
Both chromatographic profiles revealed a large paracetamol peak at 11.02 minutes. 
A tentative explanation for the existence of this peak was that the paracetamol 
might have undergone some further decomposition in the GCMS where 
temperatures (injection port 2800C) were much higher that it’s melting point of 
1690c. 
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5.1.5 Conclusion of results for the pyrolysis of heroin with the GCMS 
The results obtained from the analysis of pyrolysis products of heroin from a 
mixture of the two drugs revealed that repeatability is easily achieved for multiple 
single injections from ACS strips within one tin can and within one strip, indicating 
overall stability of the pyrolysis to analysis method.  As expected the repeatability 
of analysis between sample cans varies much more widely.  This is undoubtable as a 
result of the more unpredictability of the generation of pyrolysis products and is to 
be expected.  One very useful result obtained, however is that the nature of the 
pyrolysis mixtures did not vary significantly within a specific temperature solvent 
ratio mix and this provides a considerable confidence to the methodology.  
 
5.2 Isolation of pyrolysis products of EFV and heroin and analysis with the GCMS. 
5.2.1 Sample preparation 
Six replicate samples of EFV and heroin (from forensic case samples), were 
prepared by weighing 0.5g of each drug,  mixing the two drugs together and then 
placing the mixture with 6 separate sampling tin cans. The mixture was heated to 
3540C and pyrolysis products extracted according to the protocol described 
previously in section 4.2.2.1. The temperature was chosen as it provided the most 
quantity of the EFV pyrolysis product across both solvent ratios. The EFV was 
observed to undergo decomposition if heated above this temperature. This was 
described in detail in section 3.6.5.2. As previously described the pyrolysis products 
were trapped using four ACS in each of the six sampling cans where one of the four 
ACS strips was extracted with MeOH-DCM 90:10 and the other with MeOH-DCM 
50:50 with the final two being reserved for HPLC analysis.   
.  
5.2.2 Results and Discussions 
Results obtained (table 5.6) revealed the presence of diacetylmorphine, 6-
monoacetylmorphine, acetylcodeine, EFV, EFV product 1, hydrocortanine, caffeine, 
paracetamol and meconin lactone. Typical chromatograms of pyrolysis products 
obtained from the pyrolysis of heroin at 3540C (extracted using MeOH-DCM 90:10 
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and MeOH-DCM 50:50) are displayed in figure 5.10 and 5.11 respectively. The 
presence of some of these pyrolysis products in heroin samples (except EFV and 
EFV pyrolysis product 1) was discussed in detail earlier in this chapter, section 5.1.2,  
where they were reported as either alkaloids of the opium plant or breakdown 
products of these alkaloids. EFV was observed to undergo minimal decomposition 
when heated with heroin. 
 
Table 5.6 Pyrolysis products of EFV-heroin extracted in the two MeOH-DCM solvent ratios solvents at 354
0
C 
Pyrolysis Temperature ( 
in 
0
C) 
 
GCMS  EFV-heroin ACS 
DCM:MeOH 
50:50 
DCM:MeOH 
10:90 
315 acetaminophen 
Meconin 
caffeine 
Morphine 
Acetyl codeine 
6 Mono acetyl morphine 
Papaverine 
Noscapine 
EFV 
acetaminophen 
Meconin 
Diacetamate 
Morphine 
Acetyl codeine 
6 Mono acetyl morphine 
Papaverine 
EFV 
354 acetaminophen 
Meconin lactone 
caffeine 
hydrocatamine 
morphine 
Acetyl codeine 
6-monoacetyl morphine 
Papaverine 
EFV 
acetaminophen 
Meconin lactone 
diacetamate 
caffeine 
hydrocatamine 
Acetyl codeine 
6-monoacetyl morphine 
Diacetylmorphine 
EFV 
394 acetaminophen 
Meconin lactone 
caffeine 
hydrocatamine 
EFV 
Acetyl codeine 
6-monoacetyl morphine 
diacetylmorphine 
 
 
acetaminophen 
Meconin lactone 
caffeine 
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Acetyl codeine 
6-monoacetyl morphine 
diacetylmorphine 
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Figure 5.10 Chromatogram for pyrolysis products of heroin extracted in MeOH-DCM 50:50 at 354
0
C 
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Figure 5.11 Pyrolysis products of EFV-heroin extracted in MeOH-DCM at 354
0
C 
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5.2.3 Repeatability test for the pyrolysis products of EFV and heroin 
 
The repeatability of the method for the production of pyrolysis products of EFV and 
heroin was evaluated to determine the analytical repeatability for desorbed 
samples. This involved the establishment of repeatability of results within one 
sampling tin (within-can repeatability) and between the 6 six tin cans (in-between 
can repeatability). For within-can repeatability, two sets of 6 replicate samples each 
were prepared by weighing 0.5g of methamphetamine into 6 tin cans per set, these 
were heated and pyrolysis products trapped and extracted as per the protocol in 
4.2.2.1.  Each sampling tin can contained a total of 6 ACS strips. The trapped 
pyrolysis products from each set were desorbed using the appropriate solvent and 
ratio. Each resultant extract was analysed six times to facilitate the calculation of 
repeatability within a desorption and analysis event. Chromatographic profiles of 
pyrolysis products generated from each of the six replicate injections in each 
sample tin can were plotted and compared for similarities in retention time, peak 
shape, peak height as well as any differences in overall chemical profile.  
Within-can repeatability was evaluated through %RSDs values calculated from 
average peak areas of pyrolysis products detected from the 6 replicate injections 
performed on each of the 6 strips in each tin can using both solvents and ratios.    
To evaluate the in-between can repeatability, %RSD results for within-can 
repeatability for each pyrolysis product  obtained from the 6 cans were compiled 
(average peak areas of pyrolysis products detected from the 6 injections in each of 
the 6 tin cans (n=36);  their %RSDs values were calculated and used to establish 
between-can repeatability.   
 
5.2.3.1 Repeatability test results for pyrolysis products of EFV and heroin 
Typical chromatographic profiles of the detected pyrolysis products from the 6 
injections in tin can 1, (extracted using both MeOH-DCM 90:10 and MeOH-DCM 
50:50 solvents at 3540C) are displayed in figures 5.12 and 5.13 (appendix A).  They 
all show similar retention times, similar pyrolysis products and quantities and a 
large paracetamol peak at 11.022 minutes. Tables 5.2 and 5.3 (appendix B) show 
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calculated %RSDs for tin can 1 using MeOH-DCM 90:10 and MeOH-DCM 50:50 
respectively. Obtained %RSD values for both solvents were in the analytical range 
of 0.12-5.44, indicating excellent repeatability.  
Chromatographic profiles of pyrolysis products generated across the six different 
tin cans were also compared. This was followed by the calculation of %RSDs across 
these samples.  Figures 5.14 and 5.15 (appendix A) shows chromatographic profiles 
of heroin pyrolysis products generated at 3540C for the MeOH-DCM 50:50 and 
90:10 solvents respectively.  Profiles revealed similar retention times but calculated 
%RSD values (tables 5.4 and 5.5) (appendix B) were all ≥5%, indicating that 
repeatability was considerably more challenging. Plots of pyrolysis product versus 
product peak area (figure 5.16 and 5.17) for heroin pyrolysis products also revealed 
variations in product quantities.  This is not unreasonable given the nature of the 
pyrolysis event and that some variation would be expected. 
Both chromatographic profiles revealed a large paracetamol peak at 11.02minutes; 
a tentative explanation for the existence of this peak was that the paracetamol 
might have undergone decomposition in the GCMS where temperatures (injection 
port 2800C) were much higher that it’s melting point of 1690c. 
  
The results obtained from the analysis of pyrolysis products of heroin from a 
mixture of the two drugs also revealed that repeatability is easily achieved for 
multiple single injections from the 6 ACS strips within a tin can and within one strip, 
indicating overall stability of the pyrolysis to analysis method.  As expected the 
repeatability of analysis between sample cans varies much more widely.  This is 
undoubtable as a result of the more unpredictability of the generation of pyrolysis 
products and is to be expected.  One very useful result obtained, however is that 
the nature of the pyrolysis mixtures did not vary significantly within a specific 
temperature solvent ratio mix and this provides a considerable confidence to the 
methodology.  
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It was observed that the presence of EFV in the mixture did not interfere with the 
pyrolysis of heroin; however the EFV was observed to have remained stable and did 
not undergo any transformation.  
 
5.3 Isolation of pyrolysis products of heroin and analysis with the HPLC  
Heroin samples used for the HPLC analysis were the two remaining ACS strips from 
the four prepared and detailed in section 5.1.1. In this case two of the ACS strips 
were analysed using the HPLC where one was extracted using MeOH-DCM 90:10 
and the second extracted using the mobile phase. The samples were obtained from 
finished forensic work. 
 
5.3.1 Results and discussions 
The results obtained (table 5.11 and figure 5.16a) for extractions with the mobile 
phase revealed the presence of morphine, meconin, noscapine, papaverine and 
other unidentified products, while those extracted with MeOH-DCM 9010 v/v (table 
5.12 and figure 5.16b) showed the presence of meconin, noscapine and papaverine 
and other  some unidentified products.  All detected products were alkaloids of 
opium; their presence was expected since these are street samples where purity is 
not always prioritised. Cutting agents and other impurities have been reported in 
street samples [24- 29]. The presence of morphine amongst the pyrolysis products 
of heroin is indicative of incomplete deacetylation reaction. 
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Table 5.11 Pyrolysis of heroin extracted in the mobile phase at 354
0
C 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
 
HPLC  heroin 
Mobile phase  25Mm buffer-ACN (53:47) Retention time  (minutes) 
315 Morphine 
Meconin 
Noscapine 
papaverine 
1.35 
1.72 
2.85 
8.45 
354 Morphine 
Meconin 
Noscapine 
papaverine 
1.35 
1.72 
2.85 
8.45 
358 Morphine 
Meconin 
Noscapine 
papaverine 
 
1.35 
1.72 
2.85 
8.45 
 
 
 
 
Table 5.12 Pyrolysis products of heroin extracted in MeOH:DCM 90:10 at 354
0
C 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
HPLC  heroin 
MeOH-DCM 9010 v/v Retention time  (minutes) 
315 Meconin 
Noscapine 
papaverine 
1.91 
2.75 
7.90 
354 Meconin 
Noscapine 
papaverine 
1.91 
2.75 
7.90 
358 Meconin 
Noscapine 
papaverine 
1.91 
2.75 
7.90 
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Figure 5.16 Chromatograms of pyrolysis products of heroin extracted in (a) the mobile phase and 
(b) MeOH-DCM 90:10 at 354
0
C 
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5.3.2 Method repeatability test for pyrolysis products of heroin 
The repeatability of the analytical methods (pyrolysis generation and desorption) 
method for heroin pyrolysis products using the HPLC was evaluated through 
calculation of %RSDs from peak areas. Average peak areas for all the 6 replicate 
injections from the 6 ACS in sample can 1 were used to represent the within-can 
analytical repeatability. The results obtained for samples pyrolysed at 354OC from 
the mobile phase are presented in table 5.13 while those from the MeOH-DCM 
(90:10) are in table 5.14 (appendix B) Both results revealed %RSD values of ≤5%, 
indicating very good repeatability. 
The repeatability of inter-can results was also evaluated. This was obtained from 
%RSDs values calculated from average peak areas of pyrolysis products generated 
from the 6 injections in each of the 6 sample cans (n=36). The results obtained 
using the mobile phase are presented in table 5.15 while those for the MeOH:DCM 
90:10 are in table 5.16 (appendix B). Both results revealed %RSD values of ≥5%, 
indicating that repeatability was poorer as expected for this kind of work. Plots of 
peak area versus pyrolysis (figures 5.17 and 5.18) (appendix A) also revealed 
variations in the quantities of pyrolysis products. 
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5.4 Isolation of pyrolysis products from a mixture of EFV and heroin and analysis 
with the HPLC 
Six replicate samples of EFV and heroin from finished case work were prepared by 
weighing 0.5g of each drug, mixing together and placing the mixture into a sample 
can.  6 mixed samples where prepared in this way. The mixture was heated to 
3540C and pyrolysis products extracted according to the protocol described 
previously. 
  
5.4.1 Results and Discussions 
The results obtained (Table 5.17) (figure 5.19a) for mobile phase extractions and 
(Table 5.18 (figure 5.19b) for the MeOH-DCM 9010 v/v revealed the presence of the 
same set of pyrolysis products in both extracts.  This consisted of a mixture of 
meconin, acetyl codeine, 3.6 acetyl morphine, noscapine, EFV and EFV pyrolysis 
product 1. The first three compounds are breakdown products from alkaloids of 
opium and are expected due to the type of samples analysed. 
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Table 5.17 Pyrolysis products of EFV-heroin extracted in the mobile phase 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
 
HPLC  EFV and heroin 
Mobile phase  25Mm buffer-ACN 
(53:47) 
Retention time  
(minutes) 
315 EFV product 1 
meconin 
unidentified peak 
codeine 
EFV 
1.01 
1.70 
2.11 
2.80 
10.07 
354 
 
EFV product 1 
meconin 
unidentified peak 
codeine 
EFV 
1.01 
1.70 
2.11 
2.80 
10.07 
 
 
 
Table 5.18 Pyrolysis products of EFV-heroin extracted in MeOH-DCM 90:10 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
 
HPLC  EFV and heroin 
Mobile phase  25Mm buffer-ACN 
(53:47) 
Retention time  (minutes) 
315 EFV product 1 
Meconin 
Noscapine 
Acetylcodeine 
3,6 acetyl morphine 
EFV 
1.12 
1.70 
2.79 
3.88 
4.80 
10.09 
354 EFV product 1 
Meconin 
Noscapine 
Acetylcodeine 
3,6 acetyl morphine 
EFV 
1.12 
1.70 
2.79 
3.88 
4.80 
10.09 
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Figure 5.19 Chromatograms of pyrolysis products of EFV and heroin extracted using the a) mobile 
phase and b) MeOH-DCM 90:10 (b) 
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5.4.2 Method repeatability test for pyrolysis products of EFV-heroin 
The repeatability of the method for the EFV-heroin pyrolysis products was 
evaluated through the calculation of %RSDs of product peak areas extracted using 
both solvents. The peak areas for all the 6 replicates injections from the 6 ACS in 
one sample can as before provided an extraction to instrument analytical check 
(tables 5.19 and 5.20) (appendix B) indicating very good repeatability. The inter-can 
analytical repeatability presented in tables 5.21 and 5.22 (appendix B) were more 
variable.  
Plots of peak area versus pyrolysis (figures 5.20 and 5.21) (appendix A) also 
revealed variations in the quantities of detected pyrolysis products. Quantities of 
the pyrolysis products for when heroin was heated on its own (figure 4. 28a) were 
compared with those obtained from when heating its mixture with EFV; figure 4.27 
shows results obtained from extractions with the mobile phase. The two results 
were plotted against each other for a better comparison.  
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Figure 5.22 Comparison of quantities of pyrolysis products of heroin after it was a) heated alone 
(a) and (b) when it was heated in EFV – both extracted with the mobile phase  
 
The results showed that more pyrolysis products were obtained when heroin was 
heated on its own. They also showed that the EFV underwent very little 
decomposition when heated with heroin. Based on these findings, it can be 
concluded that when a mixture of both drugs is smoked for abuse, the inhaled 
pyrolysis products are likely to contain varying amounts of a mixture of products 
from both drugs and that the products are likely to contain more EFV compound 
than others. These finding correlate with those obtained from the GCMS. 
 
5.5 Summary of the pyrolysis EFV and heroin. 
The pyrolysis of heroin revealed pyrolysis product formation via processes of 
deacetylation and acetylation. Other detected pyrolysis products were cutting 
agents like caffeine and paracetamol, which are commonly found in heroin street 
samples. Just like with the ATS, the presence of EFV in a mixture of heroin did not 
alter the expected pyrolysis reactions of heroin. However EFV was found to 
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undergo very little decomposition when heated with heroin. A conclusion drawn 
from the pyrolysis of the two drugs was that when the two are smoked together as 
a mixture, the inhaled pyrolysis products will likely comprise of a higher quantity of 
the EFV compound than those of heroin.  
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CHAPTER 6: EFFECTS OF EFAVIRENZ ON NATURAL DRUGS ALLEDGED TO BE IN THE 
NYAOPE MIXTURE 
 
6.1 Isolation of pyrolysis products of opium and analysis with the GCMS 
6.1.1 Sample preparation 
Opium samples were first homogenised by crushing them into fine powder using a 
mortar and pestle. 0.5g of the powdered material was weighed into 6 separate into 
tin cans. Each tin can was covered with a lid, heated to the desired temperature 
and removed from the hot plate. The covering lid was then replaced with the one 
with prepared ACS strips (section 4.2.2.1) and incubated for 16 hours at 800C to 
trap the pyrolysis products. The products were trapped using four ACS in each tin 
can.  Following this, the analysis sampling strategy in section 4.2.2.2 was applied.  
For GCMS analysis one of the four ACS strips was extracted with MeOH-DCM 90:10 
and the other with MeOH-DCM 50:50. The samples were obtained from finished 
forensic cases. 
 
6.1.2 Results and Discussions 
Results obtained from samples extracted with the two different solvents ratios are 
displayed in table 6.1. They showed the detection of noscapine, papaverine, 
thebaine, codeine, morphine, hydrocortanine and 6,7-dimethoxy-1(3H)-
Isobenzofuranone (meconin). The first five compounds are the main alkaloids of 
opium while hydrocortanine and 6,7-dimethoxy-1(3H)-Isobenzofuranone, are 
breakdown products of noscapine [191]. Noscapine is the second most abundant 
alkaloid in opium poppy latex after morphine, with the highest content found in 
Russian and Indian opium at 12 and 7.7%, respectively [191-193]. Typical 
chromatograms for pyrolysis products obtained from the pyrolysis of opium at 
3540C (extracted using MeOH-DCM 90:10 and 50:50) are displayed in figure 6.1 and 
6.2 respectively. 
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Table 6.1 Pyrolysis products of opium extracted in the two solvents at various temperatures 
 
 
ACS 
extracting solvent 
 
 
 
Pyrolysis Temperature (0C) 
315 354 396 
 
MeOH:DCM 50:50 
 
 
 
 
 
 
Meconin 
Hydrocortanine 
Codeine 
Morphine 
thebaine 
papaverine 
noscapine 
Meconin 
Hydrocortanine 
Codeine 
Morphine 
thebaine 
papaverine 
noscapine 
Meconin 
Hydrocortanine 
Codeine 
Morphine 
thebaine 
papaverine 
noscapine 
MeOH:DCM 90:10 
 
Meconin 
Hydrocortanine 
Codeine 
Morphine 
Thebaine 
papaverine 
Meconin 
Hydrocortanine 
Codeine 
Morphine 
Thebaine 
papaverine 
Meconin 
Hydrocortanine 
Codeine 
Morphine 
Thebaine 
papaverine 
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Figure 6.1 Chromatogram for pyrolysis products of opium extracted in MeOH-DCM 90:10 at 354
0
C 
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Figure 6.2 Chromatogram for pyrolysis products of opium extracted in MeOH-DCM 50:50 at 354
0
C 
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6.1.3 The repeatability of the method for the production of pyrolysis products of 
opium 
 
The repeatability of the method for the production of pyrolysis products of heroin 
was evaluated to determine the analytical repeatability for desorbed samples. This 
involved the establishment of repeatability of results within one sampling tin 
(within-can repeatability) and between the 6 six tin cans. For within-can 
repeatability, two sets of 6 replicate samples each were prepared by weighing 0.5g 
of methamphetamine into 6 tin cans per set, these were heated and pyrolysis 
products trapped and extracted as per the protocol in 4.2.2.1.  Each sampling tin 
can contained a total of 6 ACS strips. The trapped pyrolysis products from each set 
were desorbed using the appropriate solvent and ratio. Each resultant extract was 
analysed six times to facilitate the calculation of repeatability within a desorption 
and analysis event. Chromatographic profiles of pyrolysis products generated from 
each of the six replicate injections in each sample tin can were plotted and 
compared for similarities in retention time, peak shape, peak height as well as any 
differences in overall chemical profile.  
Within-can repeatability was evaluated through %RSD values calculated from 
average peak areas of pyrolysis products detected from the 6 replicate injections 
performed on each of the 6 strips in each tin can using both solvents and ratios.    
%RSD results for within-can repeatability for each pyrolysis product  obtained from 
the 6 cans were compiled (average peak areas of pyrolysis products detected from 
the 6 injections in each of the 6 tin cans (n=36);  their %RSDs values were calculated 
and used to establish between-can repeatability.   
 
6.3.1.1 Repeatability test results  
Typical chromatographic profiles of the detected pyrolysis products obtained from 
the 6 injections in tin can 1, (extracted using both MeOH-DCM 90:10 and MeOH-
DCM 50:50 solvents at 3540C) are displayed in figures 6.3 and 6.4.  They all show 
similar retention times, similar pyrolysis products and quantities. Tables 6.2 and 6.3 
show calculated %RSDs for tin can 1 using MeOH=DCM 90:10 and MeOH-DCM 
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50:50 respectively. Obtained %RSD values for the both solvents were in the 
analytical range of ≤5%, indicating excellent repeatability.  
Chromatographic profiles of pyrolysis products generated across the six different 
tin cans were also compared. This was followed by the calculation of %RSDs across 
these samples.  Figures 6.3 and 6.4 shows chromatographic profiles of heroin 
pyrolysis products generated at 3540C for the MeOH-DCM 50:50 and 90:10 solvents 
respectively.  Profiles revealed similar retention times but calculated %RSD values 
(tables 6.4 and 6.5) were all ≥5%, indicating that repeatability was considerably 
more challenging. Plots of pyrolysis product versus product peak area (figure 6.5 
and figure 6.6) for pyrolysis products of opium also revealed variations in product 
quantities.  This is not unreasonable given the nature of the pyrolysis event and 
that some variation would be expected to occur. 
 
6.2 Isolation of pyrolysis products of opium and analysis with the HPLC 
6.2.1 Sample preparation 
Opium samples used for the HPLC analysis were the two remaining ACS strips from 
the four prepared and detailed in section 5.1.1. In this case two of the ACS strips 
were analysed using the HPLC where one was extracted using MeOH-DCM 90:10 
and the second extracted using the mobile phase. The samples were obtained from 
finished forensic work. 
 
6.2.1.1 Results and Discussions 
The results obtained (table 6.6 and figure 6.7a) and (table 6.7 and figure 6.7b) for 
extractions using the mobile phase and for the MeOH-DCM 90:10 respectively, 
revealed the detection of the same pyrolysis products of meconin, codeine, 
morphine, noscapine, and papaverine. The last four pyrolysis products were 
alkaloids of opium while meconin is a breakdown product of noscapine. 
 
.  
233 
 
 
 
Table 6.6 Results for pyrolysis products of opium extracted in the HPLC mobile phase 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
 
HPLC  opium 
Mobile phase  25Mm buffer-ACN 
(53:47) 
Retention time  (minutes) 
315 Morphine 
Meconin 
Codeine 
Noscapine 
Thebaine 
papaverine 
 
1.31 
1.76 
2.29 
2.98 
5.87 
9.06 
358 Morphine 
Meconin 
Codeine 
Noscapine 
Thebaine 
papaverine 
 
1.31 
1.76 
2.29 
2.98 
5.87 
9.06 
398 Morphine 
Meconin 
Codeine 
Noscapine 
Thebaine 
papaverine 
 
1.31 
1.76 
2.29 
2.98 
5.87 
9.06 
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Table 6.7 Results for the pyrolysis products of opium extracted in the MeOH-DCM 90:10 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
 
HPLC  opium 
Mobile phase  25Mm buffer-ACN 
(53:47) 
Retention time  
(minutes) 
315 Morphine 
Codeine 
Noscapine 
Thebaine 
papaverine 
 
1.24 
2.34 
2.73 
4.90 
7.92 
354 Morphine 
Codeine 
Noscapine 
Thebaine 
papaverine 
 
1.24 
2.34 
2.73 
4.90 
7.92 
358 Morphine 
Codeine 
Noscapine 
Thebaine 
papaverine 
 
1.24 
2.34 
2.73 
4.90 
7.92 
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Figure 6.7 Chromatogram of pyrolysis products of opium extracted using the mobile phase (a) and 
MeOH-DCM 90:10 
 
The results obtained revealed the detection of all five major alkaloids of opium and 
also the presence of the meconin, which is a breakdown product of noscapine. 
Although noscapine is known to be the second most abundant opium alkaloid after 
morphine, it was detected in a rather large amount, which might suggest its use as 
a cutting agent in the analysed samples. The use of noscapine as a cutting agent in 
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heroin samples has been reported [191]. Noscapine is also a rather larger molecule 
(figure 5.3) (molecular weight 413.4 g/mol) when compared to other alkaloids of 
opium, and may not be easy to be broken down. Its analysis with the GCMS 
following ACS desorption might have helped with further decomposition and 
enabled its detection in larger amounts than on the HPLC.  
 
 
Figure 6.8 Chemical structure for noscapine [191] 
 
6.3 Isolation of pyrolysis products of EFV and opium and analysis with the GCMS. 
6.3.1 Sample preparation 
Six replicate samples of EFV and opium were prepared by weighing 0.5g of each 
drug, mixing the two drugs together and then placing the mixture with 6 separate 
sampling tin cans. The mixture was heated to 3540C and pyrolysis products 
extracted according to the protocol described previously in section 4.2.2.1. The 
temperature was chosen as it provided the most quantity of the EFV pyrolysis 
product across both solvent ratios. Work regarding the selection of suitable EFV 
pyrolysis temperature was discussed in detail in chapter 3.4.3. The pyrolysis 
products were trapped using four ACS in each of the six sampling cans where one of 
the four ACS strips was extracted with MeOH-DCM 90:10 and the other with 
MeOH-DCM 50:50 with the final two being reserved for HPLC analysis.  Heroin 
samples were obtained from finished forensic work. 
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6.3.2 Results and Discussions 
The results obtained from the pyrolysis of a mixture EFV and opium revealed the 
presence of meconin, EFV and its pyrolysis product 1 (table 6.8) and across the 6 tin 
cans using both solvent ratios. Typical chromatograms for pyrolysis products 
obtained from the pyrolysis of opium at 3540C (extracted using MeOH-DCM 50:50) 
is displayed in figure 6.9 and   figure 6.10 (for the MeOH-DCM 90:10). 
The EFV was found to produce the expected pyrolysis products when it heated with 
opium, but its presence in the mixture was discovered to mask the pyrolysis of 
opium. The presence of opium on the other hand did not affect the expected 
pyrolysis pattern for EFV. 
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Table 6.8 Pyrolysis products of EFV and opium extracted in the two MeOH-DCM solvent ratios at 354
0
C 
 
 
ACS 
extracting solvent 
 
 
 
Pyrolysis Temperature (0C) 
315 354 396 
 
MeOH:DCM 50:50 
 
 
 
 
 
Meconin 
EFV 
EFV pyrolysis product 1 
Meconin 
EFV 
EFV pyrolysis product 1 
Meconin 
EFV 
EFV pyrolysis product 1 
MeOH:DCM 90:10 
 
Meconin 
EFV 
EFV pyrolysis product 1 
Meconin 
EFV 
EFV pyrolysis product 1 
Meconin 
EFV 
EFV pyrolysis product 1 
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Figure 6.9 Chromatogram for pyrolysis products of EFV-opium extracted in MeOH-DCM 90:10 at 354
0
C 
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Figure 6.10 Chromatogram for the pyrolysis products of EFV-opium extracted in MeOH-DCM 50:50 at 354
0
C 
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The repeatability of the method for detected pyrolysis products of EFV and opium 
using the GCMS was not performed. This was because the repeatability of all the 
three detected products had already been performed for similar drug i.e. heroin, 
where within can repeatability was found to be excellent while the inter can results 
indicated that repeatability was not achievable for all the three pyrolysis products. 
 
6.4 Isolation of pyrolysis products of EFV and opium and analysis with the HPLC 
6.4.1 Sample preparation 
Six replicate samples of EFV and opium from finished case work were prepared by 
weighing 0.5g of each drug, mixing together and placing the mixture into a sample 
can.  6 mixed samples where prepared in this way. The mixture was heated to 
3540C and pyrolysis products extracted according to the protocol described 
previously. 
  
6.4.2 Results and Discussions 
The results obtained (table 6.9) (figure 6.11a) for mobile phase extractions and 
(table 6.10) (figure 6.11b) for the MeOH-DCM 9010 v/v revealed the presence of 
the same set of pyrolysis products in both extracts.  This consisted of a mixture of 
EFV pyrolysis product 1, meconin, codeine, papaverine and EFV. The existence of 
these products amongst known pyrolysis products of opium has already been 
discussed in the previous chapters of this thesis.  
All pyrolysis products except EFV and its pyrolysis product were detected in 
negligible amounts. This could probably be used to explain why only three products 
were detected with the GCMS; if the detected quantities were very little in the 
extracts, then they might have all decomposed upon injection in the GCMS 
(injection port) where temperatures were very high.   
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Table 6.9 Results for the pyrolysis of mixture of EFV and opium extracted in the HPLC mobile phase.  
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
 
HPLC  EFV and opium 
Mobile phase  25Mm buffer-ACN 
(53:47) 
Retention time  
(minutes) 
315 EFV product 1 
Codeine 
meconin 
Noscapine 
papaverine 
EFV 
1.01 
1.72 
2.24 
2.79 
8.12 
10.18 
354 EFV product 1 
Morphine 
meconin 
Codeine 
Noscapine 
papaverine 
EFV 
1.01 
1.35 
1.72 
2.24 
2.79 
8.12 
10.18 
 
 
 
 
Table 6.10 Results for the pyrolysis of a mixture of EFV and opium extracted in the MeOH-DCM 
90:10 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
HPLC  EFV and opium 
Mobile phase  25Mm buffer-ACN 
(53:47) 
Retention time  
(minutes) 
315 EFV product 1 
morphine 
Meconin 
Codeine 
Noscapine 
papaverine 
EFV 
1.13 
1.34 
1.71 
2.33 
2.78 
7.65 
10.23 
354 EFV product 1 
Meconin 
Codeine 
Noscapine 
Papaverine 
EFV 
1.13 
1.71 
2.33 
2.78 
7.65 
10.23 
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Figure 6.11 Chromatogram of pyrolysis products of opium extracted in the (a) mobile phase and 
(b) MeOH-DCM 90:10 
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The results obtained from the two extraction solvents were similar except for the 
absence of noscapine in the MeOH-DCM 9010 v/v and meconin in the mobile 
phase.  
Quantities of detected products were compared for the two solvents by drawing, 
plots of product vs peak area (figures 6.12a and6.12b).  The results obtained from 
both solvents revealed the detection of significant amounts of EFV and its pyrolysis 
product, and negligible amounts of opium alkaloids in bot.  A tentative explanation 
for not detecting the alkaloids with the GCMS earlier was that there was a 
possibility of the EFV masking the opium from pyrolysing which may lead to only a 
small amount being extracted. These may have been completely destroyed by the 
GCMS during analysis. The HPLC on the other hand doesn’t involve the application 
of heat hence their detection.  
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Figure 6.12 Plot of quantities of pyrolysis products of EFV and opium extracted with the a) MeOH-
DCM 90:10 and b) mobile phase  
 
Figure 6.12a and b show various amounts of opium pyrolysis products detected 
with the HPLC. Both figures confirm the negligible quantities of detected pyrolysis 
products for all products except EFV and its pyrolysis product 
 
6.5 Isolation of pyrolysis products of cannabis and analysis with the GCMS 
6.5.1 Sample preparation 
Six replicate cannabis samples were prepared following the protocol described in 
section 4.2.2.1.  The samples were from finished forensic work.  They were first 
homogenised by crushing them into fine powder using a mortar and pestle. 0.5g of 
the powdered material was weighed into 6 separate into tin cans. Each tin can was 
covered with a lid, heated to the desired temperature and removed from the hot 
plate. The covering lid was replaced with the one with prepared CAS strips (section 
4.2.2.1) and incubated for 16 hours at 800C to trap the pyrolysis products. The 
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products were trapped using four ACS in each of the six tin cans.  Following this, the 
analysis sampling strategy in section 4.2.2.2 was applied.  For GCMS analysis one of 
the four ACS strips was extracted with MeOH-DCM 90:10 and the other with 
MeOH-DCM 50:50.  
 
6.5.2 Results and Discussions 
The results obtained (Table 6.11 for both solvent extracts revealed the presence of 
cannabinol, cannabidiol, clovanediol, terpenes and flavonoids. Typical 
chromatograms of pyrolysis products obtained from the pyrolysis of heroin at 3540C 
(extracted using MeOH-DCM 90:10 and MeOH-DCM 50:50) are displayed in figure 
6.13 and 6.14 respectively.   
  
Table 6.11 Pyrolysis products of cannabis 
 
 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
 
Pyrolysis products of cannabis 
DCM:MeOH 
50:50 
DCM:MeOH 
10:90 
315 Cannabinol 
Cannabidiol 
Clovanediol 
Humulene epoxide II 
Caryophylene oxide 
Isoaromadenderene 
Terpineol 
Cannabinol 
Cannabidiol 
Clovanediol 
Humulene epoxide II 
Caryophylene oxide 
Isoaromadenderene 
Terpineol 
358 Cannabinol 
Cannabidiol 
Clovanediol 
Humulene epoxide II 
Caryophylene oxide 
Isoaromadenderene 
Terpineol 
Cannabinol 
Cannabidiol 
Clovanediol 
Humulene epoxide II 
Caryophylene oxide 
Isoaromadenderene 
Terpineol 
398 Cannabinol 
Cannabidiol 
Limoneneoxide 
Isoaromadenderene 
Terpineol 
Humulene epoxide II 
Caryophylene oxide 
Caryophylene 
1,2-dimethyl-2-octadecyl  cyclohexane 
Alcohols 
 
 
Cannabinol 
cannabicoumaronone 
Cannabidiol 
Clovanediol 
Humulene epoxide II 
Caryophylene oxide 
Caryophylene 
Isocaryophylene 
Terpineol 
Fenchol 
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Figure 6.13 Chromatogram for pyrolysis products of cannabis extracted in MeOH-DCM 50:50 at 
354
0
C 
 
 
 
 
Figure 6.14 Chromatogram for the pyrolysis of cannabis extracted in MeOH-DCM 90:10 at 354
0
C  
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Cannabinoids are a characteristic class of substances unique to cannabis. More than 
400 chemical compounds have been isolated from Cannabis sativa L., of which 
more than 80 have been reported as cannabinoids [194-195]. The most abundant 
are ∆9-tetrahydrocannabinol (∆9-THC or THC, the main psychoactive cannabinoid), 
cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG) and cannabichromene 
(CBC) [195-197].    
THC was not however detected in the samples analysed, but its degradation 
product, cannabinol, was detected in quite a substantial amount.  Cannabis samples 
with prolonged storage have been reported to have a diminished THC and an 
increased CBN content [197-199]. This probably explains why the THC was not 
detected in the used samples. Both cannabidiol and clovanediol are reportedly non-
psychoactive, however medicinal benefits of cannabidiol have been reported [200-
201].  Cannabis plants also contain other constituents commonly encountered in 
nature like terpenes, alkanes, flavonoids and nitrogenous compounds. Terpenes are 
reported to vary from one variety of cannabis to another and thought to be 
primarily responsible for differences in fragrance among the different strains [5, 
201]. Few studies exist but terpenes are thought to be contributory to the 
distinctive smoking qualities and to the character of the "high" associated with 
smoking cannabis [202]. Some studies  [203, 204] suggest that terpenes may 
somehow modify or enhance the physiological effects of the cannabinoids,  
however this has been only been assumed as hypothetical since there was no  pre-
clinical evidence at the time of these studies to support the hypothesis and also, no 
clinical trials on this subject have been carried out [204].  
 
6.5.3 Method repeatability test for pyrolysis products of cannabis 
The repeatability of the analytical methods (pyrolysis generation and desorption) 
method for cannabis pyrolysis products using the HPLC was evaluated through 
calculation of %RSDs from peak areas. Average peak areas for all the 6 replicate 
injections from the 6 ACS in sample can 1 were used to represent the within-can 
analytical repeatability. The results obtained for samples pyrolysed at 354OC from 
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the mobile phase are presented in table 6.12 while those from the MeOH-DCM 
(90:10) are in table 6.13. 3 Both results revealed %RSD values of ≤5%, indicating 
very good repeatability. 
The repeatability of inter-can results was also evaluated. This was obtained from 
%RSDs values calculated from average peak areas of pyrolysis products generated 
from the 6 injections in each of the 6 sample cans (n=36). The results obtained 
using the mobile phase are presented in table 6.14 while those for the MeOH-DCM 
90:10 are in table 6.15. Both results revealed %RSD values of ≥5%, indicating that 
repeatability was poorer as expected for this kind of work. Plots of peak area versus 
pyrolysis (figures 6.15 and 6.16) also revealed variations in the quantities of 
pyrolysis products. 
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6.6 Isolation of pyrolysis products of cannabis and analysis with the HPLC 
6.6.1. Sample preparation 
Opium samples used for the HPLC analysis were the two remaining ACS strips from 
the four prepared and detailed in section 6.1.1. In this case two of the ACS strips 
were analysed using the HPLC where one was extracted using MeOH-DCM 90:10 
and the second extracted using the mobile phase. The samples were obtained from 
finished forensic work. 
 
6.6.2 Results and Discussions 
The results obtained from samples extracted with the mobile phase (table 6.16) 
(figure 6.17a) and MeOH-DCM 90:10 (table 6.17) (figure 6.17b) revealed the 
presence of same pyrolysis products being cannabinol, cannabidiol and other 
unidentified impurities. The impurities were thought to the possibly cannabis 
terpenes or flavonoids [33, 39] as these had been detected previously in samples 
analysed with the GC-MS.  
The main psychoactive substance of cannabis, ∆9 THC, was not detected from both 
extractions but its degradation product, cannabinol was present; its absence in the 
samples is indicative that the samples used have been on storage for a long time. 
 
Table 6.16 Pyrolysis products of cannabis extracted in the mobile phase 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
HPLC  Cannabis 
Mobile phase  25Mm buffer-ACN 
(53:47) 
Retention time  (minutes) 
315 Cannabinol 
Cannabidiol 
 
4.79 
2.95 
 
358 Cannabinol 
Cannabidiol 
 
5.43 
3.28 
 
398 Cannabinol 
Cannabidiol 
 
 
4.79 
2.95 
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Table 6.17 Pyrolysis products of cannabis extracted in the MeOH-DCM 90:10 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
HPLC  Cannabis 
Mobile phase  25Mm buffer-ACN 
(53:47) 
Retention time  
(minutes) 
315 Cannabinol 
Cannabidiol 
 
 
5.43 
3.28 
358 Cannabinol 
Cannabidiol 
 
5.43 
3.28 
 
398 Cannabinol 
Cannabidiol 
 
 
5.43 
3.28 
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Figure 6.17 Chromatogram of pyrolysis products of cannabis extracted in the HPLC mobile phase 
(a) and MeOH-DCM 90:10 
 
6.6.3 Method repeatability test for pyrolysis products of cannabis using the HPLC 
The repeatability of the analytical methods (pyrolysis generation and desorption) 
method for cannabis pyrolysis products using the HPLC was evaluated through 
calculation of %RSDs from peak areas. Average peak areas for all the 6 replicate 
injections from the 6 ACS in sample can 1 were used to represent the within-can 
analytical repeatability. The results obtained for samples pyrolysed at 354OC from 
the mobile phase are presented in table 6.18 while those from the MeOH-DCM 
(90:10) are in table 6.19 (appendix B). Both results revealed %RSD values of ≤5%, 
indicating very good repeatability. 
The repeatability of inter-can results was also evaluated. This was obtained from 
%RSDs values calculated from average peak areas of pyrolysis products generated 
from the 6 injections in each of the 6 sample cans (n=36). The results obtained 
using the mobile phase are presented in table 6.20 while those for the MeOH-DCM 
90:10 are in table 6.21. Both results revealed %RSD values of ≥5%, indicating that 
repeatability was poorer as expected for this kind of work. Plots of peak area versus 
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pyrolysis (figures 6.18 and 6.19) (appendix A) also revealed variations in the 
quantities of pyrolysis products. 
 
6.7 Isolation of pyrolysis products of EFV and cannabis, and analysis with the 
GCMS 
6.7.1 Sample preparation 
Six replicate samples of EFV and cannabis (from finished forensic work), were 
prepared by weighing 0.5g of each drug,  mixing the two drugs together and then 
placing the mixture with 6 separate sampling tin cans. The mixture was heated to 
3540C and pyrolysis products extracted according to the protocol described 
previously in section 4.2.2.1. As previously discussed pyrolysis products were 
trapped using four ACS in each of the six sampling cans where one of the four ACS 
strips was extracted with MeOH-DCM 90:10 and the other with MeOH-DCM 50:50 
with the final two being reserved for HPLC analysis.   
 
6.7.2 Results and Discussions 
The results obtained revealed the presence of EFV and its pyrolysis product 1 (table 
6.22) across the 6 tin cans for both solvent extracts. Typical chromatograms for 
pyrolysis products obtained from the pyrolysis of methamphetamine at 3540C 
(extracted using MeOH-DCM 90:10) is displayed in figure 6.20 4.1.  The EFV was 
found to produce the expected pyrolysis products when it heated with cannabis but 
its presence in the mixture was discovered to mask the pyrolysis of the cannabis. 
The presence of cannabis on the other hand did not affect the expected pyrolysis 
pattern for EFV. 
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Table 6.22 Pyrolysis products of EFV and cannabis extracted in the MeOH-DCM 90:10 at 354
0
C 
 
 
ACS 
extracting solvent 
 
Pyrolysis Temperature (
0
C) 
315 354 396 
 
MeOH:DCM 50:50 
 
 
 
EFV 
EFV pyrolysis product 
EFV 
EFV pyrolysis product 
EFV 
EFV pyrolysis product 1 
MeOH:DCM 90:10 
 
EFV 
EFV pyrolysis product 
EFV 
EFV pyrolysis product 
EFV 
EFV pyrolysis product  
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Figure 6.20 Chromatogram for Pyrolysis products of EFV and cannabis extracted in MeOH 90:10 at 3540C 
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Figure 6.21 Chromatogram for pyrolysis products of EFV-cannabis extracted in the MeOH-DCM 50:50 at 354
0
C 
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The repeatability of the method for desorbed pyrolysis products of EFV and 
cannabis using the GCMS was not performed because the repeatability of the two 
detected products had been performed when EFV was heated with other  drugs, 
where the within can repeatability were found to be excellent while the inter can 
results indicated that repeatability was not achievable. 
 
6.8 Isolation of pyrolysis products of cannabis and EFV and analysis with the HPLC 
6.8.1 Sample preparation 
Six replicate samples of EFV and heroin from finished case work were prepared by 
weighing 0.5g of each drug, mixing together and placing the mixture into a sample 
can.  6 mixed samples where prepared in this way. The mixture was heated to 
3540C and pyrolysis products extracted according to the protocol described 
previously. 
 
6.8.2 Results and discussions 
The results obtained (Tables 6.23) (figures 6.21a) for mobile phase extractions and 
(Table 6.23) (figure 6.21b) for MeOH-DCM 90:10 revealed the presence of EFV and 
EFV product 1.  
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Table 6.23 Pyrolysis products of EFV-cannabis extracted in the HPLC mobile phase 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
 
 
 
HPLC  Cannabis 
 
Mobile phase  25Mm buffer-ACN 
(53:47) 
 
Retention time  
(minutes) 
 
 
 
354 
 
 
 
 
 
EFV pyrolysis product 1 
EFV 
 
1.431 
10.499 
 
 
 
 
 
Table 6.24 Pyrolysis products of EFV-cannabis extracted in MeOH-DCM 90:10 
 
 
Pyrolysis 
Temperature ( in 
degrees Celsius) 
 
 
 
 
HPLC  Cannabis 
 
Mobile phase  25Mm buffer-ACN 
(53:47) 
 
Retention time  
(minutes) 
 
 
 
354 
 
 
 
 
 
 
EFV pyrolysis product 1 
EFV 
 
 
 
1.431 
10.260 
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Figure 6.22 Chromatogram of pyrolysis products of EFV and cannabis extracted in the (a) mobile 
phase and (b) MeOH-DCM 90:10 
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The results obtained from analysis of samples extracted using MeOH-DCM 90:10 
solvent and the mobile phase revealed the presence of similar pyrolysis products. 
The two results HPLC also correlate those for the GCMS. Based on the results it was 
concluded that when EFV is heated with cannabis, it will mask/supress its pyrolysis 
but cannabis does not alter the pyrolysis of EFV.  
The repeatability of the method for desorbed pyrolysis products of EFV and 
cannabis using the HPLC was not performed because the repeatability of EFV and its 
pyrolysis product was already known. This was based on results from similar 
experimental work where EFV was heated with other drugs and the within can 
repeatability were found to be excellent while the inter can results indicated that 
repeatability was not achievable. 
  
6.9 Summary results for the pyrolysis of EFV, opium and cannabis 
The pyrolysis of opium on its own produced typical alkaloids of papaverine, 
noscapine, thebaine, morphine and codeine as well as the breakdown products of 
noscapine. However, heating a mixture of EFV and opium produced only the EFV 
and its pyrolysis product. The same scenario was observed with cannabis, which 
upon heating with EFV, the same pyrolysis products were also obtained but not the 
cannabinoids as previously observed when cannabis was heated on its own. The 
two results reveal that EFV prevents the pyrolysis the pyrolysis of the two plant 
based drugs. It can therefore be safely concluded that when a mixture of EFV and 
one of the two natural drugs is smoked for abuse, pyrolysis products will comprise 
mostly of the EFV and its pyrolysis product.  
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CHAPTER 7: DISCUSSIONS  
7.1 Summary of results 
The new South African street drug nyaope drug is allegedly comprised of a mixture 
of illicit substances including methamphetamine, amphetamine heroin, opium, 
cannabis and the anti-retro viral drug EFV as the main ingredient. Available 
information reveals that the drug is mainly abused through smoking. Nyaope was 
criminalised in 2014, even though there are no documented analytical methods for 
the identification of its smoked products, especially EFV. Analytical methods for the 
analysis of pyrolysis products of most illicit drugs which are alleged to be 
components of nyaope have already been developed but none of these includes 
EFV. As a result, the development of a single analytical methodology capable of 
identifying smoked products of EFV and all other alleged components of nyaope 
was necessary.  Through this research, an analysis methodology for the analysis of 
smoked products of nyaope including EFV, was developed and validated for the 
GCMS and HPLC techniques. This bridged the gap for EFV for which, now as a 
controlled substance, a clear analytical methodology was required.  
Literature reveals GCMS and HPLC as commonly used techniques for the 
identification of pyrolysis products. To make it a more powerful technique, the LC 
may be paired with other techniques such as MS, UV-Vis, DAD, fluorescence 
spectroscopy and others. 
 The GCMS is a discriminatory technique and capable of identifying volatile pyrolysis 
products of the nyaope but since it is destructive, the collection of these products 
for further studies is impossible. Unlike the GCMS technique, HPLC allows for the 
identification of both non-volatile and volatile pyrolysis products. The products can 
be collected in the mobile phase as they elute from the column, purified and 
studied further.   
 Many laboratories include derivatisation as part of their sample preparation for GC 
analysis.  It is a process by which a compound is chemically changed, producing a 
new compound that has properties more responsive to a particular analytical 
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method [89].  Many analytical methods exist for the derivatisation and analysis of 
some of the alleged components of nyaope like heroin and methamphetamine [205, 
206]. Street heroin may contain bulking agents which possess functional groups 
which, if not derivatised prior to analysis with the GC, are likely to exhibit poor peak 
shape and poor separation.  One of such bulking agents for heroin is 
acetaminophen (commonly known as paracetamol), which has both the hydroxyl 
and carbonyl functional groups. Like paracetamol, methamphetamine and 
amphetamine possess polar amino groups, which can cause them separate poorly if 
not derivatised. Even though necessary at times, derivatisation can also complicate 
the interpretation of the analytical data because the resultant reaction may 
introduce impurities, uncertainty on the completeness of the analytes’ conversion, 
and other interference factors.  
Derivatisation of samples was not considered for this research because the main 
aim was to isolate the pyrolysis products of EFV; an analysis which had never been 
performed previously. Based on the chromatographic profile obtained, this did not 
seem to have affected the separation of EFV as very resolved peaks were obtained. 
Heroin and ATS drugs were affected by non derivatisation as poorly shaped and 
separated peaks for methamphetamine, amphetamine and paracetamol were 
obtained. It is not known as to what will happen when EFV is derivatised, but since 
it is has both the carbonyl and hydroxyl group, it might yield more than the pyrolysis 
product.    
Separation column efficiency can be improved in many ways. Factors that influence 
column efficiency and how they can be improved are elaborated under the Van 
Deemter equation theory. Chromatography literature reveals that length of the GC 
column is proportional to the number of theoretical plates and that increasing 
length will enhance the separation resolution by roughly 1.4 times [89]. The length 
of the separation column used for this research was 15 meters. It will be interesting 
to find out whether the analysis of pyrolysis products of EFV on a longer column will 
still reveal only one pyrolysis product.  
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The new method was used to investigate the effect of efavirenz on the pyrolysis of 
other alleged components of the nyaope drug mixture (amphetamine, 
methamphetamine, heroin, opium and cannabis) and vice versa. This was 
performed by heating each drug on its own followed by mixing it with EFV and 
heating the mixture. A summary of results are presented in table 7.1. 
 
Table 7.1. Summary of results obtained from the pyrolysis of EFV and other drugs alleged to be in 
the Nyaope mixture using both the GCMS and HPLC 
 
 
According to results obtained, the pyrolysis of each drug on its own yielded the 
expected pyrolysis products. EFV was found to produce only one pyrolysis product 
when heated on its own and in all drug mixtures. The presence of EFV was found 
not to have influence the expected pyrolysis processes of amphetamine type 
stimulant drugs and of heroin. However the presence of EFV in cannabis and opium 
mixtures was discovered to have prevented the pyrolysis of the two drugs. Opium 
and cannabis are both drugs derived from natural materials; it is not known why 
this happened but one possible answer could be the length time at which the 
samples were heated. It is not known what could have happened if the samples 
were heated a bit longer; but it will be interesting to see if this would still yield only 
pyrolysis product.  
Alleged  Nyaope street 
drug component 
Pyrolysis of the drug 
material on its own  
Pyrolysis of drug 
material with EFV 
Amphetamine √ √ 
Methamphetamine √ √ 
Heroin √ √ 
Opium √ EFV + pyrolysis product 1 
Cannabis √ EFV + pyrolysis product 1 
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 In forensic science, ACS is commonly used to trap traces of ignitable liquids during 
fire investigations, but recently its application has since been extended to trapping 
volatile substances from human remains [207, 208] and for trapping impurities from 
volatile chemicals during clandestine drug laboratory investigations [209]. While 
other trapping media are available and have been used successfully [210-212], the 
robustness and its successful use as a trapping media made it a preferred choice for 
use in the study given that the method was developed for Africa where the success 
of an analysis depends on other factors like the availability of finances and also 
electrical energy to operate instruments.  
When used for this research, the ACS was able to trap pyrolysis products which had 
been reported before with the use other trapping media [213]. This successful use 
of ACS as a trapping medium for pyrolysis products of EFV and other alleged 
components of the nyaope drug mixture makes it a possible cheaper alternative for 
the adsorption of pyrolysis products of illegal drugs, particularly those in the nyaope 
mixture.  
The repeatability of the method for pyrolysis products of EFV, other drugs and EFV-
drug mixtures was evaluated; %RSD results of peak areas for pyrolysis products 
from each tin can were calculated and used to represent analytical repeatability of 
products within each can (within-can repeatability). Analytical reproducibility was 
calculated using %RSD for average peak areas (n=6) of pyrolysis products detected 
within each can compared across all 6 tin cans to generate the between can 
reproducibility (n=36). The results are summarised in table 7.2 and 7.3 below. 
Calculated %RSDs for the analysis of pyrolysis products within a can were all ≤5%, 
indicating excellent repeatability while those for inter-can repeatability were all 
≥5%, indicating that repeatability was more challenging. Results for inter-can 
repeatability were expected due to the nature of the pyrolysis experiment. 
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Table 7.2 Summary of GCMS results for analytical repeatability of pyrolysis products of EFV and other alleged 
components of nyaope street drug 
 
 
 
 
 
 
 
 
 
Alleged nyaope 
component 
%RSD results for 
within-can 
analytical 
repeatability  in 
MeOH-DCM 
50:50 
%RSD results for 
inter-can analytical 
repeatability  in 
MeOH-DCM 50:50 
%RSD results for 
within-can analytical 
repeatability  in 
MeOH-DCM 90:10 
%RSD results for 
inter-can 
analytical 
repeatability  in 
MeOH-DCM 90:10 
Methamphetamine 0.8-5 64-150 0.6-5 37-87 
  
EFV and 
methamphetamine  
0.8-6 12-108 0.002-0.8 37-95 
Amphetamine 0.1-6 36-132 0.02-2 86-180 
  
EFV and 
amphetamine  
0.1-6 36-133 0.01-2 18-150 
Heroin 0.02-3 58-256 0.002-2 47-166  
EFV and heroin  0.1-5 75-198 0.27-4 48-102 
Opium 0.4-0.6 194-239 0.004-0.3 182-237 
 
Cannabis 0.8-2 40-132 0.01-2 28-245 
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Table 7.3 Summary of HPLC results for analytical repeatability of EFV and methamphetamine pyrolysis 
products 
Alleged Nyaope 
component 
%RSD results for 
within-can 
analytical 
repeatability  in 
mobile phase 
%RSD results for 
inter-can 
analytical 
repeatability  in 
mobile phase 
%RSD results for 
within-can 
analytical 
repeatability  in 
MeOH-DCM 90:10 
%RSD results for 
inter-can 
analytical 
repeatability  in 
MeOH-DCM 90:10 
Methamphetamine 0.01-4 6 -75 0.14-2 17-61 
  
EFV and 
methamphetamine  
0.7-5 24-50 0.04-0.4 10-80 
Amphetamine 0.4-2 2-118 0.0023-3 47-121 
  
EFV and 
amphetamine  
0.2-3 35-69 0.008-2 100-257 
Heroin 0.06-2 14-97 0.20-2 14-97 
  
EFV and heroin  0.1-5 75-198 0.3-4 48-102 
Opium 0.4-0.6 132-265 0.004-0.3 182-237 
 
Cannabis 
 
0.5-0.8 143-186 0.2-0.2 32-53 
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Comparison of results obtained from samples extracted using the MeOH-DCM 
90:10 for both the HPLC and the GCMS were performed for each EFV drug mixture. 
The results obtained (table 7.1) were used to draw conclusions about the suitability 
of each technique for the analysis of alleged components of the nyaope drug 
mixture following extractions with MeOH-DCM 90:10.  
 
Table 7.4 Number of pyrolysis products obtained using the MeOH-DCM 90:10 for both the GCMS and HPLC 
Alleged  nyaope 
street drug 
component 
Number of detected pyrolysis 
products in MeOH-DCM 90:10 
(GCMS) 
Number of detected pyrolysis 
products in MeOH-DCM 90:10 
(HPLC) 
Single drug EFV-drug  
mixture 
Single drug EFV-drug 
mixture 
Methamphetamine 7 9 7 8 
Amphetamine 6 11 4 6 
Heroin 6 6 3 6 
Opium 6 2 3 2 
cannabis 8 2 2 2 
 
Based on the highest number of pyrolysis products obtained between the two 
techniques, it can safely be concluded that that the method recommended for the 
analysis of alleged components of the nyaope street drug is the GCMS method. The 
analytical repeatability factor could not be used to discriminate between the two 
methods since it had already been established that the two techniques were 
capable of producing excellent within- can analytical repeatability results.  
Results obtained from both MeOH-DCM solvent ratios for the GCMS analysis (table 
7.2) were compared and used to determine the most suitable  solvent  (between 
the two) for extracting pyrolysis products of alleged components of nyaope drug 
mixture for analysis with the GCMS.  
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Table 7.5 Total number of pyrolysis products obtained from the GCMS extracted using MeOH-DCM 
50:50 and 90:10 
Alleged  nyaope 
street drug 
component 
Number of detected pyrolysis 
products in MeOH-DCM 90:10 
(GCMS) 
Number of detected pyrolysis 
products in MeOH-DCM 50:50 
(GCMS) 
Single drug EFV-drug  
mixture 
Single drug EFV-drug 
mixture 
Methamphetamine 7 9 9 13 
Amphetamine 6 11 9 11 
Heroin 6 6 8 8 
Opium 6 2 6 2 
cannabis 8 2 7 2 
 
According to the results obtained, the highest number of pyrolysis products was 
obtained from extractions using MeOH-DCM 50:50.  This therefore makes it the 
most suitable solvent for the extraction of pyrolysis products of alleged 
components of the nyaope drug mixture.  
 
7.2 CONCLUSIONS 
A methodology for routine isolation and analysis of pyrolysis products of Efavirenz 
in its mixture with other alleged components of the Nyaope street drug was 
developed and validated for the GCMS and HPLC techniques. The research has 
bridged the gap for EFV for which, now as a controlled substance, a clear analytical 
methodology was required. EFV was found to produce only one pyrolysis product 
which did not interfere with the pyrolysis processes of amphetamine type stimulant 
drugs and heroin. The pyrolysis of EFV with cannabis and opium however only 
yielded EFV and its pyrolysis product; no cannabinoids or opium alkaloids were 
detected. The successful use of ACS as a trapping medium for pyrolysis products of 
EFV and other components of the Nyaope drug mixture confirms it as a possible low 
cost option for the adsorption of pyrolysis products of illegal drugs in the Nyaope 
drug mixture. 
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7.2. RECOMMENDATIONS FOR FUTURE WORK 
Now that it has been confirmed that the pyrolysis of EFV produces a pyrolysis 
product that can be detected and quantified, it is recommended that further 
studies on this product together with determination of its correct chemical 
structure be conducted using more accurate techniques such as High Resolution 
Mass Spectroscopy (HRMS) and Nuclear Magnetic Resonance Spectroscopy (NMRS). 
Once this has been achieved the product can be synthesised and its 
neuropharmacology studied further.  
 
According to the study by Gatch et al [69], it has been confirmed that the 
behavioural pharmacology produced by EFV in mice is very similar to that produced 
by Lysergic acids (LSDs); receptor binding assays could be performed using the 
pyrolysis product and known LSD receptors. The studies could potentially 
determine if the product is abused for the same or similar hallucinogenic-type 
effects.  
The studies of the pyrolysis product(s) could also be studied to see if they correlate 
with some of the alleged EFV medication-induced side effects described as adverse 
neuropsychiatric events in the literature such as anxiety, depression and 
hallucinations [70, 214].  
 
Derivatisation of samples was not performed during this study; it is recommended 
that EFV samples and those containing EFV in mixtures with other drugs (used to 
mimic the nyaope drug mixture) be derivatised in future and the results obtained 
compared with those obtained during this study. This is important for EFV, which, 
given its chemical structure; might yield more than one pyrolysis products upon 
derivatisation.  
 
Since the study involved the use of substances that mimicked the nyaope street 
drug, it is recommended that the method be extended to the analysis of real life 
cases.  
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The use of a proper cigarette smoking machine or a smoking simulator is 
recommended to allow for further studies of the pyrolysis products of EFV. 
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Appendix A: Chromatic profiles of pyrolysis products of different drugs alleged to be components of nyaope drug mixture 
Chromatographic overlays of pyrolysis products of amphetamine, heroin, opium, and cannabis are displayed in figures 4.43 –figure 4. 
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Figure 4.43 Overlay of chromatographic profiles of amphetamine pyrolysis products extracted in MeOH-DCM 50:50 at 3540C. A large amphetamine peak is highlighted 
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Figure 4.44 Overlay of chromatographic profiles of pyrolysis products of amphetamine extracted in MeOH-DCM 90:10 at 354
0
C. A large amphetamine peak is shown. 
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Figure 4.45 Overlay of chromatographic profiles of pyrolysis products of amphetamine extracted in MeOH-DCM 50:50 and 90:10 at 354
0
C and 398
0
C 
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Figure 4.50 Overlay of chromatographic profile of pyrolysis products of EFV-amphetamine extracted with MeOH-DCM 50:50. EFV pyrolysis product 1 is shown at 
11minutes and EFV at 16 minutes 
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Figure 4.51 Overlay of chromatographic profiles of pyrolysis products of EFV-amphetamine in MeOH-DCM 90:10 at 3540c, showing EFV pyrolysis product 1 peak at 11 minutes  
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Figure 5.4 Overlay of chromatographic profiles of heroin at four different temperatures extracted in MeOH-DCM 50:50 at 354
0
C 
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Figure 5.5 Overlay of chromatographic profiles of pyrolysis products of heroin at four different temperatures extracted in MeOH-DCM 90:10 at 354
0
C 
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Figure 5.6 Overlay of chromatographic profiles of pyrolysis products of heroin extracted in MeOH-DCM 50:50 at 354
0
C, showing a large paracetamol peak at 11 minutes 
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Figure 5.7 Overlay of chromatographic profile of pyrolysis products of heroin extracted in MeOH-DCM 90:10 at 354
0
C, also showing a large paracetamol peak at 11 
minutes. 
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Figure 5.12 Overlay of chromatographic profile of pyrolysis products of EFV-heroin for within-can repeatability extracted in MeOH-DCM 50:50 at 354
0
C, showing EFV 
peak at 16 minutes 
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Figure 5.13 Chromatographic profile of pyrolysis products of EFV-heroin for within-can repeatability extracted with MeOH-DCM 90:10, also showing EFV peak at 16 
minutes 
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Figure 6.3 Overlay of chromatographic profiles for pyrolysis products of heroin extracted in MeOH-DCM 50:50 at 354
0
C 
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Figure 6.4 Overlay of chromatographic profiles of pyrolysis products of opium extracted in MeOH-DCM 90:10 at 354
0
C 
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Figure 6.15 Overlay of chromatographic profiles of cannabis extracted in MeOH-DCM 50:50 at 354
0
C 
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Figure 6.16 Overlay of chromatic profiles of cannabis extracted in MeOH-DCM 90:10 at 354
0
C 
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Appendix B. Statistical tables for pyrolysis products of different drugs (amphetamine, heroin, opium and cannabis) in single drugs and in mixtures with EFV 
 
 
Table 4.26 %RSD results for amphetamine pyrolysis product vs peak area for within-can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
 
Pyrolysis products 
 
 
Pyrolysis product Abundance 
 
ACS 1 ACS 2 ACS 3 ACS  4 ACS 5 ACS 6 Average Stdev RSD% 
2-Furan carboxaldehyde-5 methyl 395422 
 
383564 386745 391001 387676 ND 388881.6 4516 1.16 
Benzaldehyde 
 
1152712 1162610 1103211 1216546 1143242 1126716 1150839 51568 4.48 
2-furan methanol 
 
1249049 1234521 1227642 1211176 1222534 1106498 1208570 762 0.06 
dimethyl acetal-benzaldehyde 
 
80196 ND 80776 82152 81665 81315 81220 4572 5.63 
alpha-methyl, Benzeneethanol 
 
415229 ND 413721 421165 421334 411103 416510 7368 1.77 
1-phenyl-1,2-propanedione , 
 
480531 ND 484261 497052 492226 480718 486958 7368 1.51 
Isosorbide 
 
1196787 1126671 ND 1224327 1115332 1243161 1181256 503 0.04 
N-Formylamphethamine 
 
93969 93421 94606 94365 93496 93511 93895 2883 3.07 
N-acetylamphetamine 
 
214832 214217 216327 212772 221002 214441 215599 2632 1.22 
ND =not detected 
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Table 4.27  %RSD results for amphetamine pyrolysis product vs peak area for analytical within-can repeatability extracted in MeOH-DCM 90:10 at 3540C 
 
Pyrolysis products 
 
 
Pyrolysis product Abundance 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev RSD% 
 
2-Furan carboxaldehyde-5 methyl 446920 465567 453633 445763 451102 446521 451584.3 7499.689 1.66 
Benzaldehyde 
 332150 332510 332147 332151 332150 332155 332210.5 146.75 0.04 
1-phenyl-2-propanol 
 331150 331153 331153 332101 331151 331151 331309.8 387.59 0.12 
1-phenyl-1,2-propanedione 
 213172 213170 213210 213100 213111 213051 213135.7 58.44 0.03 
N-Formylamphethamine 
 836003 836003 836401 836002 836006 836002 836069.5 162.41 0.02 
N-acetylamphetamine 
 246951 246702 246977 244951 246954 246702 246539.5 788.50 0.32 
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Table 4.28  %RSD results for amphetamine pyrolysis product vs peak area for inter-can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
Pyrolysis product 
 
 
 
Relative abundance (product peak area ) 
 
Can 1 Can 2 Can 3 Can 4 Can5 Can 6 Average Stdev %RSD 
2-Furan carboxaldehyde-5 methyl 395422 2834342 89521 2267231 2480004 ND  1613304 1272289 78.86231 
 
Benzaldehyde 
 
1152712 5307573 202946 22780186 20218632 4169196 8971874 9916504 110.5288 
2-furan methanol 
 
1249049 17460378 25781 23385488 28153910 11064989 13556599 11538587 85.11417 
dimethyl acetal-benzaldehyde 
 
80196 ND 40595 5836196 3626315 340423 1984745 2628652 132.4428 
alpha-methyl, Benzeneethanol 
 
1152712 5307573 202946 22780186 20218632 4169196 8971874 9916504 110.5288 
1-phenyl-1,2-propanedione , 
 
1249049 17460378 25781 23385488 28153910 11064989 13556599 11538587 85.11417 
Isosorbide 
  
1196787 6253603 ND 22153807 14370445 14619318 11718792 8138101 69.44488 
N-Formylamphethamine 
  
93969 434212 44609 786532 50007 401475 301800.7 295016.5 97.75212 
N-acetylamphetamine  
  
214832 522217 312027 561004 300043 350405 376754.7 135716.4 36.02249 
ND = not detected 
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Table 4.29  %RSD results for amphetamine  pyrolysis products vs peak area for inter-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
 
Pyrolysis products 
 
 
Pyrolysis product Abundance 
 
can 1 can 2 can 3 can 4 can 5 can 6 Average Stdev RSD% 
 
2-Furan carboxaldehyde-5 methyl 
 
446920 578321 1932353 1229394 683311 3639779 1418346.33 1218544.83 85.91 
Benzaldehyde 
 
332150 192961 23555507 886210 327910 27682037 8829462.5 13072422 148.05 
1-phenyl-2-propanol 
 
331150 212238 6136364 2333520 823990 11274158 3518570 4399058.38 125.02 
1-phenyl-1,2-propanedione 
 
213172 143178 1633245 497467 293483 9357204 2022958.16
7 
3635110.60 179.69 
N-Formylamphethamine 
 
836003 1239531 17901073 7579575 4045002 59812121 15235550.8
3 
22721151 149.13 
N-acetylamphetamine 
 
246951 174358 2682964 932705 522124 357366 819411.33 951980.49 116.18 
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Table 4.31  %RSD results for EFV-amphetamine pyrolysis product vs peak area for within–can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
 
 
Pyrolysis product 
 
 
Relative peak area across the six tin cans 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS  6 Average Stdev RSD% 
2-Furan carboxaldehyde-5 
methyl 
395422 383564 386745 391001 387676 ND 388881.6 4515.64 1.16 
Benzaldehyde 
 
1152712 1162610 1103211 1216546 1143242 1126716 1150840 51567.86 4.48 
2-furan methanol 
 
1249049 1234521 1227642 1211176 1222534 1106498 1208570 761.80 0.06 
dimethyl acetal-benzaldehyde 
 
80196 ND 80776 82152 81665 81315 81220.8 4571.52 5.62 
alpha-methyl, Benzeneethanol 
 
415229 ND 413721 421165 421334 411103 416510.4 7368.15 1.77 
1-phenyl-1,2-propanedione , 
 
480531 ND 484261 497052 492226 480718 486957.6 7368.15 1.51 
Isosorbide 
 
1196787 1126671 ND 1224327 1115332 1243161 1181256 502.64 0.04 
N-Formylamphethamine 
 
93969 93421 94606 94365 93496 93511 93894.7 2882.83 3.07 
N-acetylamphetamine 
 
214832 214217 216327 212772 221002 214441 215598.5 2631.65 1.22 
EFV pyrolysis product 1 
 735848 745574 734471 729875 732001 744520 737048.2 5965.58 0.81 
EFV 
 
395422 383564 386745 391001 387676 ND 388881.6 4515.64 1.16 
   Key: ND = not detected 
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Table 4.32 %RSD results for EFV-amphetamine pyrolysis product vs peak area for within-can analytical repeatability extracted in MeOH-DCM 90:10 at 35
0
C 
 
 
Pyrolysis product 
 
 
Relative peak area across the six tin cans 
 
ACS 1  ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev RSD% 
 
 
2-Furan carboxaldehyde-5 methyl 
ND ND 25356554 25552339 25344765 25566632 25455072.5 120802.78 0.47 
Benzaldehyde 
 
5931887 5893187 5893186 5893884 5893266 5891789 5899533.17 15865.01 0.27 
2-furan methanol 
 
9577887 9577886 9578790 9576532 9577654 9576643 9577565.33 852.34 0.01 
dimethyl acetal-benzaldehyde 
 
1249049 1249048 1239887 1249056 1246765 1238067 1245312 5019.41 0.40 
alpha-methyl, Benzeneethanol 
 
545963 545965 545946 545599 545607 545956 545839.33 183.20 0.03 
1-phenyl-1,2-propanedione , 
 
705610 705598 705600 705776 704321 706550 705575.83 716.37 0.10 
Isosorbide 
 
5429163 5429100 5428956 5429064 5428967 5329066 5412386 40818.37 0.75 
N-Formylamphethamine 
 
88401 88423 88412 88489 88400 88422 88424.5 33.10 0.04 
N-acetylamphetamine 
 
154265 154265 154456 154332 154667 154767 154458.67 214.26 0.14 
EFV pyrolysis product 1 
 
1776931 1776653 1776865 1698866 1776524 1776543 1763730.33 31777.34 1.80 
EFV 
 
230732 243330 232225 237864 238768 245033 237992 5738.54 2.41 
   Key: ND = not detected 
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Table 4.33  %RSD results for amphetamine pyrolysis products vs peak area for inter-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
 
 
Pyrolysis product 
 
 
Relative peak area across the six tin cans 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev RSD% 
2-Furan carboxaldehyde-5 methyl ND 383564 25356554 25552339 778543 456632 10505526.4 13647419.15 129.91 
Benzaldehyde 
 
5931887 ND 13647704 15559469 14453908 166532 8313493.5 7180767.09 86.37 
2-furan methanol 
 
9577887 ND 121155 288353 550987 4352622 2978200.8 4084551.69 137.15 
dimethyl acetal-benzaldehyde 
 
1249049 ND 1162114 1590992 1347800 1776292 1425249.4 253469.30 17.78 
alpha-methyl, Benzeneethanol 
 
545963 ND 771392 1019154 6721132 9833422 3778212.6 4255207.03 112.62 
1-phenyl-1,2-propanedione , 
 
705610 88693 834380 1027662 444611 459982 593489.67 332840.37 56.08 
Isosorbide 
 
5429163 ND 6580054 18120023 5642231 6549902 8464274.6 5422739.61 64.07 
N-Formylamphethamine 
 
88401 ND 173407 556388 432218 2223114 694705.6 875131.60 125.97 
N-acetylamphetamine 
 
154265 ND 346166 718409 443232 4562221 1244858.6 1865589.08 149.86 
EFV pyrolysis product 1 
 
1776931 ND 5881957 11932547 7225454 223087 5407995.2 4641267.95 85.82 
EFV 
 
230732 ND 272225 2956722 332122 1115023 981364.8 1162728.01 118.48 
Key: ND = not detected 
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Table 4.34  %RSD results for pyrolysis products of EFV-amphetamine for inter-can can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
 
 
Pyrolysis product 
 
 
Relative peak area across the six tin cans 
 
can 1 can 2 can 3 can 4 can 5 can 6 Average Stdev RSD% 
2-Furan carboxaldehyde-5 methyl 395422 2834342 89521 2267231 2480004 ND 1613304 1272289 78.86 
Benzaldehyde 
 
1152712 5307573 202946 22780186 20218632 4169196 8971874 9916504 110.52 
2-furan methanol 
 
1249049 17460378 25781 23385488 28153910 11064989 13556599 11538587 85.11 
dimethyl acetal-benzaldehyde 
 
80196 ND 40595 5836196 3626315 340423 1984745 2628652 132.44 
alpha-methyl, Benzeneethanol 
 
415229 ND 379099 2388305 2214219 643043 1207979 1005029 83.20 
1-phenyl-1,2-propanedione , 
 
480531 ND 134261 2137052 2011194 580398 1068687 933706.2 87.37 
Isosorbide 
 
1196787 6253603 ND 22153807 14370445 14619318 11718792 8138101 69.44 
N-Formylamphethamine 
 
93969 434212 44609 786532 50007 401475 301801 295017 97.75 
N-acetylamphetamine 
 
214832 522217 312027 561004 300043 350405 376754.7 135716.4 36.02 
product 1 
 
735848 12787407 625617 34005027 13150736 3999327 10883994 12640895 116.14 
EFV 
 
211326 2241461 311057 14021370 9264184 355804 4400867 5856796 133.08 
 
  
308 
 
 
Table 4.37  %RSD results for analytical within-can repeatability for pyrolysis products of amphetamine extracted in the mobile phase at 354
0
C 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
ACS 1  ACS2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
Benzaldehyde 166.353 165.504 165.335 165.352 165.994 165.665 165.70 0.40 0.24 
Furan methanol 50.994 49.009 50. 944 49.998 51.014 50.221 50.25 0.83 1.65 
P2P 14.109 14.271 14. 326 14.76 13.786 14.86 14.36 0.45 3.14 
Dimethyl amphetamine 80.626 81.098 80.302 80.441 81.118 80.223 80.63 0.39 0.49 
 
 
Table 4.38 %RSD results for pyrolysis product of amphetamine for analytical inter-can repeatability extracted in the MeOH-DCM 90:10 at 35
40
C 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
ACS 1 ACS 2  ACS 3 ACS 4 ACS 5 ACS  6 Average Stdev %RSD 
Benzaldehyde 16.772 16.772 16.772 16.771 16.769 17.001 16.771 0.0012 0.008 
Dimethylamphetamine 60.258 59.3334 60.336 61.1 61.002 60.44 60.41 0.63 1.05 
P2P 10.669 10.212 10.656 10.668 10.663 10.664 10.59 0.18 1.74 
furan methanol 19.285 19.287 19.285 19.289 19.287 19.287 19.29 0.0015 0.008 
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Table 4.39 %RSD results for inter-can analytical repeatability for pyrolysis products of amphetamine extracted with the mobile phase at 354
0
C 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
Can  1 Can 2 Can 3 Can 4 Can  5 Can  6 Average Stdev %RSD 
Benzaldehyde 166.353 46.068 154.003 127.99 57.981 156.223 118.10 52.86 44.76 
Furan methanol 50.994 54.994 35.091 67.453 98.993 78.894 64.40 22.55 35.02 
P2P 14.109 14.123 66.99 45.143 13.786 33.786 31.32 21.77 69.49 
Dimethyl amphetamine 80.626 36.21 97.098 123.99 67.762 88.11 82.30 29.43 35.75 
 
 
Table 4.40 %RSD results for pyrolysis products of amphetamine for analytical inter-can repeatability extracted in the MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
Can  1 Can 2 Can 3 Can 4 Can  5 Can  6 Average Stdev %RSD 
Benzaldehyde 16.772 431 174.223 88.997 16.77 210.22 156.33 156.30 99.98 
Dimethylamphetamine 60.258 258 60.876 47.068 10.66 36.771 78.94 89.66 113.58 
P2P 10.669 341.695 57.33 32.261 91.408 68.662 100.34 258.33 257.46 
furan methanol 19.285 68.332 13.99 18.082 427.423 88.11 105.87 160.48 151.58 
310 
 
 
Table 4.43  %RSD results for EFV-amphetamine pyrolysis products vs peak area for within-can analytical repeatability extracted in the mobile phase at 354
0
C 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
ACS 1 ACS 2 ACS 3 ACS4  ACS 5 ACS 6 Average Stdev %RSD 
Benzaldehyde 790.989 751.684 790.989 793.897 791.673 793.99 785.54 16.64 2.12 
Furan methanol 94.342 94.341 94.299 93.998 94.212 89.567 93.46 1.91 2.05 
EFV pyrolysis product 1 160.065 160.443 160.564 159.443 160.443 161.005 160.33 0.53 0.33 
P2P 57.498 57.308 56.998 57.398 57.4 57.786 57.40 0.26 0.45 
Dimethyl amphetamine 5.537 5.537 5.334 5.675 5.347 5.475 5.48 0.13 2.36 
EFV 130.956 130.967 129.776 131.09 131 131.221 130.83 0.53 0.40 
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Table 4.44  %RSD results for EFV-amphetamine pyrolysis product vs peak area for within-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
 
Pyrolysis product 
Pyrolysis product peak area at 3540C 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
Benzaldehyde 232.351 232.349 232.35 232.34 232.349 232.339 232.35 0.005 0.0023 
Furan methanol 431.879 433.841 431.708 430.889 431.098 439.898 433.22 3.44 0.79 
EFV pyrolysis product 1 510.065 510 513.32 510.335 513.998 510.332 511.34 1.81 0.35 
P2P 325.67 323.672 323.656 323.157 323.673 323.6 323.90 0.89 0.27 
Dimethyl amphetamine 22.711 22.463 23.767 22.221 23.274 23.756 23.03 0.66 2.884 
EFV 335.042 334.987 334.092 333.989 335 335.876 334.79 0.69 0.21 
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Table 4.45  %RSD results for EFV-amphetamine pyrolysis products vs peak area for within-can analytical repeatability extracted in the mobile phase at 354
0
C 
 
 
 
 
 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
Can 1 Can 2 Can 3 Can 4 Can 5 Can 6 Average Stdev %RSD 
Furan methanol 790.989 751.684 309.875 1036.91 118.088 880.42 647.99 355.42 54.85 
Benzaldehyde 94.342 21.547 25.407 266.766 334.581 22.8 127.57 138.56 108.61 
EFV pyrolysis product 1 160.065 74.972 85.735 525.159 585.134 127.789 259.81 231.56 89.13 
P2P 57.498 29.672 14. 326 85.946 69.0944 87.053 65.85 23.68 35.96 
Dimethyl amphetamine 5.537 ND 5.702 ND ND 5.501 5.58 0.11 1.92 
EFV 130.956 78.96 16.566 29.521 321.602 20.078 99.61 117.32 117.78 
313 
 
 
 
 
Table 4.46  %RSD results for EFV-amphetamine pyrolysis product vs peak area for inter-can analytical repeatability extracted in MeOH-DCM 90:10 at 3540C 
 
 
 
 
Pyrolysis product Pyrolysis product peak area at 3540C 
 
Can 1 Can 2 Can 3 Can 4 Can 5 Can 6 Average Stdev %RSD 
Furan methanol 232.351 181.058 492.542 106.181 244.324 455 285.24 154.39 54.137 
Benzaldehyde 431.879 407.817 301.017 243.583 928.366 125.882 406.42 279.07 68.67 
EFV pyrolysis product 1 510.065 361.255 956.545 526.717 951.3811 325.099 605.17 281.59 46.53 
P2P 325.67 220.037 740.277 157.025 327.288 98.021 311.39 228.95 73.53 
Dimethyl amphetamine 22.711 15.735 44.915 10.919 23.274 34.022 25.26 12.41 49.12 
EFV 335.042 206.116 1299.377 112.498 325.118 20.078 383.04 465.10 121.42 
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Table 5.2 %RDS results for pyrolysis products of heroin vs peak area for within-can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C  
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1  
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
acetaminophen 212887618 211889422 212888774 212887661 212891170 218879551 213720699.3 2558731.06 1.20 
 
meconin lactone 31461096 31461087 31461096 31687331 31452733 32140011 31610559 275006.42 0.87 
hydrocortanine 1952080 1952080 1952088 1952082 1952080 1952911 1952220.167 338.45 0.02 
diacetamate 12094103 12094103 12094413 12094103 12092321 12908891 12229655.67 332756.85 2.72 
caffeine 120994103 120994103 120994100 120897811 120994103 120994102 120978053.7 39310.72 0.03 
acetylcodeine 11097064 11097054 11097064 11097062 11097000 11180466 11110951.67 34054.94 0.31 
6-
monoacetylmorphine 
59449638 59449666 59355225 59488892 58877745 59449044 59345035 233180.58 0.39 
papaverine 345543828 345543828 345554376 352334561 345571291 355567812 348352616 4455545.65 1.28 
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Table 5.3 %RSD results for heroin pyrolysis products vs peak area for within can analytical repeatability extracted in MeOH-DCM 9010 at 354
0
C. 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
acetaminophen 320331996 320331996 320398790 320059678 320033189 320331996 320247940.8 158437.70 0.05 
 
meconin lactone 111381498 111386758 111381498 111381498 111381498 111381498 111382374.7 2147.39 0.002 
hydrocortanine 21219928 20323428 21219944 21219927 21222298 21219928 21070908.83 366190.55 1.74 
caffeine 239598362 239587601 229522100 239582100 239598378 241576382 238244153.8 4346049.26 1.82 
morphine 28461545 27659908 28461500 28461544 28461545 28461545 28327931.17 327263.18 1.15 
acetylcodeine 44995255 46145335 44995255 44995255 44995255 44995255 45186935 469518.19 1.04 
6-onoacetylmorphine 362335492 362335495 362335889 362335394 360443667 362335412 362020224.8 772352.47 0.21 
papaverine 35240948 35240943 35240679 35240950 35248776 35248876 35243528.67 4104.73 0.01 
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Table 5.4 %RSD results for heroin pyrolysis products vs peak area for inter-can analytical repeatability extracted in MeOH-DCM 50:50 at 354
O
C. 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1 
 
 
Can 1 Can 2 Can 3 Can 4 Can 5 Can 6 Average Stdev %RSD 
 
acetaminophen 257004 29950818 10193917 20644053 205283249 56493507 53803758 76669254 
142.50 
 
Meconin lactone 31461096 176760229 2431104811 613399068 31213203 31213203 552525268 947523772.1 171.49 
hydrocortanine 1952080 119845872 1952088 87580571 93546169 33381192 56376329 50668447 89.86 
diacetamate 12094103 12094103 12094413 12094103 12092321 12908891 12229656 332756.8 2.72 
caffeine 120994103 302775207 223510540 2406558813 136684063 2334369 532142849 923842691.3 173.61 
acetylcodeine 11097064 748449657 53185688 52028045 26165585 545693086 239436521 322590193.8 134.73 
6-monoacetylmorphine 59449638 594221121 450603521 451376933 181251264 640535944 396239737 230008874.1 
58.05 
 
papaverine 44071165 53803758 28069109 25299060 - 33034605 15334036 39308558 256.35 
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Table 5.5 %RSD results for heroin pyrolysis product vs peak area for inter-can analytical repeatability extracted  in MeOH-DCM 90:10 at 354
0
C. 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1 
 
 
Can 1 Can 2 Can 3 Can 4 Can 5 Can 6 Average Stdev %RSD 
 
 
acetaminophen 
320331996 396000790 3410253 264865981 1338855779 117763201 406871333.3 478065290.1 117.50 
meconin lactone 111381498 857316179 167520732 140537964 665683830 63496562 334322794.2 338155992 101.15 
hydrocortanine 21219928 92202163 - 18283926 570508385 79879780 156418836.4 233886810.7 149.53 
caffeine 239598362 350815815 93975996 302370046 179960801 120994102 214619187 101385732.4 47.24 
morphine 28461545 40857791 677419881 28087078 - 29198804 193890888.5 322404405.4 166.28 
 
acetylcodeine 
44995255 90693265 268339550 57161497 146734286 80583010 114751143.8 83115599.31 72.43 
6-onoacetylmorphine 362335492 801873320 11505674 400843784 1178798151 716846446 578700477.8 407225834 70.37 
papaverine 35240948 65583531 440600161 41368198 109845884 9770758 117068246.7 162058442.1 138.43 
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Table 5.7 %RSD results for EFV-heroin pyrolysis product vs peak area for within-can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1  
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average stdev %RSD 
acetaminophen 257004 257004 257006 248056 257002 257003 255512.5 3652.92 1.43 
benzaldehyde 9232963 9232963 9232958 9232963 9357567 9232963 9253730 50869.78 0.55 
Meconin lactone 5067986 5344298 5135628 5026607 5065631 5067016 5117861 116376.44 2.27 
caffeine 104841 103983 104841 104799 104563 105100 1047138 425.10 0.41 
hydrocortanine 258783 258783 257779 257954 257691 257639 2581058 536.10 0.21 
EFV 50854846 58600434 58854846 58600422 58022876 58056361 57164964 3108858.50 5.44 
6-monoacetylmorphine 1534479 1537663 1534471 1534761 1538611 1534775 1535793 1844.65 0.12 
diacetylmorphine 146452 146236 147562 146443 146531 146725 146658 470.02 0.32 
 
 
 
 
 
 
 
 
319 
 
Table 5.8 %RSD results for EFV-heroin pyrolysis products vs peak area for within-can analytical repeatability extracted in MeOH-DCM 90:10 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1  
 
ACS1 ACS  2 ACS 3 ACS 4 ACS 5 ACS  6 Average Stdev %RSD 
 
EFV 1 1729.197 1743 1576.1 1665.99 1755.77 1765.88 1756.88 72.725 4.14 
Meconin 307.21 308.33 309.3 307.33 307.77 307.211 307.86 0.83 0.27 
morphine 1017.27 1011.56 1119.11 1034.44 1045.45 1030.193 1043.00 39.21 3.76 
Acetyl codeine 847.513 884.33 887.462 803.345 863.22 864.33 858.37 30.74 3.58 
3,6 Acetyl morphine  303.773 304.33 303.773 304.66 321.55 - 307.62 7.79 2.53 
EFV  49133700 49356002 49876338 48443521 49887651 49946532 49440624 590118.69 1.19 
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Table 5.9 %RSD results for EFV-heroin pyrolysis products vs peak area for inter-can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1  
 
Can 1 Can 2 Can 3 Can 4 Can 5 Can 6 Average stdev %RSD 
 
acetaminophen 257004 396834 659277 880930 16490886 91734524 18403243 36487067 198.26 
 
Meconin lactone 5067986 5344298 7712336 4926207 7086775 26576106 9452285 8466774 89.57 
diacetamate - 29724 62566 - - 73666987 24586426 42505016 172.88 
caffeine 104841 132475 186627 2381009 4462901 10073830 2890281 3924533 135.78 
hydrocortanine 258783 57927 1022939 1385508 3166828 11510801 2900464 4360907 150.35 
EFV 50854846 99720746 120145815 321691767 517619611 379987608 2483367322 185873560 74.85 
acetylcodeine - 666061 1617674 333916 1043863 9095661 2551435 3689295 144.60 
6-monoacetylmorphine 1534479 2788130 8148083 4255538 10857550 69154242 16123004 26211132 162.57 
 
diacetylmorphine 257004 396834 659277 880930 16490886 91734524 18403243 36487067 198.26 
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Table 5.10 %RSD results for EFV-heroin pyrolysis product vs peak area for inter-can analytical repeatability extracted in MeOH-DCM 90:10 MeOH-DCM at 354
0
C 
Pyrolysis product Peak area 
 
Can1 Can 2 Can 3 Can 4 Can 5 Can 6 Average Stdev %RSD 
 
Meconin lactone - 8825105 11117023 10916046 17770172 4873576 9821548.2 4708310.9 47.94 
caffeine 141382 428636 6466801 6456905 5912119 129096 3255823.2 3319107.3 101.94 
hydrocatamine 946652 2242164 5956857 5186789 7650047 448622 3738521.8 2938556.9 78.60 
EFV 118453632 252498770 318800804 789251802 277530003 69670715 304367621 256272617 84.20 
Acetyl codeine 1068648 2838179 1453417 1633813 5342653 535700 2145401.7 1743184.5 81.25 
6-monocaetyl morphine 6002978 16463693 15422431 19681060 40100849 3507949 16863160 13011312 77.16 
diacetylmorphine 1933873 5878396 2384003 2603276 2056635 423593 2546629.3 1802951.7 70.80 
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Table 5.13  %RSD results for heroin pyrolysis product vs peak area for within-can analytical repeatability extracted in the mobile phase at 354
0
C. 
Pyrolysis product Peak area 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
Morphine 
 
741.359 742.4 741.359 741.39 741.564 742.017 741.68 0.45 0.06 
Meconin 
 
133.462 133 134 133.78 133.433 133.422 133.48 0.32 0.24 
Papaverine 
 
27.513 28.955 27.56 27.563 27.434 28 27.763 0.64 2.32 
 
 
Table 5.14  %RSD results for heroin pyrolysis products vs peak area for within-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C.  
Pyrolysis product Peak area 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
Morphine 20.411 21.3 20.4 20.202 20.111 20.006 20.405 0.43 2.09 
 
Meconin 19.914 19.866 19. 891 19.899 19.985 19.899 19.9126 0.04 0.20 
 
Noscapine 51.108 50.998 51.839 51.607 51.009 50.321 51.147 0.56 0.95 
 
Papaverine 27.019 27.001 27 26.978 27.323 27.003 27.054 0.12 0.45 
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Table 5.15 %RSD results for heroin pyrolysis products of heroin for in-between can repeatability extracted in the mobile phase at 354
0
C 
Pyrolysis product Peak area 
 
Can 1 Can 2 Can 3 Can 4 Can 5 Can 6 Average Stdev %RSD 
 
Morphine 
 
741.359 8732.52 8021.034 181.168 6009 9754 5573.18 4033.85 72.38 
Meconin 
 
133.462 3334.58 3334.587 168.475 1688.395 1229.82 1648.227 1592.04 96.59 
Noscapine 
 
- 3956.28 3761.615 - 2660.576 9680.84 5014.83 698.69 13.93 
Papaverine 
 
27.513 1573.28 1573.281 - 1758.039 1479 1282.22 808.38 63.05 
 
 
Table 5.16 %RSD results for heroin pyrolysis products vs peak area for inter-can analytical repeatability test extracted in the MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Peak area 
 
Can1 Can 2 Can 3 Can 4 Can 5 Can 6 Average Stdev %RSD 
 
Morphine 20.411 204.394 77.54 12.03 12.789 116.175 73.89 69.82 94.49 
 
Meconin 19.914 116.044 58.091 14.89 15.504 47.9 1648.23 1592.04 96.59 
 
Noscapine 51.108 - 170.39 17.88 - - 5014.83 698.69 13.938 
 
Papaverine 27.019 - 43.281 - 15.669 - 1282.22 808.38 63.05 
 
324 
 
 
Table 5.19 %RSD results for pyrolysis products of EFV-heroin for within-can analytical repeatability test extracted in the mobile phase at 354
0
C 
Pyrolysis product Peak area 
 
ACS 1 ACS  2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
EFV 1 
 
1596.38 1583.7 1573.1 1577.9 1557.7 1577.1 1577.65 11.59 0.73 
Meconin 
 
307.312 307.565 307.656 307.56 307.211 307.211 307.42 0.18 0.06 
morphine 
 
76.3 76.3 76.322 76.311 76.355 76.311 76.32 0.02 0.02 
Acetyl codeine 
 
847.513 847.333 857.241 847.55 847.511 847.321 849.08 3.65 0.43 
EFV  
 
49133700 49133700 49133711 49145561 49133722 49145531 49137654.17 5580.38 0.01 
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Table 5.20 %RSD results for pyrolysis products of within-can analytical repeatability test extracted in the MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Peak area 
 
ACS 1 ACS 2 ACS  3 ACS 4 ACS  5 ACS 6 Average Stdev %RSD 
 
EFV 1 1729.197 1743 1576.1 1665.99 1755.77 1765.88 1756.88 72.725 4.14 
Meconin 307.21 308.33 309.3 307.33 307.77 307.211 307.86 0.83 0.27 
morphine 1017.27 1011.56 1119.11 1034.44 1045.45 1030.193 1043.00 39.21 3.76 
Acetyl codeine 847.513 884.33 887.462 803.345 863.22 864.33 858.37 30.74 3.58 
3,6 Acetyl morphine 303.773 304.33 303.773 304.66 321.55 - 307.62 7.79 2.53 
EFV 49133700 49356002 49876338 48443521 49887651 49946532 49440624 590118.69 1.19 
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Table 5.21 %RSD results for pyrolysis products of EFV-heroin for in-between can analytical repeatability test extracted in the mobile phase at 354
0
C 
Pyrolysis product Peak area 
 
Can1 Can 2 Can 3 Can 4 Can 5 Can 6 Average Stdev %RSD 
 
EFV 1 
 1596.38 5807.77 453.141 3818 438.254 435.141 2091.45 2244.89 107.34 
Meconin 
 307.312 559.886 148.171 61.843 9754.14 148.171 1829.92 3886.06 212.36 
morphine 
 76.300 130.193 502.57 559.886 1229.817 1153.439 608.71 491.65 80.77 
Acetyl codeine 
 847.513 - - 1634.599 327.551 9860.824 3167.62 4494.37 141.88 
 
EFV 49133700 983.344 847.623 1132810 6242900 12221.64 9420577 19605581 208.11 
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Table 5.22 %RSD results for pyrolysis products of EFV-heroin for in-between can analytical repeatability test extracted in the MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Peak area 
 
Can1 Can 2 Can 3 Can 4 Can 5 Can 6 Average Stdev %RSD 
 
EFV 1 1729.197 169393 438.254 185873 169391 1577.100 88066.93 95296.42 108.21 
Meconin 307.215 988.703 130.193 988.703 678.331 307.211 566.73 372.52 65.73 
morphine 1017.278 863.233 76.322 286.577 76.355 130.193 408.33 421.99 103.35 
Acetyl codeine 847.513 220.881 465.462 803.345 - 202.282 507.90 308.31 60.70 
3,6 Acetyl morphine 303.773 184.849 303.773 6624.612 453.776 - 1574.16 2824.90 179.46 
EFV 49133700 39576000 38609800 98332000 3.5E+08 3000528 96511788 128105735 132.74 
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Table 6.2 %RSD results for pyrolysis products of heroin for within-can repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
 
meconin 62124853 61999073 62053296 62300876 61000547 61667443 61857681 468386.34 0.76 
hydrocortanine 27829506 27829506 27650058 27847786 26888567 28475460 27753481 509995.93 1.84 
codeine 190659502 190659200 190659502 18900768 189576883 187563322 189686530 1251378.6 0.66 
morphine 288507145 288507145 288600781 288654903 299435221 288511679 290369479 4441705.6 1.53 
thebaine 31110746 31110766 31007232 31400028 31108074 31442118 31196494 178939.91 0.57 
papaverine 187010587 187000798 187665004 187010586 187505898 187665321 187309699 336321.01 0.18 
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Table 6.3 %RSD results for pyrolysis products of opium for within-can repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
meconin 15680908 15680977 15680870 15690060 15685556 15664423 104525744 57546909.31 0.01 
 
hydrocortanine 1823596 1840001 1852236 1822765 1826750 1922143 1847915.167 38112.96868 2.06 
codeine 256248560 256248577 258777304 255554097 259978211 262223106 258171642.5 2618886.93 1.01 
morphine 13125605 13233212 12899967 13132445 13121769 12902100 13069183 136679.996 1.05 
thebaine  154945492 155003424 154900346 154862441 155300218 155002384.2 174598.5893 0.11 
papaverine 21648140 21705550 21099760 21671027 20776711 21889220 21465068 429175.0861 1.99 
noscapine 115745618 115788801 114998001 115688101 115811994 114977705 115501703.3 400308.4103 0.35 
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Table 6.4 %RSD results for opium pyrolysis products for inter-can repeatability extracted in MeOH-DCM 50:50 at 354
0
C  
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each tin can  
 
 
can 1 can 2 can 3 can 4 can 5 Can 6 Average Stdev %RSD 
 
meconin 
 
62124853 29052810 67053296 1.47E+08 266497648 850093846 236924795 312284714 131.81 
hydrocortanine 27829506 5640907 36860987 8155660 136816628 48475460 43963191 48381061 110.05 
codeine 190659503 42216046 2.46E+08 3.82E+08 507312603 290338985 276400819 159824800 57.82 
morphine 288507145 51453041 1.93E+08 6.21E+08 431877474 501812148 347967663 210024493 60.36 
thebaine 31110746 7977150 1.7E+08 1.1E+08 86940133 107219213 85595440 58708506 68.59 
papaverine 187010587 75788872 2.42E+08 3.79E+08 524068885 21889220 238219531 188290989 79.04 
noscapine 345895760 2.36E+08 3.97E+08 3.63E+08 - 114977705 291454536 115623859 39.67 
  
331 
 
 
 
Table 6.5 %RSD results for opium pyrolysis products for inter-can repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in each ACS in tin can 1 
 
 
can 1 Can 2 Can 3 Can 4 Can 5 Can 6 Average Stdev %RSD 
 
meconin 15680908 21373009 48500646 29035736 21432088 28799678 27470344.17 11481463.44 41.80 
hydrocortanine 1823596 11222920 21431106 10788972 11497214 15050685 11969082.17 6389509.185 53.38 
codeine 256248560 182332848 171226883 101012317 182379908 179667078 178811265.7 49259725.93 27.55 
morphine 13125605 321814742 299588622 163030635 321814742 315204048 239096399 126479351.7 52.90 
papaverine 21648140 3450012 4354012 43000876110 8863422 5466381 7174109680 17551460657 244.65 
noscapine 115745618 233451 207885 11580943 44536627 33002598 34217853.67 43769344.53 127.91 
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Table 6.18 %RSD results for pyrolysis products of cannabis for within can analytical repeatability extracted in mobile phase at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
 
cannabinol 3212.5212 3212.5212 3212.52 3251.89 3212.51 3213.5611 3220.60 17.497215 0.50 
cannabidiol 5303.6406 5303.64 5302.647 5299.112 5301.6201 5202.1233 5285.46 40.863111 0.77 
 
 
 
Table 6.19 %RSD results for pyrolysis products of cannabis for within-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
 
cannabinol 195.6904 195.6097 194.76 195.69 195.6904 194.342 195.2971 0.59 0.30 
cannabidiol 112.3989 112.3007 112.3989 112.3899 113.112 112.2877 112.4814 0.31 0.28 
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Table 6.20 %RSD results for the pyrolysis products of cannabis for inter-can analytical repeatability extracted in the MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
 
cannabinol 195.6904 127.588 104.336 97.696 171.098 208.786 150.87 47.55 31.52 
cannabidiol 112.3989 129.221 208.412 437.712 236.446 386.68 251.81 133.67 53.08 
 
 
Table 6.21 %RSD results for the pyrolysis products of cannabis for inter-can analytical repeatability extracted in the mobile phase at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
 
cannabinol 3212.521 211.33 284.63 129.77 443.648 313.411 765.89 1098.36 143.41 
cannabidiol 5303.641 196.387 256.645 51.371 208.39 165.814 1030.38 1912.09 185.57 
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Table 6.12 %RSD results for pyrolysis products of cannabis for within can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
 
cannabinol 192817867 192817844 192817866 1.93E+08 1.9E+08 1.93E+08 192349700 1078964 0.56 
cannabidiol 337736498 336582956 337765564 3.38E+08 3.38E+08 3.34E+08 336883160 1491169 0.44 
 
 
Table 6.13 %RSD results for the pyrolysis products of cannabis for within-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
 
cannabinol 674619964 674619981 674677828 679896320 674619964 67460076 675505804 2151063.6 0.32 
cannabidiol 1083886325 1083886732 1082800025 1083886325 108388465 108388642 1083705486 443584.98 0.04 
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Table 6.14 %RSD results for pyrolysis products of cannabis for inter-can analytical repeatability extracted in MeOH-DCM 50:50 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
 
cannabinol 192817867 480750943 319099306 334944305 8057755928 363845896 1624869041 3152806061 194.03 
 
cannabidiol 337736498 767936140 580148840 567220070 136766877956 652239588 23278693182 55597807669 238.83 
 
 
Table 6.15 %RSD results for the pyrolysis products of cannabis for the inter-can analytical repeatability extracted in MeOH-DCM 90:10 at 354
0
C 
Pyrolysis product Pyrolysis product average peak area from the 6 replicate injections in tin can 1 
 
 
ACS 1 ACS 2 ACS 3 ACS 4 ACS 5 ACS 6 Average Stdev %RSD 
 
 
cannabinol 674619964 480750943 319099306 334944305 8057755928 363845896 1624869041 3152806061 194.03 
 
cannabidiol 1083886325 767936140 580148840 567220070 136766877956 652239588 23278693182 55597807669 238.83 
 
